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ALTERNATIVE SPLICING REGULATION IN PROGRAMMED CELL DEATH AND 
NEUROLOGICAL DISORDERS: A SYSTEMS BIOLOGY APPROACH 
 
Abstract 
Alternative splicing (AS) is a major source of biological diversity and a crucial 
determinant of cell fate and identity. Characterizing the role of AS regulatory networks in 
physiological and pathological processes remains challenging. The work presented here 
addresses this challenge using systems biology analyses of AS regulatory networks in 
programmed cell death and neurological disorders. 
The first study describes a genome-wide screen based on splicing-sensitive 
reporters to identify factors that affect the AS of apoptosis regulators Bclx and Mcl1. The 
screen identified over 150 factors that affect apoptosis through modulating the pro- and 
anti-apoptotic splicing variants of these apoptosis regulators. This screen revealed a new 
functional connection between apoptosis regulation and cell-cycle control through an AS 
network. It also unearthed many disease-associated factors as AS effectors. 
The second study describes the functions of the Polyglutamine-binding protein 1 
(PQBP1)-mediated AS regulatory network in neurological disorders. PQBP1 is a factor 
linked to intellectual disability and was unexpectedly identified as an AS effector from 
the screen described above. We found that PQBP1 influences the splicing of many 
mRNAs and is associated with a wide range of splicing factors. Depletion of PQBP1 in 
mouse primary cortical neurons caused defects in neurite outgrowth and altered AS of 
mRNAs enriched for functions in neuron projection regulation. Disease-mutants of 
PQBP1 lose associations with splicing factors and cannot complement the aberrant AS 
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patterns and neuron morphology defects in PQBP1 depleted-neurons. This study revealed 
a novel function of PQBP1 in AS regulation associated with neurite outgrowth and 
indicated that aberrant AS underlies the pathology of PQBP1-related neurological 
disorders.  
A final study examines the dynamics of the Drosophila Sex-lethal AS regulation 
network using a combination of experimental tools and mathematical modeling. This 
study demonstrates that the features of Sxl AS regulation have great potentials in building 
synthetic memory circuits in mammalian cells to track cell fate. 
Collectively, this work describes the landscape of three diverse AS regulatory 
networks in various biological processes. The results and methods presented here 
contribute to our rapidly advancing knowledge of AS regulation in biology and human 
disease.   
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MESSENGER RNAS: A DYNAMIC READOUT OF GENETIC INFORMATION 
The central dogma of molecular biology states that the genetic information of life 
is stored in DNA and transferred to messenger RNA (mRNA) for expression as proteins 
(Crick 1970). mRNA however, is more than a passive intermediate in the expression of 
genetic information. Instead, multiple mechanisms on mRNA processing enable mRNA 
to selectively extract and re-organize information from DNA. mRNA provides a dynamic 
readout of the genetic information stored in DNA in a tissue- and cell type-specific way.  
It is now appreciated that the number of protein-coding genes in a genome is not 
proportional to the degree of complexity of that organism (Lodish et al. 2008). For 
example, the human genome encodes around 25,000 protein-coding genes, only four 
times as many as the yeast Saccharomyces and comparable to that of the plant 
Arabidopsis thaliana, the nematode C. elegans and the fruit fly Drosophila. Furthermore, 
human and chimpanzee genomes show a 98% sequence identity, even though humans 
exhibit far more complicated cognitive behaviors such as the use of language (Lander et 
al. 2001; Olson and Varki 2004). These examples illustrate that the phenotypic 
complexity of an organism is not solely determined by the number of protein-coding 
genes it possesses. Rather, it has been proposed that the diversity and sophistication of 
the eukaryotic proteome is augmented by mRNAs via regulatory mechanisms at the 
transcriptional and post-transcriptional levels. 
Regulatory mechanisms at the post-transcriptional level, in particular, contribute 
to mRNA and proteome diversity in eukaryotes. One of the most prominent mechanisms 
is precursor mRNA (pre-mRNA) splicing. In most eukaryotes genes are ‘split’: the 
protein-coding regions (exons) of a gene are interrupted by ‘silent’, non-coding regions 
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(introns). The maturation of an mRNA transcript requires the excision of introns and the 
concomitant joining of exons (Gilbert 1978; Matlin et al. 2005). In many cases of multi-
exon mRNA transcript maturation there is more than one way to remove introns and join 
exons, enabling a gene to generate multiple mRNA and protein variants (Wang et al. 
2008; Pan et al. 2008) in a process termed alternative splicing. In addition to pre-mRNA 
splicing, mRNA transcripts are subject to many other regulatory processes, such as 
control of mRNA stabilization, transport and RNA editing. These mRNA processing 
steps greatly increase the genome’s capacity to generate different mRNA profiles and 
expand the number of functionally distinct proteins that can be encoded by the genome 
(Nilsen and Graveley 2010). 
Multicellular organisms are typically composed of hundreds of distinct cell types 
that are specialized in a variety of functions. These cells share largely identical genetic 
information, but are capable of generating diversified gene expression patterns in 
response to tissue- and development stage-specific needs. The mRNA profiles are thus of 
special importance as a dynamic reflection of how genes are expressed and regulated. 
Moreover, aberrant mRNA profiles are associated with human diseases and could provide 
valuable information on pathology and potential treatment strategies. 
 
MECHANISM OF PRE-MRNA SPLICING  
The exon-intron structure of eukaryotic genes greatly facilitates the generation of 
diverse mRNA profiles and pre-mRNA splicing is a crucial process in the eukaryotes. 
Pre-mRNA splicing is carried out by the spliceosome, a large and highly dynamic 
ribonucleoprotein (RNP) machine. The spliceosome is assembled from five basic small 
 
 
 
 
4 
nuclear RNP (snRNP) elements (U1, U2, U4, U5 and U6) and is dynamically associated 
with up to 300 additional proteins (Rappsilber et al. 2002; Wahl et al. 2009).  
The basic splice sites in eukaryotic pre-mRNAs are generally defined by short 
consensus sequences (Figure 1-1A) and the spliceosome is assembled onto the pre-
mRNA in a step-wise manner on those sites. During initiation of the spliceosome 
assembly (spliceosomal E complex), the 5’ splice site (5’SS) is recognized by the U1 
snRNP, the branch point sequence (BPS) by SF1 (splicing factor 1) and 3’ splice site (3’ 
SS) by U2AF (U2 auxiliary factor) (Figure 1-1B). Following the formation of the E 
complex, U2 snRNP docks to the BPS and replaces SF1, forming the pre-spliceosome—
complex A. Subsequently, U4/U5/U6 pre-assembled tri-snRNPs are recruited to the A 
complex, forming the pre-catalytic spliceosome—complex B. The spliceosome then 
undergoes major conformational changes in which U1 and U4 snRNPs are released, 
giving rise to the activated spliceosome—the B* complex. The spliceosomal B* complex 
performs the first catalytic step of pre-mRNA splicing: the 2’-hydroxyl group of the 
adenine base at the BPS attacks the phosphodiester bond at the 5’SS, generating a free 5’ 
exon and an intron lariat-3’ exon. This intermediate together with the remaining snRNPs 
forms the C complex. A second round of spliceosome conformational change takes place 
here and the second catalytic step of pre-mRNA splicing is performed: the 
phosphodiester bond at the 3’SS is attacked by the 3’-hydroxyl of the 5’ exon, giving rise 
to exon ligation and excision of the lariat intron. After this the spliceosome dissociates 
and disassembles, releasing the spliced mRNA and snRNPs for recycling for the next 
splicing reaction (Figure 1-1B; Wahl et al. 2009). 
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Figure 1-1: Consensus sequences of eukaryotic splice sites and step-wise spliceosome 
assembly on splice sites. 
(A) The consensus sequences of splice sites in metazoans and yeasts. Schematics of a pre-mRNA 
are shown, with green rectangles representing exons and black lines between exons representing 
introns. 5’ splice site is represented by the consensus sequence “GUAAGU” in yeast and “GU” in 
metazoans; branch point sequence by the sequence “UACUAAC” in yeast and “A” in metazoans; 
3’ splice site by “AG” in both metazoans and yeasts. The consensus sequences of the 5’ splice 
site, branch point sequence and 3’ splice site in yeast are highly conserved but in metazoans are 
degenerate. 
(B) Step-wise assembly of the spliceosome on splice sites in metazoans. Schematics of a pre-
mRNA are shown, with green rectangles representing exons and black lines between exons 
representing introns. “GU” marks the 5’ splice site (5’ SS), “A” the branch point sequence (BPS) 
and “AG” the 3’ slice site (3’ SS). See text. 
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Figure 1-1 (Continued). 
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ALTERNATIVE SPLICING IN BIOLOGICAL DIVERSITY AND REGULATORY NETWORKS 
Alternative splicing (AS) depicts the phenomenon in higher eukaryotes that 
introns can be removed and exons are pieced together in different patterns to produce 
functionally distinct mRNA and protein variants from one gene. AS is a major source of 
biological diversity in eukaryotic transcriptomes and proteomes. The contribution of AS 
to eukaryotic complexity is likely even greater than previously recognized, as high-
throughput studies showed that >90% of mammalian genes undergo AS and generate 
polymorphic mRNA transcripts (Pan et al. 2008; Wang et al 2008). The number of 
mRNA transcripts that a multi-exon gene is able to encode varies from several to 
thousands, a staggering level of diversity. As an example, the Drosophila gene Down 
syndrome cell adhesion molecule (Dscam) is able to make approximately 38,000 mRNA 
isoforms, far surpassing the number of total protein-coding genes (~14,500) in the 
organism (Schmucker et al. 2000).  
There are seven basic patterns that pre-mRNAs can follow during AS (Figure 1-2; 
Black 2003). An exon can be alternatively included or excluded in the transcript, and is 
defined as a cassette exon (Figure 1-2A). Multiple cassette exons can be mutually 
included or excluded to generate different isoforms (Figure 1-2B). Part of an exon can be 
alternatively spliced, introducing alternative 5’ or 3’ splice sites within that exon (Figure 
1-2C,D). Furthermore, the use of alternative promoters or polyadenylation (poly-A) sites 
can also contribute to AS by extending, shortening or changing the first or last exon of 
the mRNA transcript (Figure 1-2E,F). Finally, an intron that is supposed to be removed 
can be retained in the transcript (Figure 1-2G).       
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Figure 1-2: Seven basic AS patterns in multicellular eukaryotes.  
Schematics of hypothetic pre-mRNAs are shown under different AS patterns, with green 
rectangles representing exons and gray rectangles represent alternatively spliced exons or exonic 
regions. Arrows show transcription start site. Arrowheads show poly-A sites. 
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products from the same gene in response to different stimuli, and can work as a switch in 
cell fate determination (Figure 1-3A). For example, the gene encoding Bcl-2-like protein 
1 (Bcl2l1 or Bcl-x), a member of the Bcl-2 family of apoptosis regulators, produces two 
major splicing isoforms—anti-apoptotic Bclx-L and pro-apoptotic Bclx-S due to the usage 
of an alternative 5’ splice site in exon 2 (Figure 1-3A; Akgul et al. 2004). The switch of 
the two splicing isoforms of Bcl-x affects the cell’s decision on whether to commit 
apoptosis. Besides Bcl-x, several other apoptosis regulators also generate pro- and anti-
apoptosis isoforms (Akgul et al. 2004). As another mechanism, AS can introduce 
premature termination codons in an mRNA, leading to degradation of the mRNA through 
nonsense-mediated mRNA decay (AS-NMD) (Lewis et al. 2003) (Figure 1-3B). Here, 
AS directly regulates the total abundance of a target, rather than the expression of 
specific isoforms. As an example, the Drosophila sex determination master gene Sex-
lethal (Sxl) can produce the male-specific isoform or female-specific isoform based on 
the inclusion or exclusion of exon 3, which contains a premature stop codon (Figure 1-
3B; Baker 1989). AS-NMD causes the degradation of the male-specific isoform and lack 
of functional Sxl protein in male flies, leading to male-related phenotypes. On the other 
hand, the female-specific isoform lacking exon 3 is translated into functional Sxl proteins 
in female flies. Sxl is itself a splicing regulator, and alters the splicing of a cascade of 
downstream mRNA transcripts, resulting in female-related phenotypes (Baker 1989). The 
two example AS mechanisms above can be found in many biological regulatory 
networks, serving as crucial determinants of cell fate and identity.   
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Figure 1-3: Two examples AS mechanisms in biological regulatory networks. 
(A) AS enables Bcl-x to generate functionally distinct mRNA isoforms and protein variants to 
affect cells’ decision in committing apoptosis. A schematic of Bcl-x is shown. Green rectangles 
represent exons and black lines between exons are introns. Gray rectangle represents the 
alternatively spliced exonic region. Arrows show translation start site.  
(B) AS regulates the abundance of Sxl through AS-NMD in Drosophila. A schematic of Sxl is 
shown. Gray rectangles represent exons and black lines between exons are introns. Dark rectangle 
represents the alternatively spliced exon 3, with the stop sign representing a premature 
termination codon.  
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A HIERARCHICAL CONTROL OF ALTERNATIVE SPLICING REGULATION 
The selection of splice sites by the spliceosome determines AS decisions. In yeast 
where constitutive splicing is dominant and AS is rare, the sequence elements for 5’SS, 
BPS and 3’SS are conserved and well recognized by U1 snRNP, SP1 and U2AF of the 
spliceosome machinery (Figure 1-1A; Izquierdo et al. 2006). However in higher 
eukaryotes where AS is more a rule than exception, the splice site sequence elements are 
degenerate and not strong enough to direct the spliceosome on their own (Figure 1-1A).  
AS in multicellular eukaryotes is under the regulation of a large repertoire of 
trans-acting non-snRNP RNA-binding proteins (RBPs) and additional cis-elements in the 
pre-mRNA sequences (Wahl et al. 2009). Two classical classes of these RBPs are serine-
arginine repeat proteins (SR proteins) and heterogeneous nuclear ribonucleoproteins 
(hnRNPs) (Matlin et al. 2005). RBPs recognize cis-elements within the pre-mRNA 
sequences and help to recruit or dissociate the spliceosome machinery to/away from a 
particular splice site (Figure 1-4A; Singh and Valcárcel 2005). These cis-elements 
associated with RBPs are short regulatory sequences flanking splice sites, including 
exonic or intronic splicing enhancers or silencers (Figure 1-4A). Collectively, AS 
decision is the combinatorial result from the ‘splicing code’ embedded in the pre-mRNA 
sequences and a large repertoire of proteins devoted to interpreting the code (Matlin et al. 
2005).  
The splicing code in AS is analogous to transcription factor binding sites in DNA 
sequences in the transcription network. Much effort has been dedicated to deciphering the 
splicing code (Wang and Burge 2008; Hartmann and Valcárcel 2009; Nilsen and 
Graveley 2010), although the process proves to be experimentally and computationally  
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Figure 1-4: A hierarchical control of AS regulation. 
(A) The interplay of cis-elements within the pre-mRNA sequence and trans-acting RBPs in AS 
regulation. A schematic of a hypothetic pre-mRNA is shown. Green rectangles represent exons 
and black lines between exons are introns. 5’ splice sites are marked by “GU”, branch sites by A 
and 3’ splice sites by “AG”. Orange and red bands within the middle exon represent an exonic 
splicing enhancer (ESE) and an exonic splicing silencer (ESS). Blue short lines within introns 
represent an intronic splicing enhancers (ISE) and an intronic splicing silencers (ISS). SR proteins 
and hnRNPs can bind to these cis-elements and cast positive (+) or negative (-) effects on the 
selection of the nearby splice sites. 
(B) A hierarchical control of AS regulation in multicellular eukaryotes. AS decision is under the 
regulation of cis-elements (red short lines) within pre-mRNA sequences and a large repertoire of 
RNA-binding proteins (RBPs, purple and blue circles). These RBPs are further controlled by 
many regulatory mechanisms that can cause tissue-specific synthesis, re-localization or 
modification of these RBPs so as to affect AS decisions. Circled P on one of the RBPs represents 
phosphorylation as an example of post-translational modification that can change the activities of 
RBPs. These regulatory mechanisms on RBPs are incorporated to the cellular signaling pathways 
and respond well to environmental cues. 
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challenging for several reasons. Cis-element sequences in multicellular eukaryotes are 
usually short and degenerate, occurring frequently in the genome and not highly specific 
(Singh and Valcárcel 2005). In addition, the RBPs bind to cis-elements and associate 
with the spliceosome with low affinity. The decision on a given splice site is the 
combinatorial product of many antagonistic-acting splicing factors (Smith and Valcárcel 
2000), complicating the prediction of AS decisions (Figure 1-4A). However, it is possible 
that examination of AS at a global scale with fast developing high-throughput techniques 
will improve our understanding of the combinatorial interplay between the cis-elements 
and the RBPs in AS decisions, and contribute to decipher the splicing code. Recently, 
some groups applied high-throughput genomic technologies to seek the splicing code 
from analyzing large samples of splicing events in different tissues and cell types (Barash 
et al. 2010). The resulted code is used to predict AS patterns under specific contexts and 
received positive results (Barash et al. 2010).  
To further complicate the regulation of AS, there are many cellular regulatory 
mechanisms that regulate the activities of RBPs and consequently affect AS decisions 
(Moore and Silver 2008). These mechanisms span from transcriptional to post-
translational levels, and can cause significant AS changes through modification, re-
localization or tissue-specific synthesis of RBPs (Figure 1-4B; Moore and Silver 2008; 
Stamm 2002). For example, post-translational modifications such as protein 
phosphorylation can change the location and activities of RBPs and alter splice site 
choices (Stamm 2008). These regulatory mechanisms on RBPs are responsive to cellular 
signaling pathways and environment cues, establishing a hierarchical control of AS 
regulation (Figure 1-4B; Moore and Silver 2008).  
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ABERRANT SPLICING AND HUMAN DISEASES 
AS is strictly regulated and provides diverse mRNA profiles in response to 
environmental cues. However, such diversity and flexibility come at a price: mis-
regulation and defects can occur at multiple levels of AS regulation and cause aberrant 
splicing leading to human diseases. Indeed, it is estimated that 15% and maybe as many 
as 50% of disease-causing human hereditary mutations affect splicing decisions (Ward 
and Cooper 2010; López-Bigas et al. 2005). Aberrant AS is most frequently involved in 
diseases associated with functions of complex tissues or regulations of intricate biological 
processes (Blencowe 2006; Mills and Janitz 2012). As the most structurally complicated 
organ in animals, the brain generates more AS transcripts than all other tissues (Johnson 
et al. 2009; Yeo et al. 2004). It is perhaps not a surprise, then, that a fast growing list of 
neurological disorders are found associated with misregulaton in AS (Licatalosi and 
Darnell 2006). Apoptosis is a complicated cellular process under many layers of 
regulation, part of which is from AS (Akgul et al. 2004). To evade strict control of 
apoptosis, tumors show significantly altered AS profiles compared to normal tissues 
(Venables et al. 2009), establishing a critical role of AS misregulation in cancer.  
Disease-related aberrant splicing can occur from either disruptions in cis-elements 
within a pre-mRNA sequence or from malfunctioning trans-acting RBPs, and can thus be 
classified into cis-acting and trans-acting splicing defects. Mutations in the core splicing 
machinery can also cause context-specific splicing deficiencies.  
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Cis-acting splicing defects: disruption of the ‘splicing code’ 
Cis-acting splicing defects are caused by mutations in splice sites and auxiliary 
cis-elements in the pre-mRNA sequences, disrupting the splicing code. The effect of cis-
acting splicing defect is usually local, affecting only specific splicing decisions on a 
particular pre-mRNA.  
One example of cis-acting splicing defects is from the disease frontotemporal 
dementia with Parkinsonism linked to chromosome 17 (FTDP-17). This disease is caused 
by any of a series of mutations in the gene encoding microtubule-associated protein tau 
(MAPT) that is predominantly expressed in the central nervous system (Faustino and 
Cooper 2003). Exon 10 of MAPT encodes the last of four microtubule-binding domains 
in the protein and can be alternatively included or excluded, generating MAPT proteins 
with either three or four microtubule-binding domains (3R-tau or 4R-tau) (Goedert et al. 
1989; Andreadis et al. 1992). FTDP-17 is associated with aggregations of MAPT in 
neuronal cytoplasmic inclusions, and 4R-tau is predominantly in MAPT aggregates in 
individuals with FTDP-17 (Buée et al. 2000; Hutton et al. 1998; Spillantini et al. 1998). 
The 4R-tau/3R-tau ratio of MAPT is strictly regulated by exonic and intronic splicing 
enhancers/silencers around exon 10 in the pre-mRNA sequence (Faustino and Cooper 
2003). In normal brain tissues, MAPT produces equal amounts of 4R-tau and 3R-tau 
(Goedert and Jakes 1990; Kosik et al. 1989). One class of MAPT mutations in FTDP-17 
changes the splicing cis-elements around exon 10 and increases the production of 4R-tau. 
As low as a two-fold change in the 4R/3R ratio could result in disease syndromes 
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(Faustino and Cooper 2003). Thus, the mis-splicing of exon 10 in MAPT due to 
mutations in the pre-mRNA cis-elements underlies the pathology of FTDP-17.   
 
Trans-acting splicing defects: disruption of the RNA splicing ‘regulon’ 
Trans-acting splicing defects are caused by malfunctioning splicing regulators 
like RBPs. In AS, the splicing of functionally related pre-mRNAs is usually coordinately 
regulated by one or a few splicing regulators. This phenomenon is proposed as RNA 
splicing ‘regulon’ (Keene 2007) that is analogous to operons in prokaryotes, where a 
cluster of genes are under the regulation of a single promoter (Jacob et al. 1960), or 
transcriptional regulation in eukaryotes where multiple functionally related genes are 
regulated by a single transcription factor. Consequently, trans-acting splicing defects are 
usually global and could affect the AS of many pre-mRNAs that are targets of the 
disrupted splicing regulator.  
One example of trans-acting splicing defects is from the autoimmune disorder 
paraneoplastic opsoclonus-myoclonus ataxia (POMA). POMA is a paraneoplastic 
neurological syndrome in which neural damage is caused by remote effects of cancer 
unrelated to metastasis, tumor-related infection or metabolism disruption (Darnell and 
Posner 2003). Disruption of Nova-1 function is the primary cause of POMA. Nova-1 is a 
member of the neuro-oncological ventral antigen (Nova) family and is an RNA-binding 
protein exclusively expressed in the central nervous system (Buckanovich et al. 1993; 
Buckanovich et al. 1996). Nova-1 regulates the AS of a network of pre-mRNAs whose 
protein products are functionally enriched in neuron synapse formation and development 
(Ule et al. 2005). In POMA, tumors express antigens that are identical to Nova-1 and 
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cause immune responses toward the tumor as well as endogenous, Nova-1-expressing 
neurons (Luque et al. 1991; Darnell and Posner 2003). The autoimmune attack on Nova-1 
inhibits Nova-1–RNA interactions and disrupts Nova-1’s regulation of neuron-specific 
AS (Buckanovich et al. 1996; Jensen et al. 2000; Ule et al. 2005). The collective effects 
of splicing changes in the Nova-1–regulated mRNA network leads to neurodegenerative 
phenotypes observed in POMA (Licatalosi and Darnell 2010).    
As another example, studies on cancer-associated AS provide evidence that 
aberrant splicing patterns in cancer are mostly caused by global splicing alteration due to 
the malfunctioning of trans-acting splicing factors (Wang and Cooper 2007; Ward and 
Cooper 2010). For instance, SR protein ASF/SF2 is recognized as a proto-oncogene and 
is over-expressed in many tumors (Karni et al. 2007). The oncogenic properties of 
ASF/SF2 can be directly linked to its splicing regulation of many downstream cancer-
related genes (Wang and Cooper 2007; Karni et al. 2007).  
 
Pathological mutations in the core splicing machinery 
There have been very few cases where mutations in the core splicing machinery 
are found to be associated with human diseases. It is possible that defects in core 
spliceosome components are generally incompatible with the survival of organisms, 
whereas errors in specific AS decisions can be sufficiently tolerable to cause diseases but 
not immediate death. One surprising and poorly understood observation is that mutations 
in universally expressed core spliceosomal components can cause highly tissue-specific 
pathologies. 
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  Retinitis pigmentosa (RP) is a degenerative eye disease characterized by a 
gradual vision loss that often leads to blindness, due to progressive death of rod 
photoreceptor cells of the retina. Many genetic mutations have been discovered to be 
associated with this disease and among them are HPRP3, PRP31, and PRPC8—factors 
crucial for the assembly and functioning of U4/U5/U6 tri-snRNPs in the spliceosome 
(McKie et al. 2001; Vithana et al. 2001; Chakarova et al. 2002). These discoveries 
indicate that certain defects in the spliceosome assembly pathway caused by the 
mutations may be behind the death of photoreceptor cells and the symptoms in RP. 
However, how mutations in the universal splicing machinery could lead to retina-specific 
pathological manifestations but not in other tissues remains unclear.  
 
ALTERNATIVE SPLICING REGULATION AND HUMAN DISEASES: A SYSTEMS BIOLOGY 
APPROACH 
The diverse splicing patterns and the hierarchical control of AS regulation make it 
necessary to investigate AS at a global level. Systems biology provides effective tools 
and perspectives for addressing such complex biological phenomena, using a holistic 
perspective (Alon 2006). Systems biology is an interdisciplinary field combining tools 
from mathematics, computer science, experimental biology and other subjects with an 
aim of understanding such complex biological systems. 
        
High-throughput tools for systematic AS studies 
Several genome-wide approaches have been developed to study AS from a 
systematic perspective. Different kinds of microarrays have been designed to investigate 
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global AS profiles in eukaryotes, such as exon-junction arrays (with probes spanning 
splicing junctions), exon tiling arrays (with probes within every known and predicted 
exons), and genomic tiling arrays (with probes tiled across the whole genome) (Moore 
and Silver 2008). More recently, whole transcriptome sequencing (RNA-seq) technology 
has provided an unbiased method for AS profiling by direct sequencing. RNA-seq avoids 
many drawbacks of microarrays, including the limitations from array probe design and 
biases from probe cross-hybridization, and is now the preferred method for global AS 
profiling. Microarrays and RNA-seq have both been applied to study the global AS 
profiles of normal or disease-associated tissues and cell types, and have been used to 
detect genome-wide AS changes upon the perturbation of a splicing regulator (Wang et 
al. 2008; Pan et al. 2008; Ule et al. 2005; Gehman et al. 2011; Charizanis et al. 2012). 
The combination of high-throughput techniques and molecular experimental 
methods is greatly improving our understanding of AS regulation, especially the 
regulation of trans-acting splicing factors. Specifically, CLIP (cross-linking and 
immunoprecipitation) provides an effective way to study the target pre-mRNAs of a 
splicing factor (Ule et al. 2003). CLIP employs UV-crosslinking between the RNA-
binding regulatory protein and its target RNAs followed by immunoprecipitation with 
antibodies against the protein (Ule et al. 2003). CLIP can be used in conjunction with 
high-throughput sequencing in a procedure called CLIP-seq: cross-linking 
immunoprecipitation-high-throughput sequencing. CLIP-seq has been used to identify the 
target mRNA network of splicing factors, and to characterize the specific cis-elements 
within the target mRNAs that these splicing factors bind to (Ule et al. 2003; Licatalosi et 
al. 2008).       
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Computational challenges in evaluating global alternative splicing 
Next-generation sequencing allows us to study AS on a genome-wide scale. 
However, the rapid development of the sequencing technology itself brings forward a 
new challenge of analyzing the massive amount of data generated. For microarray data, 
numerous methods have been developed to quantify splicing variants and analyze 
differential AS between conditions (Moore and Silver 2008). RNA-seq technique is a 
more powerful technique, but it necessitates a new quantification paradigm by 
digitalizing the expression level of each mRNA transcript with read counts. 
Computational methods to quantify global AS and analyze differential AS using read 
counts from RNA-seq are still under intensive development (Mortazavi et al. 2008; 
Trapnell et al. 2010; Katz Y et al. 2010; Anders and Huber 2010). Moreover, the methods 
for AS quantification from RNA-seq data are also dependent on the ongoing development 
of basic RNA-seq analysis tools, such as mapping a tremendous amount of short reads to 
the reference genome and ab initio building of genomic structure from the sequencing 
data (Trapnell et al. 2009; Langmead et al. 2009; Trapnell et al. 2010; Guttman et al. 
2010).    
  
Screening for unidentified links between alternative splicing regulation and human 
diseases 
High-throughput cell-based screening is a powerful strategy to identify genes or 
compounds that are involved in the regulation of a biological process (An and Tolliday 
2010). The broad, unbiased scope of screening facilitates the recognition of previously 
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unidentified functions of genes, including disease associations. Several cellular screens 
have been performed to study the effect of potential factors or chemicals on specific AS 
events using splicing-sensitive reporters (Bonano et al. 2006; Orengo et al. 2006; Stoilov 
et al. 2008; Warzecha et al. 2009). These reporters are usually designed so that they 
produce different fluorescent or chemiluminscent products depending on how they are 
spliced (Cooper 2005). As an example, a MAPT exon 10-sensitive splicing reporter was 
built so that RFP is generated when exon 10 is included but GFP is produced if exon 10 
is skipped (Stoilov et al. 2008). In a small-molecule screen using this system researchers 
successfully identified cardiotonic steroids as a regulator for the splicing of exon 10 in 
MAPT (Stoilov et al. 2008). Recently, the implementation of genome-wide RNA-
interference (RNAi) screening has provided a way to examine the effects brought to the 
cell by loss-of-function of every known gene in an organism. Splicing sensitive reporters 
can then identify any potential factor whose loss-of-function affects the splicing event 
studied (Boutros et al. 2008; Oberdoerffer et al. 2008; Venables et al. 2008).  
 
Dynamics of the alternative splicing regulatory network and applications in synthetic 
biological circuits 
AS regulatory networks incorporate standard network motifs such as positive and 
negative feedback loops. For instance, Sxl, the master sex determinant in Drosophila, is a 
splicing factor and auto-regulates its own pre-mRNA splicing toward the female-specific 
isoform. This positive feedback loop of Sxl splicing regulation maintains a steady 
production of Sxl protein in female flies (Baker 1989; Figure 1-3B). A unique feature of 
the post-transcriptional regulation such as the AS regulatory network is that it enables 
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cells to change protein levels rapidly in response to environmental cues without transcript 
synthesis (Pleiss et al. 2007). This feature suggests the existence of kinetic mechanisms 
that link rapid regulatory response to the combinatorial binding of splicing factors to cis-
elements and splicing activating by the spliceosome. Multiple kinetic models have been 
proposed for transcription factors binding DNA and RNA Polymerase II activating 
transcription, with model behaviors highly predictive of the in vivo experimental readout 
(Tay et al. 2010; Raj et al. 2006). It is of interest to model potential mechanisms of 
splicing factors binding pre-mRNA and triggering splicing, and compare the response 
time scale to a model of transcriptional regulation.  
If indeed a unique, fast-responding kinetic mechanism of AS regulatory network 
is confirmed, the network motifs could have great potentials in synthetic biology. 
Synthetic biology is an emerging field that utilizes natural biological regulatory 
mechanisms to design and constructs synthetic circuits for industry, medicine and other 
application areas (Serrano 2007). For example, devices that can retain memory of 
transient exposures to a pulse signal have many potential applications in progressive 
diseases such as cancer. Such devices can track cells that have experienced a transient 
harmful stimulus and follow the subsequent cancerous development. A speedy memory 
response to the transient signal will be crucial in the performance of such devices. 
Synthetic memory circuits built to-date have mostly relied on the use of transcriptional 
regulatory network motifs (Vilaboa et al. 2005; Ajo-Franklin et al. 2007; Burrill and 
Silver 2011; Burrill et al. 2012). Especially in mammalian cells, these circuits show 
heterogeneous performances in retaining memory among cells (Burrill and Silver 2011; 
Burrill et al. 2012). This performance inconsistency is potentially due to the relatively 
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slow response time of the transcription-based device versus that of the cell cycle (Burrill 
and Silver 2011). In contrast, using a natural “memory device,” every Drosophila cell 
homogeneously remembers its sex due to the splicing of Sxl through differentiation, 
development and many generations of cell divisions. AS regulatory network is currently 
underutilized in synthetic biology. Elucidation of AS regulatory network dynamics will 
greatly increase its potential applications in synthetic biological circuits. 
 
THIS WORK  
The past three decades’ research in molecular biology, genetics and cell biology 
have established mechanisms of AS, the regulation of AS and the important roles AS 
plays in generating biological diversity, controlling regulatory pathways, and influencing 
human diseases. However, instead of getting a relatively complete atlas of knowledge on 
AS, we have discovered AS to be a far more complicated process than expected. Recent 
studies have investigated AS at a global level, and revealed AS to involve a complex, 
highly dynamic, and context-specific regulatory network. Consequently, new challenges 
have been brought forth in the field: to explore the significance and functions of the 
global AS network in different biological and physiological contexts will require new 
tools and a more integrated view of post-transcriptional regulation. The work presented 
here aims to address these challenges with a systems biology approach and examines the 
functions of AS regulatory network in a pathological context.     
Chapter 2 describes work in studying AS regulation in apoptosis, a programmed 
cell death pathway that is closely associated with many important biological processes 
and diseases, specifically cancer. In this study, a genome-wide screen was carried out 
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through splicing-sensitive reporters of Bclx and Mcl1, both apoptosis regulators that can 
generate antagonistic splicing variants regulating apoptosis. The screen identified >150 
novel factors that affect the AS of Bclx and Mcl1 and are involved in apoptosis decisions 
through the modulation of anti-apoptotic and pro-apoptotic splicing variants. This screen 
revealed novel functional links between cell-cycle control and apoptosis through an AS 
network. Specifically, aurora kinase A is identified to be a potent factor that, when 
inhibited, can cause significant splicing shift towards pro-apoptotic variants in both Bclx 
and Mcl1. The inhibition of aurora kinase A can also cause AS changes in other 
apoptosis-related transcripts, including a pro-apoptotic shift in the splicing of caspase-9. 
These pro-apoptotic AS shifts in the transcripts were linked to the turnover of ASF/SF2, 
which directly binds the target pre-mRNAs and regulates their splicing. In addition, this 
screen unearthed several factors related to various diseases for which a link to aberrant 
splicing was not previously recognized. 
Chapter 3 describes Polyglutamine-binding protein 1 (PQBP1)’s function in AS 
regulation and the effect of PQBP1-mediated AS regulatory network in neurons and 
neurological disorders. PQBP1, a factor associated with a series of X-linked mental 
retardation diseases, was unexpectedly identified as a splicing effector from the screen 
described in Chapter 2. We found that PQBP1 is capable of influencing the splicing of 
multiple mRNAs and is associated with many splicing factors, including the key U2 
snRNP component SF3B1. Loss of functional PQBP1 reduced SF3B1-substrate mRNA 
association and caused significant changes in AS decisions. Depletion of PQBP1 in 
mouse primary neurons led to defects in neurite outgrowth and altered the AS of a 
network of pre-mRNAs that encode factors functionally enriched in neuron projection 
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development. Interestingly, disease mutants of PQBP1 lose associations with splicing 
factors and cannot complement the neurite outgrowth defects and aberrant AS patterns 
found in PQBP1-depleted cells. Collectively, this work shows that PQBP1 affects AS of 
many pre-mRNAs and that aberrant splicing caused by malfunctioning of PQBP1 may 
contribute to the pathology of PQBP1-linked neurological disorders.      
Chapter 4 presents a junction-based method for differential analysis of global AS 
under different conditions using RNA-seq data. This method is among the first 
explorations to quantify AS using only read counts that are mapped directly to splicing 
junctions. Statistical methods were developed to perform differential analysis on the 
‘usage’ (number of mapped reads) of competitive AS junctions and decide if significant 
AS changes occur among the junctions between conditions. This method does not depend 
on prior knowledge of the genome annotation and performs a thorough and unbiased 
investigation of AS patterns under different conditions. Moreover, this method integrates 
variability among biological replicates, producing reliable statistical tests of global AS 
changes. Using this method we identified 585 AS events that experience significant 
changes upon PQBP1 knockdown in mouse primary cortical neurons, distributed among 
457 genes. Ten identified potential PQBP1 AS targets were randomly selected for 
experimental validation and all were verified by RT-PCR. One of the experimentally 
validated targets, Ncam1 can only be identified as an AS target of PQBP1 using our 
method but not other currently used bioinformatics tools, due to an extremely short 
alternatively spliced exon in Ncam1. These results demonstrated the specificity and 
sensitivity of our method.     
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Chapter 5 presents a synthetic circuit in mammalian cells that confers memory of 
extracellular stimuli based on the auto-regulatory feedback loop from the splicing 
regulation of Sex-Lethal (Sxl), the Drosophila sex determination master gene. We show 
that the positive feedback loop of Sxl regulating the splicing of its own pre-mRNA can be 
transported from Drosophila to mammalian cells. Furthermore, with quantitative 
modeling and experimental data, we show that this positive feedback loop can serve as a 
device to rapidly establish memory of transient exposure to doxycycline stimuli in 
mammalian cells. This memory device can be applied to the study of disease 
development in progressive disorders, such as investigating the long-term effects of 
transient hypoxia stimuli in early cancerous cells. 
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ABSTRACT 
Alternative splicing is a vast source of biological regulation and diversity that is 
misregulated in cancer and other diseases. To investigate global control of alternative 
splicing in human cells, we analyzed splicing of mRNAs encoding Bcl2 family apoptosis 
factors in a genome-wide siRNA screen. The screen identified many regulators of Bcl-x 
and Mcl1 splicing, notably an extensive network of cell-cycle factors linked to aurora 
kinase A. Drugs or siRNAs that induce mitotic arrest promote proapoptotic splicing of 
Bcl-x, Mcl1, and caspase-9 and alter splicing of other apoptotic transcripts. This response 
precedes mitotic arrest, indicating coordinated upregulation of prodeath splice variants 
that promotes apoptosis in arrested cells. These shifts correspond to posttranslational 
turnover of splicing regulator ASF/SF2, which directly binds and regulates these target 
mRNAs and globally regulates apoptosis. Broadly, our results reveal an alternative 
splicing network linking cell-cycle control to apoptosis. 
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INTRODUCTION 
Nearly all human precursor messenger RNAs (pre-mRNAs) undergo alternative 
splicing (AS), with tremendous variation and specificity across tissues, development, and 
disease (Pan et al. 2008). This vast complexity is a formidable challenge to experimental 
and informatic analysis of AS and its physiological roles (Blencowe 2006). One emergent 
concept is that functionally coherent transcript populations, termed RNA “regulons,” are 
coregulated by dedicated RNA-binding proteins (RBPs) to promote specific biological 
functions (Keene 2007). These RBPs, notably SR proteins and hnRNPs, “decode” 
transcript cis elements and control stepwise assembly of spliceosomal snRNPs: U1 at the 
5’ splice -site (ss), then U2 near the 3’ ss, and finally U5/4/6 (Wahl et al. 2009; Black 
2003). Splicing control is integrated with signal transduction pathways, promoting 
dynamic, context-driven regulation. Collectively, these features produce robust cell- and 
tissue-specific signatures of exon use that shape many aspects of cell fate (Moore and 
Silver 2008). Exon signatures are radically transformed in tumors, but the causes and 
consequences are unknown. 
In this study, we examine AS of Bcl2 family apoptosis regulators Bcl-x and Mcl1. 
Bcl2-like proteins contain up to four Bcl2-homology (BH) domains (BH1–4) (Hardwick 
and Youle 2009). Factors possessing all four BH domains, including Bcl2, Bcl-xL, and 
Mcl1L, antagonize apoptosis by preventing mitochondrial outer membrane 
permeablization (MOMP), thus sequestering proapoptotic factors in mitochondria. 
Factors lacking one or more BH domain, including Bid, BAD, and BAX, are 
proapoptotic and promote MOMP. A finely tuned balance of pro- and antiapoptotic Bcl2-
like factors therefore controls mitochondrial integrity and hence downstream steps in 
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apoptosis such as apoptosome formation and caspase activation (Wang and Youle 2009). 
Remarkably, Bcl-x, Mcl1, and some other Bcl2 family mRNAs are alternatively spliced to 
yield both long (L) antiapoptotic and short (S) proapoptotic forms. For Bcl-x, use of an 
alternative 5’ ss in exon 2 excludes the BH1 and BH2 domains (Akgul et al. 2004). For 
Mcl1, exon 2 skipping excludes the BH1 and BH2 domains and eliminates the 
downstream transmembrane domain via frame shift. 
Many cis-regulatory elements and trans-acting factors exert combinatorial control 
of Bcl-x splicing. Most known regulators, including Sam68, ASF/SF2, hnRNP F/H, 
SRp30c, and RBM25, altered Bcl-x AS in vitro or when overexpressed in cell culture 
(Cloutier et al. 2008; Zhou et al. 2008; Paronetto et al. 2007; Garneau et al. 2005). In 
addition, in RNA interference (RNAi)-based loss-of-function assays, depletion of Sam68 
and hnRNPA1 favored Bcl-xL formation, while depletion of U2 snRNP component 
SF3B1/SAP155 favored Bcl-xS (Paronetto et al. 2007; Massiello et al. 2006). 
Comparably little is known of Mcl1 splicing regulation. 
Beyond Bcl2-like factors, caspases, “death receptors,” ligands and various 
adaptors are regulated by AS, suggesting broad roles in controlling apoptosis (Schwerk 
and Schulze-Osthoff, 2005). Many apoptosis regulators, including Bcl2-like proteins, are 
proto-oncogenes that contribute to apoptosis resistance in cancer (Letai 2008; Fesik 
2005). Modulation of apoptotic factors by targeting the splicing machinery is thus an 
attractive strategy to facilitate tumor cell death. Furthermore, while the divergent 
functions of Bcl-x and Mcl1 isoforms in apoptosis are well established, the physiological 
contexts and upstream regulation of their expression are poorly defined. These 
unanswered questions illustrate a pervasive challenge in defining physiological contexts 
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of AS regulation, because strategies for systematic evaluation of upstream regulation are 
limited. 
Genome-scale screening of RNA regulatory events is complicated by the 
difficulty of visualizing RNAs in vivo, and the technical infeasibility of high-throughput 
measurements by RT-PCR and other methods. Splicing-sensitive fluorescent reporters are 
an alternative strategy that produce a robust, visual output suitable for screening efforts 
(Stoilov et al. 2008; Warzecha et al. 2009; Orengo et al. 2006). Here, we present high-
throughput assays that recapitulate physiological regulation of Bcl-x and Mcl1 AS. In a 
whole-genome siRNA screen, we identified new factors that regulate the balance of anti- 
and proapoptotic splice isoforms, with striking enrichment for cell-cycle factors. These 
results define functional interactions between the cell cycle and splicing machineries in 
human cells that manifest in a coordinated program of AS controlling apoptosis. 
 
RESULTS 
Reporter assays for Bcl-x and Mcl1 alternative splicing 
To develop splicing assays for high-throughput analysis, we designed splicing-
sensitive reporters for the Bcl2 family apoptosis regulators Bcl-x and Mcl1. 5’ 
untranslated region (UTR), open reading frame (ORF), and intervening intron sequences 
for Bcl-x and Mcl1 were cloned in C-terminal fusions with Venus (yellow) and mCherry 
(red) complementary DNAs (cDNAs), respectively (Figure 2-1A). In HeLa cells, these 
constructs expressed long and short spliced mRNAs at ratios similar to endogenous 
mRNAs (Figure 2-1B). To render constructs splicing-sensitive, premature termination 
codons (PTCs) were introduced in alternative exon regions exclusive to long splice  
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Figure 2-1: Bcl-x and Mcl1 alternative splicing reporters. 
(A) Bcl-x and Mcl1 minigene splicing reporters are schematized. Green rectangles are exons, with 
dark gray as alternative regions. Black lines depict introns. Large arrows denote translation start 
sites, and arrowheads show primer sets used for qPCR. Inserted PTCs, exclusive to long (L) 
isoforms, are shown by red “stop signs.” 
(B) Minigene constructs are spliced like endogenous mRNAs. Splice isoforms from minigene- or 
mock-transfected (endogenous) HeLa cells were analyzed by RT-PCR with primer sets from (A). 
Because of high transient minigene expression, cDNA from minigene samples was diluted 1:105 
relative to mock (endogenous). At this dilution, endogenous mRNAs do not contribute to 
products in the “minigene” lanes. 
(C) A PTC introduced to the alternative exon region eliminated Bcl-xL-Venus but not Bcl-xS-
Venus protein expression. HeLa cells were transfected with Bcl-x-Venus (PTC-) or Bcl-x-Venus-
PTC (PTC+) constructs, and lysates were analyzed by western with indicated antibodies. 
Migration of isoforms is indicated to the left of images (last two lanes overexposed to show Bcl-
xS-Venus). 
(D) SF3B1 knockdown activated proapoptotic splicing of Bcl-x and Mcl1 reporters. Stable 
reporter lines were transfected with SF3B1 or non-targeting siRNA pools and imaged in the 
indicated channels. SF3B1 knockdown increased minigene expression versus controls in both 
cases. SF3B1 depletion also decreased CFP modestly, possibly reflecting a role in splicing the 
EF1α intron. Subsequent experiments showed this effect on CFP expression was restricted to 
SF3B1 (see Supplemental Figures S2-2B and S2-2F). 
(E) Upregulation of Bcl-xS by SF3B1 depletion was confirmed by western analysis. Lysates from 
cells treated as in (D) were analyzed with antibodies indicated to the left of images. SF3B1 
knockdown depleted SF3B1 and increased Bcl-xS-Venus relative to controls. 
(F) Results in (D) and (E) were verified at the RNA level by RT-PCR. Migration of Bcl-xS, Bcl-
xL (PTC causes nonsense-mediated decay), and GAPDH (loading control) are indicated to left of 
the images. 
(G) Results in (D), (E), and (F) model the regulation of endogenous Bcl-x and Mcl1 mRNAs. 
Unmodified HeLa cells were transfected with SF3B1 or control siRNAs. RT-PCR analysis 
confirmed that SF3B1 knockdown favored short, proapoptotic forms. S/L ratios are quantified to 
the right of the images; values are the means of three independent measurements ± SD, 
normalized to controls. 
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Figure 2-1 (Continued). 
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forms. As expected, PTCs eliminated expression of long protein variants, but short forms 
were retained (Figure 2-1C).  
To produce screen assay cell lines, splicing reporters were stably transfected into 
HeLa cells along with a constitutive mCerulean fluorescent protein (CFP) construct. All 
constructs used the human EF1α promoter, which contains a 5’ UTR intron, allowing 
dual measurements of minigene splicing and a constitutively spliced CFP reporter under 
identical control. To test the Bcl-x reporter line, we verified that siRNA-depletion of 
known regulator SF3B1 increased Bcl-xS-Venus expression relative to a non-targeting 
control (Figure 2-1D, left panels) (Massiello et al. 2006). Immunoblotting confirmed 
efficient siRNA knockdown of SF3B1, and upregulation of Bcl-xS-Venus reporter 
protein (Figure 2-1E). RT-PCR confirmed upregulation of the Bcl-xS-Venus mRNA 
(Figure 2-1F). Finally, RT-PCR analysis of endogenous Bcl-x transcript in HeLa cells 
verified that SF3B1 knockdown shifted splicing toward Bcl-xS, demonstrating congruous 
regulation of minigene and endogenous splicing (Figure 2-1G, upper panel).  
We had no a priori knowledge of Mcl1 regulators, but SF3B1 knockdown also 
upregulated Mcl1S-mCherry in the splicing assay, establishing a positive assay control 
(Figure 2-1D, right panels). Analysis of endogenous Mcl1 verified this shift toward 
Mcl1S (Figure 2-1G, lower panel). 
 
High-throughput siRNA screens for alternative splicing regulators 
To identify regulators of Bcl-x AS, >21,000 siRNA pools targeting known and 
predicted human genes were screened for upregulation of the Bcl-x reporter (Figure 2-
2A). Three hundred and sixty-nine positive hits were identified with a Support Vector  
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Figure 2-2: Whole-genome siRNA screen for regulators of Bcl-x alternative splicing. 
(A) Screening, analysis, and hit selection are schematized. Of 369 primary hits, 274 revalidated. 
The pie chart indicates how many of 274 validated hits reconfirmed with one, two, three, or four 
siRNAs. One hundred and sixty “high-confidence” hits validated with two or more siRNAs (see 
the Supplemental Experimental Procedures for complete analysis methods). 
(B) SVM probability scores are plotted for the whole-genome siRNA screen, with confidence on 
the x axis and strength on the y axis. The blue region shows the SVM cutoff for hit selection (see 
Figures S2-1, S2-2, and S2-3 and Tables S2-1 and S2-2 for detailed analysis and validation). 
(C) GO functional enrichments from primary, revalidated (one or more siRNAs), and high-
confidence (two or more siRNAs) hits are shown, plotted by relative statistical significance. See 
also Figures S2-1, S2-2, and S2-3 and Tables S2-1 and S2-2. 
 
Machine (SVM) model that determined reproducibility (i.e., “confidence”) across 
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triplicates and signal “strength” relative to positive and negative control siRNAs (Figure 
2-2B, and Supplemental Figure S2-1 and Table S2-1). Hits had strong gene ontology 
(GO) enrichments for mRNA splicing/processing, protein kinase signaling, cytoskeleton 
association, and cell-cycle functions (Figure 2-2C). Importantly, the screen blindly 
recovered positive control SF3B1 and several of its interactors. 
For validation, hits were retested in the screen assay with four individual siRNAs 
from deconvoluted SMARTpools. Two hundred and seventy-four of 369 factors 
validated with at least one siRNA, and 160 validated with two or more (Figure 2-2A and 
Table S2-2). In the primary and validation screens, Bcl-x-Venus expression correlated 
significantly with cell death (Figures S2-2A and S2-2C). Venus showed no systematic 
correlation to CFP, indicating that nonspecific promoter effects were not a major source 
of positives (Figures S2-2B and S2-2F). In the validation screen, apoptosis was tracked 
by Annexin-V-Cy5 staining and showed strong coupling to proapoptotic Bcl-x splicing 
and cell death (Figures S2-2D and S2-2E). Functional enrichments, notably splicing and 
cell-cycle regulation, were similar between validated hits and the primary screen (Figure 
2-2C). Subsequent analyses focused on “high-confidence” factors validated with two or 
more siRNAs. We focused specifically on aurora kinase A (AURKA) and other mitotic 
regulators because of their strong functional enrichment and their novelty in the context 
of splicing regulation. 
Physiological function for screen hits was confirmed by analysis of endogenous 
Bcl-x AS in HeLa cells. siRNAs against 19 factors were tested, and 16 (∼85%) 
significantly shifted Bcl-x splicing toward Bcl-xS (Figure S2-3A). The magnitude of these 
shifts matched or exceeded fold changes that promote apoptosis in various cell types,  
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Figure 2-3: Apoptosis inhibition by Bcl2 suppressed a subset of Bcl-x regulators. 
(A) Screen hits (lightning bolts) may affect Bcl-x AS by many potential mechanisms. Regulation 
may be direct, such as (1) direct suppression of Bcl-xS formation or (2) facilitation of Bcl-xL. 
Indirect or downstream regulators may (3) promote cell survival pathways or (4) suppress 
proapoptotic pathways. We predicted that Bcl2 overexpression would suppress the splicing 
regulatory effect of siRNAs targeting indirect mechanisms, but not direct regulators. 
(B) Bcl2 overexpression did not suppress the effect of SF3B1 depletion, consistent with direct 
regulation of Bcl-x splicing. 
(C) Bcl2 suppressed the effect of siRNAs against mRNA export factors NXF1 and NUPL2, but 
not AURKA, on Bcl-x splicing (compare Venus images between “wild-type” and “Bcl2 
overexpression”). By contrast, Bcl2 suppressed cell death in all cases (compare DAPI images). 
(D) Thirty-three percent of hits were suppressed by Bcl2 overexpression, while 67% showed 
partial to no suppression. GO functional enrichments within these subsets are shown with p 
values (see Table S2-3). See also Table S2-3. 
 
indicating physiological significance (Mercatante et al. 2002; Taylor et al. 1999). As 
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further indication of this significance, AURKA knockdown strongly shifted endogenous 
Bcl-x protein toward Bcl-xS (Figure S2-3B). This shift was larger than the corresponding 
mRNA shift, suggesting an amplification effect during translation. Regulation of 
endogenous Bcl-x by AURKA and other hits also confirmed in MCF7 (breast 
adenocarcinoma) and PANC1 (pancreatic carcinoma) cells (Figure S2-3C). These lines 
differ markedly in steady state AURKA levels, with MCF7 (like HeLa) expressing high 
levels, and PANC1 levels closer to “normal” tissue (Ross et al. 2000). Thus, splicing 
regulation by AURKA inhibition was not restricted to HeLa cells and occurred 
irrespective of steady state AURKA levels. 
 
Apoptosis suppression defines direct regulators of Bcl-x alternative splicing 
In screening experiments, proapoptotic Bcl-x splicing correlated to apoptosis 
induction and increased cell death (Figure S2-2). However, screen hits are likely to 
include both direct regulators of Bcl-x splicing and factors that influence splicing 
indirectly via upstream activation of proapoptotic pathways (Figure 2-3A). To define 
systematically the relationship of screen hits to apoptosis, we retested all 274 validated 
regulators in Bcl-x reporter cells engineered to overexpress Bcl2. Bcl2 overexpression 
suppresses mitochondrial permeablization and hence canonical apoptosis progression 
(Kroemer 1997). Importantly, Bcl2 directly antagonizes the function of Bcl-xS, so this 
strategy also suppresses potential downstream effects of Bcl-xS-Venus produced by the 
reporter construct. We predicted that Bcl2 overexpression would attenuate the effects of 
proapoptotic siRNAs that alter Bcl-x splicing as part of a general proapoptotic response, 
but not siRNAs that target more direct regulators of splicing. Supporting the latter 
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prediction, depletion of direct regulator SF3B1 increased reporter expression despite Bcl2 
overexpression (Figure 2-3B). 
Thirty-three percent of 160 high-confidence Bcl-x regulators were totally 
suppressed by Bcl2 overexpression (Table S2-3). For example, Bcl2 suppressed both cell 
death and changes in Bcl-x splicing in response to depleting mRNA export factors NXF1 
or NUPL2 (Figure 2-3C). By contrast, 67% of factors, including AURKA, showed partial 
or no suppression of proapoptotic Bcl-x splicing, despite the fact that cell counts showed 
efficient suppression of cell death. Thus, AURKA, not previously implicated in splicing 
regulation, functioned independently of Bcl2, whereas mRNA export factors, which 
directly interact with the spliceosome, were suppressed. Overall, most mRNA splicing 
and cell-cycle regulators showed no or partial suppression (Figure 2-3D). Suppressed 
factors were enriched for functions in transcription, while signaling factors spanned both 
categories. 
 
Discovery of Mcl1 alternative splicing regulators 
To explore functional coordination of apoptotic AS events, we determined all Bcl-
x regulators that also control functionally analogous AS of Mcl1. Fifty-two of 160 “high-
confidence” factors regulated both events, and we validated a subset on endogenous Mcl1 
(Figure 2-4A, Figure S2-4, and Table S2-4). Cell-cycle functions were enriched for 
factors that coregulated Bcl-x and Mcl1, but not factors that regulated only Bcl-x (Figure 
2-4A). Similarly, common regulators were disproportionately enriched for splicing 
functions versus those that only regulated Bcl-x. This result indicates extensive 
coregulation of Bcl-x and Mcl1 by cell-cycle and splicing factors. In contrast,  
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Figure 2-4: Coordinated regulation of Bcl-x and Mcl1 alternative splicing. 
(A) Bcl-x screen hits were tested for Mcl1 regulation to identify common regulators. 
High-confidence hits are depicted as a Venn diagram, with GO enrichments listed with p values 
in the subsets where they were most significantly enriched (see Figure S2-4 and Table S2-4). 
(B) Spliceosome-associated proteins (SAPs) that were Bcl-x screen hits are shown with 
established physical interactions and functional roles. Blue ellipses represent known RNP or 
protein complexes; pink ellipses contain functionally or structurally related factors. Low-
confidence hits are italicized. Factors in gray rectangle have unknown roles in splicing but were 
identified in proteomic analyses or are similar to known splicing factors (Chen et al., 2007). 
Factors are marked as follows: *, high-confidence hit for Mcl1; underlined, phosphorylated in 
mitosis; +, putative AURKA target; x, putative CDK1 target; and #, putative PLK1 target 
(Dephoure et al., 2008). 
(C) Hits from a kinase/phosphatase screen for Mcl1 splicing regulation are shown, with 
corresponding Bcl-x regulators. A cutoff of p < 10-5 in three replicates, or p < 10-7 in two 
replicates was applied (see Table S2-5). Cell cycle factors are underlined. See also Figure S2-4 
and Tables S2-4 and S2-5. 
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Figure 2-4 (Continued). 
 
 
 
 
52 
transcription regulators were enriched only for Bcl-x. Figure 2-4B schematizes hits in the 
Bcl-x and Mcl1 screens with known or postulated functions in mRNA metabolism. Hits 
included “core” spliceosome components in Sm ring domains and snRNPs, as well as 
hnRNP and SR proteins. Interestingly, factors acting late in spliceosome assembly, 
including U5 snRNP components and factors previously linked to cell-cycle regulation 
(e.g., CDC40, CDC5L), scored positively for both Bcl-x and Mcl1 (Makarova et al. 
2004). 
As an unbiased analysis of Mcl1 AS, we tested siRNA pools for >700 human 
kinases and phosphatases in the Mcl1 screening assay. Common regulators for Bcl-x and 
Mcl1 included cell-!cycle kinases AURKA, PLK1, and WEE1 (Figure 2-4C and Table 
S2-5). Further, BUB1 scored strongly for Bcl-x and weakly positive for Mcl1, though the 
latter did not surpass the confidence threshold. Conversely, CDK1 (CDC2) was strongly 
positive for Mcl1, and weakly so for Bcl-x. These data independently confirm Mcl1 AS 
regulation by cell-cycle disruption. 
 
Coupling of cell-cycle control and alternative splicing 
The screen identified many cell-cycle factors, including cancer therapy targets 
AURKA, PLK1, and survivin (BIRC5). Protein interaction network analysis of screen 
hits revealed AURKA-centered interactions spanning the cell cycle, spliceosome, and 
tumor suppressors (Figure 2-5A). As independent validation of this regulation, 
nocodazole, an inhibitor of microtubule polymerization, and aurora kinase inhibitors 
ZM447439 and VX-680 strongly induced Bcl-xS formation in a dose-dependent manner 
(Figure 2-5B). By contrast, the broad-spectrum kinase inhibitor staurosporine induced  
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Figure 2-5: Alternative splicing regulation is coupled to cell-cycle control. 
(A) Screen hits span an AURKA-centered protein interaction network. Circles (“nodes”) depict 
proteins, connected by lines (“edges”) representing validated protein-protein interactions. A 
maximum of two nonhit bridges was permitted to connect hits to AURKA, as described in the 
Supplemental Experimental Procedures. 
(B) Drugs disrupting the cell-cycle promote proapoptotic Bcl-x AS. Bcl-x reporter cells were 
treated with nocodazole, aurora inhibitors VX-680 or ZM447439, or staurosporine for 18 hr. 3-
fold dilution series were tested with the following maximum concentrations: 200 nM nocodazole, 
10 µM VX-680, 30 µMZM447439, and 33 nM staurosporine. Percent-Venus-positive values for 
drug treatments were normalized to DMSO treatments; plotted values reflect means of 8–12 
measurements± SD. Nocodazole, VX-680, and ZM447439, but not staurosporine, caused 
significant proapoptotic shifts in Bcl-x splicing (p < 0.001). LD50 ranges derived from cell counts 
are shown below the x axis. Wells with >33 nM staurosporine had >95% death, so they were not 
quantified (see Figure S2-5). 
(C) Aurora inhibitors induced mitotic arrest coupled with proapoptotic Bcl-x splicing. Bcl-x 
reporter cells were treated with 3 µM VX-680, 10 µM ZM447439, or DMSO, stained with 
propidium iodide, and analyzed for DNA content and Venus fluorescence by flow cytometry. 
(D) Asynchronous, actively cycling cells from (C) show little to no Bcl-x splicing fluctuations 
relative to arrested cells. 
(E) S phase arrest by double thymidine block did not alter Bcl-x splicing, indicating specificity for 
mitotic arrest. Cells were analyzed as in (C). 
(F) Bcl-x splicing regulation precedes mitotic arrest. Asynchronous or thymidine-synchronized 
cells from (E) were treated with the indicated inhibitors or DMSO. Cells were analyzed by 
automated microscopy 16 hr after thymidine release, precluding an intervening round of mitosis 
for synchronized cells. The response in presynchronized cells confirms a splicing shift upstream 
of mitotic arrest. See also Figure S2-5. 
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Figure 2-5 (Continued). 
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apoptosis but not Bcl-xS formation, demonstrating specific regulation by cell-cycle 
inhibitors. ZM447439 and VX-680 inhibit the three mammalian aurora kinases AURKA, 
AURKB, and germline-restricted AURKC. However, ZM447439 is ∼20-fold more potent 
toward AURKB than AURKA in vitro, while VX-680 is ∼30-fold more potent against 
AURKA (Ditchfield et al. 2005; Harrington et al. 2004). Since Bcl-x splicing regulation 
in screening assays was AURKA specific, VX-680 was used subsequently because of its 
higher specificity for AURKA. Importantly, nocodazole and VX-680 treatment also 
shifted endogenous Bcl-x and Mcl1 splicing (Figure S2-5). 
In flow cytometry experiments, aurora inhibitors induced mitotic arrest 
concomitant with upregulation of the Bcl-x reporter (Figure 2-5C). Bcl-xS-Venus levels 
in actively cycling G2/M cells were slightly higher than in G1, but the difference was not 
significant compared to arrested cells (Figure 2-5D). In addition, S phase arrest by 
double-thymidine block did not affect Bcl-xS-Venus levels, so the splicing response was 
specific to mitotic arrest (Figure 2-5E). Since transcription and splicing are primarily 
silenced in M phase (Shin and Manley 2002), we considered two possibilities: (1) 
splicing changes preceded arrest or (2) a subset of cells underwent an abnormal division 
prior to full arrest, leading to a proapoptotic stress response. To test the latter scenario, 
cells were synchronized by double-thymidine block, released, and treated with VX-680. 
Venus fluorescence was measured 16 hr after thymidine release, thus ruling out an 
intervening mitotic cycle. Figure 2-5F shows the splicing response to VX-680 in 
synchronized cells was comparable to asynchronous cells. Apoptosis induction by 
staurosporine caused no splicing response, regardless of synchronization. These results 
show that stimuli that activate G2/M and spindle checkpoints trigger proapoptotic Bcl-x 
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splicing, but the response precedes actual arrest. 
 
Downstream mechanisms of splicing regulation 
To identify direct splicing regulators downstream of cell-cycle inhibition, we 
examined expression of splicing factors upon AURKA knockdown, focusing on strong 
screen hits or factors previously linked to Bcl-x splicing (Figure S2-6A). Among these 
factors, only ASF/SF2 (SFRS1)—an SR protein previously linked to cell-cycle regulation 
and a strong hit in the primary screen—!showed specific downregulation upon AURKA 
knockdown (Figure 2-6A) (Li et al. 2005). Inhibition of AURKA with VX-680 also 
resulted in dose-responsive downregulation of ASF/SF2 (Figure 2-6B). 
ASF/SF2 mRNA was not significantly reduced upon AURKA inhibition, ruling 
out transcriptional downregulation or effects on RNA stability (Figure S2-6B). However, 
VX-680 treatment reduced exogenous green fluorescent protein (GFP)-tagged ASF/SF2 
in a manner similar to endogenous ASF/SF2, indicating posttranslational turnover as the 
main source of ASF/SF2 depletion (Figure 2-6C). AURKA inhibition also induced 
ASF/SF2 downregulation in apoptosis-resistant cells that overexpress Bcl2 (Figure S2-
6C). Therefore, this regulatory pathway functions in cells where apoptosis is suppressed, 
consistent with our finding that AURKA knockdown shifts Bcl-x splicing when apoptosis 
is suppressed (Figure 2-3C). 
To determine whether Bcl-x is a direct target of ASF/SF2, we used the CLIP 
method (ultraviolet [UV] crosslinking and immunoprecipitation) to analyze RNAs bound 
directly by ASF/SF2 in vivo. RNP complexes were covalently crosslinked in living cells 
by UV exposure, and ASF/SF2-RNA complexes were immunopurified (Figure 2-6D).  
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Figure 2-6: ASF/SF2 regulates splicing downstream of AURKA. 
(A) siRNA depletion of AURKA downregulated ASF/SF2. Cells were transfected with two 
different siRNAs for AURKA or AURKB, or control siRNAs. Lysates were analyzed by western 
analysis for indicated factors. No other splicing factors measured in these samples showed 
significant changes (Figure S2-6A), indicating specificity for ASF/SF2. 
(B) VX-680 treatment downregulated ASF/SF2 in a dose-dependent manner. 
(C) ASF/SF2 is downregulated posttranslationally upon AURKA inhibition (see also Figure S2-
6B). HeLa cells were transfected with a GFP-ASF/SF2 construct, and then treated with VX-680 
or DMSO. Western analysis showed that VX-680 downregulated exogenous ASF/SF2, indicating 
posttranslational turnover. ASF/SF2 downregulation also occurred in apoptosis-resistant cells 
overexpressing Bcl2 (see Figure S2-6C). 
(D) Visualization of ASF/SF2-RNA complexes by CLIP is shown. RNP complexes were UV 
crosslinked in live HeLa cells, ASF/SF2 was immunopurified, and RNA was end labeled with γ-
32P-ATP. Complexes were run on SDS-PAGE and visualized by autoradiography. 
Noncrosslinked ASF/SF2 (UV– lane) was also labeled, as observed in Sanford et al. (2009). 
(E) ASF/SF2 directly binds Bcl-x and Mcl1 mRNAs. RT-PCR analysis of ASF/SF2-bound RNAs 
showed significant enrichment of Bcl-x, Mcl1, and known target TPX2 versus an irrelevant IgG 
control. Values are the means of three independent measurements ± SD. 
(F) Exogenous expression of ASF/SF2 attenuated the effect of AURKA inhibition on Bcl-x 
splicing. Bcl-x reporter cells were transfected with mCherry-tagged ASF/SF2, a mutant lacking 
the second RRM domain (ΔRRM2), or mCherry alone. Eighteen hours after transfection, cells 
were treated with 3 µm VX-680 or DMSO for 24 hr. The fraction of Venus-positive cells among 
mCherry-positive cells was determined by automated microscopy. VX-680-treated samples were 
background corrected by subtraction of values from DMSO treatment. Values are the means of 
three separate measurements ± SD, expressed relative to the mCherry-transfected control. 
ASF/SF2-WT attenuated the Bcl-x response to VX-680 by ~50% versus ΔRRM2. CFP expression 
was not affected, indicating specific attenuation of Bcl-x splicing. 
(G) ASF/SF2-ΔRRM2 shows deficient association with Bcl-x and Mcl1 mRNAs. CLIP analysis 
of exogenous, GFP-tagged ASF/SF2-WT or -ΔRRM2 was performed with α-GFP antisera. 
Values are the means of three independent measurements ± SD. See also Figure S2-6. 
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Figure 2-6 (Continued). 
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RT-PCR analysis showed significant enrichment of Bcl-x mRNA in ASF/SF2-RNA  
immunoprecipitations (IPs) versus an irrelevant IgG control, along with Mcl1 and 
previously known target TPX2 (Figure 2-6E) (Sanford et al. 2009). APAF1 and TNFSF13 
mRNAs were detectable in input but not ASF/SF2 IPs, demonstrating that crosslinking 
was specific. 
Our data show direct regulation of Bcl-x and Mcl1 splicing by ASF/SF2 and 
downregulation of ASF/SF2 by AURKA inhibition. To test whether ASF/SF2 functions 
downstream of AURKA inhibition, we examined whether exogenous ASF/SF2 
expression could “rescue” the splicing response to AURKA inhibition. Bcl-x reporter 
cells were transfected with mCherry-tagged constructs expressing wild-type (WT) 
ASF/SF2 or a variant lacking the second RNA recognition motif (ΔRRM2) domain. After 
VX-680 treatment, the Bcl-x splicing response in cells expressing ASF/SF2-WT was 
reduced ∼50% relative to cells expressing ΔRRM2 or mCherry alone (Figure 2-6F). CLIP 
of exogenous GFP-tagged ASF/SF2 constructs confirmed deficient recognition of 
endogenous Bcl-x mRNA by the ΔRRM2 mutant (Figure 2-6G) (Cáceres et al. 1997). 
Therefore, enforced ASF/SF2 expression rescued the effect of AURKA inhibition on Bcl-
x splicing, and rescue was dependent on intact splicing regulatory function. 
ASF/SF2 regulates apoptosis globally in response to cell-cycle inhibition. 
Consistent with previous reports, siRNA depletion of ASF/SF2 activates markers of 
apoptosis (e.g., Annexin-V staining, DNA fragmentation, and caspase cleavage) (data not 
shown) (Li et al. 2005; Karni et al. 2007). To analyze apoptosis regulation by ASF/SF2 in 
the context of cell-cycle disruption, we depleted ASF/SF2 by RNAi and analyzed 
apoptosis markers upon AURKA inhibition with VX-680. ASF/SF2 depletion enhanced 
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caspase activation and Annexin-V staining relative to a nontargeting siRNA control 
(Figures 2-7A and 2-7B). In addition, we compared the effects of ASF/SF2 depletion to 
the depletion of two splicing factors (SRPK1 and SNRP70) that had no significant effect 
on endogenous Bcl-x splicing and a third factor (Sam68) that has antagonistic effects to 
ASF/SF2 on Bcl-x splicing (Figure S2-3A and Table S2-1) (Paronetto et al. 2007). 
ASF/SF2 depletion sensitized cells to VX-680-induced apoptosis relative to SRPK1, 
SNRP70, or Sam68 depletion. In contrast, ASF/SF2 depletion did not enhance 
staurosporine-induced apoptosis relative to SRPK1, SNRP70, or Sam68 depletion (Figure 
S2-6D). We could not reliably analyze the effects of enforced ASF/SF2 expression on 
apoptotic markers because overexpression was toxic in the time frame required for this 
analysis. In sum, ASF/SF2 loss-of-function triggers apoptosis and specifically sensitizes 
cells to apoptosis induced by AURKA inhibition. 
To examine broader functions of AS in this apoptotic response, we analyzed 
caspase-9 (CASP9) and caspase-2 (CASP2) mRNAs, which produce short (S), 
antiapoptotic, or long (L), proapoptotic isoforms (Schwerk and Schulze-Osthoff 2005). 
Depletion of ASF/SF2 and AURKA favored proapoptotic CASP9 splicing (Figure 2-7C) 
(Massiello and Chalfant 2006). In addition, ASF/SF2 depletion favored proapoptotic 
CASP2 splicing, although AURKA knockdown had no significant effect. We extended 
our analysis to additional factors with diverse apoptotic functions and AS patterns, 
including exon skipping, alternative 5’ ss use, and intron retention. Splice isoforms were 
measured with an isoform-sensitive qPCR strategy upon knockdown of various screen 
hits, revealing widespread changes in splicing upon silencing of cell-cycle regulators 
(Figures 2-7D). This approach is only semiquantitative, so we focused on identifying  
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Figure 2-7: An apoptotic alternative splicing program linked to cell-cycle control. 
(A) ASF/SF2 downregulation triggers apoptosis and sensitizes cells to apoptosis induction by 
AURKA inhibition. HeLa cells were transfected with indicated siRNAs, incubated to allow factor 
depletion, and then treated with varying concentrations of VX-680. Apoptosis was measured via 
cleavage of a fluorescent caspase-3 substrate. Depletion of ASF/SF2, but not SRPK1, SNRP70, 
or Sam68, sensitized cells to VX-680-induced apoptosis. This selective sensitization by ASF/ 
SF2 depletion was not observed for staurosporine-induced apoptosis (see Figure S2-6D). Data 
reflect the means of three independent transfections± SD. 
(B) Analysis in (A) was repeated with Annexin-V staining used as the apoptosis marker. 
(C) CASP9 and CASP2 AS were analyzed in HeLa cells by qPCR after transfection with the 
indicated siRNAs. Relative levels of proapoptotic isoform (L) normalized to negative controls are 
shown. Values are the means of three independent measurements ± SD. 
(D) Results of AS profiling by real-time qPCR are shown in a heat-map of Z scores averaged 
across four biological replicates, along with unsupervised hierarchical clustering (see Figure S2-7 
for an expanded view and validation of these data). 
(E) A model of cell-cycle arrest coupled to apoptosis via AS is shown. We propose anticipatory, 
proapoptotic splicing decisions in interphase that later promote apoptosis in arrested cells. 
Lightning bolts represent siRNAs, drugs, or other stimuli that disrupt the cell cycle and promote 
proapoptotic splicing of Bcl-x, Mcl1, CASP9, and other targets. See also Figures S2-6 and S2-7. 
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Figure 2-7 (Continued). 
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biologically robust events by Z score analysis of four independent experiments (Figures 
S2-7A and S2-7B). Hierarchical clustering of knockdown profiles revealed overlapping 
regulation by cell-cycle kinases AURKA, CDC2, and BUB1. In addition, splicing factor 
profiles grouped by validated spliceosomal interactions; the U2 snRNP factors SF3B1 
and SF3A1 overlapped significantly, as did U5 factors PRPF6 and U5-200K. 
Interestingly, ASF/SF2 targets clustered with AURKA and kinetochore component 
NDC80, suggesting overlapping regulation in this specific set of mRNAs. As 
confirmation of direct regulation, binding of ASF/SF2 to selected targets CASP9, CASP2, 
ATG4, and BMF was established by CLIP (Figure S2-7D). 
 
DISCUSSION 
Genome-wide identification of alternative splicing regulators in human cells 
We developed a strategy for systematic, high-throughput analysis of AS 
regulation in human cells. Our siRNA screens identified many spliceosomal regulators of 
Bcl-x and Mcl1 splicing, as well as functional connections to cell-cycle control, 
cytoskeleton dynamics, and signal transduction (Figure 2-2C). Strong functional 
enrichment for known splicing factors was an encouraging indication of specificity. In 
addition, a high validation rate of screen hits on endogenous AS indicated faithful 
modeling of physiological regulation in our reporter assays (Figure S2-3). Broadly, our 
efforts expand the catalog of factors linking mRNA metabolism and apoptosis and 
provide a platform for future high-throughput analyses of mRNA processing in living 
cells. 
Screen hits spanned essential processes, such as transcription, cell division, and 
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prosurvival signaling, with extensive mechanistic links to apoptosis, implicating splicing 
regulation in diverse proapoptotic pathways. The strong correlation of Bcl-xS formation 
with apoptosis induction and cell death further support a physiological function for 
splicing regulation in apoptosis (Figure S2-2). To investigate the functional connection 
between splicing regulation and apoptosis, we retested factors in cells rendered resistant 
to apoptosis by exogenous Bcl2 expression (Figure 2-3). Surprisingly, cell-cycle factors, 
like most spliceosomal factors, were generally not affected by Bcl2 expression. 
Therefore, functional coupling of cell-cycle disruption to proapoptotic splicing remained 
intact in cells in which the canonical apoptosis pathway was suppressed. This finding 
suggests that coordinated, proapoptotic splicing could be exploited to target apoptosis-
resistant cell populations, such as tumors. 
Our screening experiments also revealed functional coordination of proapoptotic 
splicing events. Fifty-two of 160 “high-confidence” Bcl-x regulators affected functionally 
analogous splicing of Mcl1, and common regulators were disproportionately enriched for 
splicing and cell-cycle functions (Figure 2-4A). Overlapping spliceosomal regulators of 
Bcl-x and Mcl1 included “alternative splicing factors” (e.g., hnRNPs and SR proteins) 
and “core” spliceosome components spanning most steps in spliceosome assembly 
(Figure 2-4B). Interestingly, U5 snRNP and associated factors that function late in 
spliceosome assembly affected splice-site choice for Bcl-x, Mcl1, and other mRNAs 
(Figures 2-4B, 2-7C, and 2-7D). Current mechanistic models support splice-site pairing 
early in spliceosome assembly upon U2 snRNP recruitment (Dassah et al. 2009). Our 
findings suggest that perturbations of late steps in spliceosome function may promote 
remodeling of splice-site choice downstream of the rate-limiting steps that normally 
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determine splicing decisions. 
 
Cell-cycle disruption coupled to proapoptotic alternative splicing  
Our screen for AS regulators identified factors involved in mitotic spindle 
assembly, kinetochore and centromere dynamics, microtubule transport, centrosome 
duplication and dynamics, and cell division (Figure 2-5A). Well-characterized 
pharmacological inhibitors, notably for AURKA, confirmed functional coupling of cell-
cycle and splicing regulation (Figure 2-5B and Figure S2-5). In flow cytometry 
experiments, proapoptotic Bcl-x splicing was coupled to mitotic arrest, but not S phase 
arrest or G2/M in actively cycling cells (Figures 2-5C–2-5E). Since prevailing evidence 
supports suppression of transcription and splicing in mitosis, it is unlikely that the 
observed response initiates in mitotically arrested cells (Shin and Manley 2002). 
Moreover, when cells were presynchronized to preclude an intervening cell division, VX-
680 still induced a robust splicing response (Figure 2-5F). Therefore, this splicing 
regulation precedes mitotic arrest, indicating accumulation of prodeath factors in 
anticipation of G2/M and/or mitotic spindle checkpoints. Since cell-cycle disruption also 
promoted a proapoptotic switch in CASP9 splicing and altered splicing of other apoptotic 
regulators, this regulation likely extends to many coregulated mRNAs (Figures 2-7C and 
2-7D). 
Many previous studies have linked cell-cycle and splicing regulation, reaching 
back to the seminal isolation of cell-division cycle (CDC) loci in S. cerevisiae that 
encode spliceosome components, including factors (CDC5L and CDC40) identified here. 
Recent genetic and proteomic analyses of mitotic spindle assembly have reasserted the 
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notion that the cell-cycle and splicing machineries are intertwined, but functional 
consequences have not been established (Björklund et al. 2006, Rines et al. 2008). We 
observe coordinated proapoptotic splicing upon inhibition of key cell-cycle factors, but 
preceding mitotic arrest, indicating anticipatory upregulation of prodeath factors that may 
subsequently propagate apoptosis in arrested cells. Since arrested cells cannot mount de 
novo transcriptional and splicing responses, this finding suggests a genetic mechanism 
for cell-cycle checkpoint response. 
 
ASF/SF2 regulates an apoptotic splicing network 
We present evidence that ASF/SF2 downregulation mediates a proapoptotic 
splicing response to cell-cycle disruption. ASF/SF2 was a hit in the Bcl-x and Mcl1 
screens, and its overexpression was previously shown to favor Bcl-xL formation 
(Paronetto et al. 2007). AURKA inhibition triggered posttranslational turnover of 
ASF/SF2, but not other SR proteins or splicing factors identified in the screen (Figures 2-
6A–2-6C and Figure S2-6A). In addition, ASF/SF2 directly binds Bcl-x and Mcl1 
mRNAs, and its enforced expression attenuated the effect of AURKA inhibition on Bcl-x 
splicing (Figures 2-6D–2-6G). 
ASF/SF2 regulation extends beyond Bcl-x to global regulation of apoptosis (Li et 
al. 2005). ASF/SF2 depletion, but not depletion of several splicing factors that were not 
validated screen hits, sensitized cells to apoptosis induction by AURKA inhibition 
(Figures 2-7A and 2-7B). In contrast, ASF/SF2 depletion did not specifically enhance 
apoptosis in response to staurosporine (Figure S2-6D). ASF/SF2-mediated splicing 
regulation extended to other functional targets, including CASP9, which underwent a 
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proapoptotic splicing shift upon depletion of AURKA and ASF/SF2 (Figure 2-7C). Our 
analysis of some 25 additional AS targets revealed overlapping effects of AURKA and 
ASF/SF2 inhibition (Figure 2-7D). The fact that some mRNAs (e.g., CASP2) did not 
respond identically to AURKA and ASF/SF2 knockdown may reflect differential effects 
of targeting upstream versus direct regulators of splicing, or the activity of additional, 
unidentified splicing regulators. Nonetheless, these experiments strongly indicate that 
ASF/SF2 downregulation globally shifts alternative splicing patterns to promote 
apoptosis upon disruption of the cell cycle. 
 
Alternative splicing in a global context 
Our data link coordinated proapoptotic splicing to activated cellcycle checkpoints 
(Figure 2-7E). These findings are relevant to basic mechanisms of apoptosis in arrested 
cells, which are poorly defined, and the exploitation of these pathways in cancer therapy. 
Aberrant expression of AURKA and other prodivision factors promotes spindle 
checkpoint abrogation, chromosomal instability, and aneuploidy in tumors (Lapenna and 
Giordano 2009). Our findings indicate that AURKA activation may also propagate 
oncogenesis by promoting antiapoptotic splicing of crucial cell-death regulators. 
Conversely, AURKA inhibition elicits parallel upregulation of prodeath variants, which 
may contribute to its demonstrated efficacy as a cancer drug target. Importantly, this 
regulation remains intact in apoptosis-resistant cells, suggesting functional and potential 
therapeutic relevance in tumors. 
ASF/SF2 downregulation triggers proapoptotic splicing and promotes apoptosis. 
Importantly, ASF/SF2 is a proto-oncogene in its own right, and its depletion is linked to 
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genome instability and G2/M arrest (Karni et al. 2007; Li and Manley 2005). Our data 
highlight RNA targets that may contribute to its transforming properties. Taken together, 
these findings suggest that ASF/SF2 has multiple, synergistic functions in controlling cell 
arrest and apoptosis, underscoring its role as a central regulator!of mRNA metabolism in 
cancer. Finally, it bears reiterating that our systematic screening approach was the 
original source of these biological insights, as well as many new regulators and functional 
connections not expounded here. We believe future screening efforts will be instrumental 
in defining global roles for AS in physiological and disease contexts. 
 
MATERIALS AND METHODS 
siRNA screening 
Cells were transfected in triplicate in 384-well plates with >21,000 siRNA 
SMARTpools (Thermo-Fisher) for known and predicted human genes. Seventy-two 
hours later, cells were fixed, DAPI stained, and imaged on the Image Xpress Micro 
microscope (Molecular Devices). Cell counts (DAPI), percent of Venus-positive cells, 
and average per-cell CFP signal were determined with MetaXpress software. Wells were 
then assigned probabilistic “strength” and “confidence” scores in the Venus channel 
using a support vector machine (SVM) model trained on positive and negative control 
data (Figure S2-1, Table S2-1, and the Supplemental Materials). For independent 
verification, plate-wide, median-normalized Z scores were also tabulated. Wells with 
SVM strength scores with false discovery rate (FDR) <10, or z > 2.6 were inspected 
visually.  
Three hundred and sixty-nine positives were retested in a validation screen with 
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four siRNAs from deconvoluted SMARTpools. siRNAs >2 standard deviations (SDs) 
above negative controls in the Venus channel were deemed positive (Table S2-2). Bcl2-
overexpression and Mcl1 screens were performed and analyzed as for the validation 
screen (Tables S2-3 and S2-4). 
 
RNA extraction and RT-PCR 
Cellular RNA was extracted with Trizol (Invitrogen) reagent, and 2.5–5 µg were 
reverse transcribed with Superscript III (Invitrogen) and oligo-dT. Bcl-x, Mcl1, CASP9, 
and CASP2 isoforms were analyzed by qPCR with primers flanking alternative exon 
sequences. For each product, a linear range of cDNA input was determined empirically 
by running of a 2-fold dilution series in 26–28 cycle reactions. Products were run on 5% 
TBE-PAGE gels, stained with Sybr-Gold (Invitrogen), and quantified with QuantityOne 
software (Biorad).  
Real-time qPCR primer sets were designed with Primer3 webware and tested by 
electrophoresis to verify correctly sized products (Table S2-6). Reactions were prepared 
with Sybr-Green PCR mix (ABI), run on the ABI 7900HT system, and quantified by a 
ΔΔC(t) method. Amplicons from alternative regions were first normalized to a 
constitutive amplicon from the same transcript. To correct for differential primer 
efficiencies, data were then normalized to negative controls. Z scores were tabulated 
across four independent experiments and clustered with Eisen Cluster 2.0. 
 
Splicing assays with drug treatments 
Sources for inhibitors are in the Supplemental Materials. Cells were treated in 96-
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well plates for 18–24 hr and analyzed by automated microscopy. For flow cytometry, 
cells were fixed in 3% PFA/1X PBS then 70% ethanol, permeablized in 1X PBS/0.1% 
Triton X-100, and stained with 20 µg/ml propidium iodide. DNA content and Venus 
fluorescence were analyzed on the LSRII system (BD Biosciences). 
 
Western blotting 
Proteins were extracted in RIPA buffer (IX PBS, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, protease inhibitors) and quantified by Protein Dye-Binding 
Assay (Biorad). Ten to fifty micrograms of total protein were run on 4%–12% Bis-Tris 
polyacrylamide gels (Invitrogen), transferred to PVDF membranes, and probed with 
antibodies listed in Supplemental Materials. 
 
CLIP 
UV crosslinking and RNP purification/visualization were performed as described 
(Sanford et al., 2009). For quantification, CLIP and input samples were treated with 
Proteinase K (Ambion), and RNA was extracted, reverse transcribed, and analyzed by 
real-time qPCR. 
 
Apoptosis assays 
Annexin-V-Cy5 (Abcam) staining was quantified by automated microscopy. 
Caspase activation was measured with the DEVD-Nucview 488 reagent (Biotum), which 
stains nuclei specifically after it is cleaved by caspase-3. Cells were incubated for 1 hr 
with 2.5 µM substrate, fixed, and analyzed by automated microscopy. 
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ABSTRACT 
Polyglutamine binding protein 1 (PQBP1) is a highly conserved protein 
associated with neurodegenerative disorders. Herein, we identify PQBP1 as an alternative 
mRNA splicing (AS) effector, capable of influencing splicing of multiple mRNA targets. 
PQBP1 is associated with many splicing factors including the key U2 snRNP component 
SF3B1. Loss of functional PQBP1 reduced SF3B1-substrate mRNA association and led 
to significant changes in AS patterns. Depletion of PQBP1 in primary mouse neurons 
reduced dendritic outgrowth and altered AS of mRNAs enriched for functions in neuron 
projection development. Disease-linked PQBP1 mutants were deficient in splicing factor 
associations and could not complement neurite outgrowth defects. Our results indicate 
that PQBP1 can affect AS of multiple mRNAs and indicate specific affected targets 
whose splice-site determination may contribute to the disease phenotype in PQBP1-
linked neurological disorders. 
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INTRODUCTION 
Alternative splicing (AS) is a major source for biological diversity and a crucial 
determinant of cell identity and fate. To date, more than 90% of human precursor 
messenger RNAs (pre-mRNAs) are reported to undergo AS, with immense variation 
across tissue types and developmental stages (Wang et al. 2008). The regulation of AS is 
carried out by the interaction of RNA-binding proteins (RBPs), notably hnRNPs and SR 
proteins, with cis-elements in the pre-mRNAs (Black 2003). The dynamics of RBP-cis-
element recognition are further modulated by a wide spectrum of spliceosome-associated 
proteins and are responsive to signal transduction networks (Varani and Nagai 1998; 
Wahl et al. 2009). Tissue-specific AS regulation is especially prominent in the nervous 
system (Castle et al. 2008), where neurons must promptly respond to complex stimuli and 
perform downstream functions with flexibility and precision (Dredge et al. 2001). 
Accordingly, neuron-specific AS networks modulate such diverse functions including 
neurotransmission, receptor activity and ion channel function, and thus impact higher 
brain functions including cognition, coordination and learning (Grabowski and Black 
2001).  
Aberrant AS is a primary cause for many human diseases (Wang and Cooper 
2007). Diverse neurological disorders are closely linked to aberrant splicing and can be 
classified as cis-acting and trans-acting splicing defects (Licatalosi and Darnell 2006). 
Cis-acting defects originate from mutations in the disease-associated gene that change 
sequences important for the correct splicing of the pre-mRNA. A representative example 
is frontotemporal dementia with Parkinsonism linked to chromosome 17, which arises 
from mutations causing mis-splicing of the mRNA for the microtubule-associated protein 
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tau (Licatalosi and Darnell 2006). Trans-acting defects arise from mutations or 
misregulation of splicing regulatory factors. One example is retinitis pigmentosa 
characterized by a progressive loss of rod photoreceptor cells, which results from 
mutations in HPRP3, PRP31, and PRPC8—factors crucial for the assembly and 
functioning of U snRNPs in pre-mRNA splicing (McKie et al. 2001; Vithana et al. 2001; 
Chakarova et al. 2002). Although increasing numbers of splicing-related disorders have 
been identified, the molecular link between AS regulation and the disease phenotype 
remains to be elucidated. 
Polyglutamine binding protein 1 (PQBP1) is a highly conserved protein with 
mutations associated with about 10 familial X-linked mental retardation (XLMR) 
diseases (Kalscheuer et al. 2003; Stevenson et al. 2005). Patients with these diseases 
share similar symptoms such as intellectual deficiency, microcephaly, and short stature 
(Kalscheuer et al. 2003; Stevenson et al. 2005). Although these diseases were separately 
discovered and originally thought to be unrelated, they were recently grouped together as 
“Renpenning Syndrome” because of the common symptomatic manifestation and 
mutations in PQBP1 (Stevenson et al. 2005). 
The molecular function of PQBP1 remains unclear. PQBP1 is linked to 
transcription regulation based on its interaction with RNA Polymerase II and other 
transcription factors (Waragai et al. 1999; Okazawa et al. 2002). Recent studies also 
reported that PQBP1 was dynamically associated with stress granules and interacted with 
dynactin components, indicating a possible role for PQBP1 in RNA transport or 
cytoplasmic RNA processing (Kunde et al. 2011). Also, PQBP1 has been implicated in 
pre-mRNA splicing: PQBP1 interacts with known splicing factors, such as WBP11 and 
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U5-15KD (Komuro et al. 1999; Waragai et al. 2000) and is part of the early spliceosome 
(Makarova et al. 2004). Consistent with this view, a disease-associated mutant of PQBP1 
decreased splicing efficiency (Tapia et al. 2010).  
We previously identified PQBP1 in a screen for factors that affect the AS of the 
mRNA for Bcl-X, a mammalian apoptosis regulator (Moore et al. 2010). Here, we show 
that PQBP1 affects AS of numerous other pre-mRNAs in human cells. In addition, we 
used whole-transcriptome sequencing to identify a global set of PQBP1 AS targets in 
primary mouse neurons, which revealed that PQBP1 coordinates important neuronal 
functions and maintains normal neurite development. Collectively, our findings indicate 
that aberrant AS contributes to the disease pathology of PQBP1-associated neurological 
disorders. 
 
RESULTS 
PQBP1 affects the AS of mRNAs encoding apoptotic factors 
We previously identified PQBP1 as a potential effector for Bcl-x splicing in HeLa 
cells in a genome-wide siRNA screen using a fluorescence-based minigene assay (Moore 
et al. 2010; Figure 3-1A). To verify the effect of PQBP1 on the AS of Bcl-x, we 
examined the splicing of endogenous Bcl-x after depletion of PQBP1 with two different 
siRNAs (Figure 3-1B) using RT-PCR primers flanking the alternatively spliced region 
(Figure 3-1A). As expected, depletion of PQBP1 favored a shift from the anti-apoptotic 
isoform Bcl-xL toward the pro-apoptotic isoform Bcl-xS, via increased usage of an 
alternative 5’ splice site in the second exon (Figure 3-1A,C; Supplemental Figure S3-
1A,B). These results confirmed that PQBP1 affects the AS of Bcl-x in HeLa cells. 
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Figure 3-1: AS targets of PQBP1 in HeLa cells. 
(A) Schematic of Bcl-x. Light rectangles are exons, with dark color marking the alternatively 
spliced region; black lines are introns. Arrows show translation start site; arrowheads mark qPCR 
primer sets. 
(B) Western blot of HeLa cell lysates where PQBP1 is knocked down by siRNA. The control 
sample was treated with a siRNA targeting firefly luciferase mRNA. Antibodies are listed on the 
right. Knockdown with two different siRNAs is shown.  
(C) Gel analysis of RT-PCR of Bcl-x splicing isoforms for control and PQBP1 KD samples is 
shown (left panel), with quantification (right panel). Mean of three independent measurements +/- 
SD are shown. Changes were tested by 1-way ANOVA. **: statistically significant with p-
value<0.01. See also Supplemental Figure S3-1A,B. 
(D) Quantification of real-time PCR data on 14 mRNAs that showed significant AS changes 
between control and PQBP1 KD samples, with Mcl1 (not a target of PQBP1) as the negative 
control. Y-axis depicts the ratio between amplicons for constitutive and alternative exonic 
regions; TPX-2 and CASP6 follow the y-axis on the right side while the rest follow the y-axis on 
the left side. Light columns show the ratio of two amplicons from the control sample and dark 
columns from the PQBP1 KD sample. Mean of three independent measurements +/- SD are 
shown. Difference of the ratio between control and PQBP1 KD samples was analyzed by 1-way 
ANOVA test. ∗: statistically significant with p-value<0.03; ∗∗: statistically significant with p-
value<0.01; n.s.: not significant. See also Supplemental Figure S3-1C. 
 
 
 
 
 
 
 
 
 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 (Continued). 
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We now show that PQBP1 affects additional AS events. We analyzed 31 mRNAs 
encoding apoptosis-related factors with annotated alternatively spliced isoforms. We 
designed primers to amplify the alternatively spliced exonic region and constitutive 
exonic region of each mRNA and the ratio of the two amplicons was compared between 
the control and PQBP1 knockdown (KD) samples by RT-PCR. Approximately half of 
these mRNAs showed significant changes in AS when PQBP1 was knocked down 
(Figure 3-1D; Supplemental Figure S3-1C). These results provided further evidence that 
PQBP1 affects the AS of many mRNAs. 
 
PQBP1 is associated with splicing factors  
To further clarify PQBP1’s role in AS regulation, we systematically determined 
the spectrum of proteins that are associated with PQBP1. In addition, to understand the 
aberrant function of disease-related PQBP1 mutants, we compared the associated protein 
profile of wildtype (WT) PQBP1 and two mutant variants identified in Renpenning 
Syndrome patients.  
PQBP1 protein contains a WW domain, a polar amino-acid rich domain and a 
carboxyl-terminal domain with a nuclear localization signal (NLS) (Waragai et al. 1999; 
Figure 3-2A). The mutations in PQBP1 identified from Renpenning Syndrome patients 
can be classified into two categories: frame-shifting mutations in the AG dinucleotide 
hexamer in the polar amino-acid rich domain and missense mutations in the WW domain 
(Musante et al. 2009). Here, we examined two representative disease-linked variants—
one with an AG di-nucleotide deletion (ΔAG) in the polar amino-acid rich domain 
resulting in a truncated protein and one with a point mutation (Y65C) in the WW domain 
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Figure 3-2: The spectrum of proteins associated with PQBP1 and disease-linked 
mutants. 
(A) Schematics of the protein domain organization of WT PQBP1 and two disease-linked 
mutants. Boxes are protein domains with names shown in the center (WW: WW domain; NLS: 
nuclear localization signal; CTD: carboxyl-terminal domain). Red arrowheads show the mutation 
sites in the disease-linked PQBP1 variants. 
(B) Immunofluorescence (IF) staining of HeLa cells stably expressing FLAG-HA tagged WT 
PQBP1, ΔAG or Y65C. Cells were fixed and stained with antibodies or dyes listed on the bottom 
of each panel column.  
(C) Western blot of HeLa cell lines stably expressing empty FLAG-HA vector, FLAG-HA tagged 
WT PQBP1, FLAG-HA tagged ΔAG and FLAG-HA tagged Y65C. Antibodies used are indicated 
at the bottom of each panel. 
(D) Silver staining of proteins co-purified with FLAG-HA tagged empty plasmid, FLAG-HA 
tagged WT PQBP1, FLAG-HA tagged ΔAG or FLAG-HA tagged Y65C. 
(E) Gene Ontology (GO) term enrichments of proteins that were pulled down with WT PQBP1. 
Statistics were calculated with human genes as the background. X-axis is the corrected p-value 
(fdr) in negative log for enrichment. 
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Figure 3-2 (Continued). 
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(Kalscheuer et al. 2003; Figure 3-2A). PQBP1 localizes predominantly in the nucleus 
(Waragai et al. 1999; Komuro et al. 1999; Kalscheuer et al. 2003; Figure 3-2B). 
Interestingly, both ΔAG and Y65C mutants localize to the nucleus (Figure 3-2B), 
although ΔAG loses a potential NLS (Figure 3-2A) indicating there must be an additional 
unidentified NLS or it enters together with another protein(s). 
Proteins associated with WT PQBP1 were strongly enriched for known or 
potential splicing factors and spliceosome components (Figure 3-2E; Table 3-1). HeLa 
cells expressing stably integrated FLAG-HA tagged full-length PQBP1, ΔAG or Y65C 
were generated by stable integration of retroviral constructs, and shown by Western 
blotting to express exogenous proteins at a level comparable to endogenous PQBP1 
(Figure 3-2C). Tandem affinity purification with FLAG and HA antibodies followed by 
mass spectroscopy was performed to identify PQBP1- or mutant-associated proteins 
(Figure 3-2D; Table 3-1). WBP11, a previously known PQBP1 interactor (Komuro et al. 
1999) was detected in all three replicate purifications of WT PQBP1, confirming the 
validity of our approach (Table 3-1). U5-15KD, another proposed interactor of PQBP1 
(Waragai et al. 2000), was not identified possibly because of cell specificity or the 
interaction is not strong enough to be detected in our tandem affinity purification. ΔAG 
showed significantly reduced splicing factor association compared to WT PQBP1, while 
Y65C lost associations with all splicing-related factors (Table 3-1). These results 
established an association, either direct or indirect, of PQBP1 to the splicing machinery 
and identified the WW domain as important for linking PQBP1 to splicing complexes. 
This finding is consistent with the idea that disease-linked mutations may disrupt splicing 
related functions of PQBP1. 
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Table 3-1. Comparison of associated protein spectrums for WT PQBP1, ΔAG and 
Y65C. 
83 proteins identified to be associated with WT PQBP1, ΔAG or Y65C are listed (Y=associated 
with the corresponding PQBP1 or variants; N=not associated). Associated proteins for each 
PQBP1 protein were first pulled-down by tandem affinity IP and then identified from LC-
MS/MS. The list was further filtered by deleting proteins that appeared also in the empty FLAG-
HA vector control IP sample. The rest are listed, sorted by a general categorization based on their 
functions. 
 
  WT 
PQBP1 
ΔAG Y65C 
Protein Description Entrez Gene 
Symbol 
   
WW domain-binding protein 11  WBP11 Y Y N 
splicing factor 3B subunit 4  SF3B4 Y N N 
splicing factor 3B subunit 3 SF3B3 Y Y N 
splicing factor 3B subunit 2 SF3B2 Y Y N 
splicing factor 3B subunit 1 SF3B1 Y Y N 
splicing factor, suppressor of white-apricot 
homolog  
SFSWAP Y Y N 
serine/arginine-rich splicing factor 7 SRSF7 Y N N 
serine/arginine-rich splicing factor 6 SRSF6 Y Y N 
serine/arginine-rich splicing factor 5 SRSF5 Y N N 
serine/arginine-rich splicing factor 3  SRSF3 Y Y N 
serine/arginine-rich splicing factor 2  SRSF2 Y N N 
serine/arginine-rich splicing factor 1 SRSF1 Y Y N 
serine/arginine repetitive matrix protein 2  SRRM2 Y N N 
serine/arginine repetitive matrix protein 1 SRRM1 Y Y N 
splicing factor 45 RBM17 Y Y N 
RNA-binding protein 14  RBM14 Y N N 
RNA-binding protein 10 RBM10 Y Y N 
signal recognition particle 9 kDa protein SRP9 Y N N 
U2 snRNP-associated SURP motif-containing 
protein  
SR140 Y Y N 
U2 small nuclear ribonucleoprotein A' SNRPA1 Y N N 
survival of motor neuron-related-splicing 
factor 30 
SMNDC1 Y N N 
small nuclear ribonucleoprotein Sm D3  SNRPD3 Y N N 
small nuclear ribonucleoprotein-associated 
proteins B and B' 
SNRPB Y N N 
pre-mRNA-processing-splicing factor 8 PRPF8 Y N N 
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Table 3-1 (Continued). 
    
pre-mRNA-processing factor 19 PRPF19 Y N N 
heterogeneous nuclear ribonucleoprotein U-
like protein 1 
HNRNPUL
1 
Y Y N 
heterogeneous nuclear ribonucleoprotein M HNRNPM Y N N 
heterogeneous nuclear ribonucleoprotein F HNRNPF Y N N 
heterogeneous nuclear ribonucleoprotein D HNRNPD Y N N 
heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 Y N Y 
heterogeneous nuclear ribonucleoprotein A/B HNRNPAB Y N N 
ATP-dependent RNA helicase A  DHX9 Y Y N 
putative pre-mRNA-splicing factor ATP-
dependent RNA helicase DHX15 
DHX15 Y Y N 
probable ATP-dependent RNA helicase 
DDX5 
DDX5 Y Y N 
nucleolar RNA helicase 2  DDX21 Y Y N 
probable ATP-dependent RNA helicase DDX17 Y Y N 
poly(U)-binding-splicing factor PUF60  PUF60 Y N N 
polyadenylate-binding protein 4  PABPC4 Y N N 
protein disulfide-isomerase precursor  P4HB Y N N 
putative RNA-binding protein Luc7-like 2 LUC7L2 Y N N 
la-related protein 1 LARP1 Y N N 
interleukin enhancer-binding factor 3 ILF3 Y Y N 
interleukin enhancer-binding factor 2 ILF2 Y N N 
insulin-like growth factor 2 mRNA-binding 
protein 3  
IGF2BP3 Y N N 
zinc finger CCCH-type antiviral protein 1 ZC3HAV1 Y N N 
X-ray repair cross-complementing protein 6 XRCC6 Y Y N 
X-ray repair cross-complementing protein 5 XRCC5 Y Y N 
THO complex subunit 4 THOC4 Y N N 
heterogeneous nuclear ribonucleoprotein Q SYNCRIP Y N N 
activated RNA polymerase II transcriptional 
coactivator p15  
SUB1 
 
Y Y N 
DNA-binding protein A CSDA Y N N 
calcium homeostasis endoplasmic reticulum 
protein 
CHERP Y Y N 
coiled-coil domain-containing protein 86  CCDC86 Y N N 
hypothetical protein LOC84310  C7orf50 Y Y N 
transcription factor IIB  C16orf80 Y Y N 
high mobility group protein HMG-I/HMG-Y  HMGA1 Y N N 
glutamate-rich WD repeat-containing protein 
1  
GRWD1 Y N N 
guanine nucleotide-binding protein-like 3 GNL3 Y N N 
ubiquitin-like protein fubi and ribosomal 
protein S30 precursor 
FAU Y Y N 
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Table 3-1 (Continued). 
    
eukaryotic translation initiation factor 5B  EIF5B Y Y N 
DNA topoisomerase 2-alpha TOP2A Y Y N 
DNA topoisomerase 2-beta  TOP2B Y N N 
DNA topoisomerase 1  TOP1 Y Y N 
histone H2B type 1-C/E/F/G/I  HIST1H2B
G 
Y Y N 
histone H2A type 1 HIST1H2AI Y N N 
histone H1.3  HIST1H1D Y Y N 
histone H1.5 HIST1H1B Y Y N 
histone H1x  H1FX Y N N 
replication factor C subunit 1 RFC1 Y N N 
protein PRRC2A  PRRC2A Y N N 
serine/threonine-protein phosphatase PP1-beta 
catalytic subunit  
PPP1CB Y N N 
prolyl 4-hydroxylase subunit alpha-1 
isoform1 precursor  
P4HA1 Y Y N 
mRNA turnover protein 4 homolog  MRTO4 Y N N 
MAP7 domain-containing protein 1 MAP7D1 Y N N 
acyl-CoA dehydrogenase family member 11 ACAD11 Y N N 
FACT complex subunit SSRP1  SSRP1 N Y N 
SPATS2-like protein SPATS2L N Y N 
polypyrimidine tract-binding protein 1 PTBP1 N Y N 
histone H2A.Z H2AFZ N Y N 
guanine nucleotide-binding protein G(t) 
subunit alpha-3  
GNAT3 N N Y 
acetyl-CoA acetyltransferase, mitochondrial 
precursor 
ACAT1 N N Y 
GTP-binding nuclear protein Ran  RAN N  N Y 
FERM domain-containing protein 5 FRMD5 N N Y 
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PQBP1 influences SF3B1’s recognition of splicing sites  
To explore the mechanism of PQBP1 in AS regulation, we first examined whether 
PQBP1 directly binds pre-mRNAs whose splicing it affects. Although previous studies 
showed PQBP1 bound to polyrG resin in vitro (Komuro et al. 1999), PQBP1 protein 
itself has no known RNA-binding domains (Figure 3-2A; Lunde et al. 2007). We used the 
CLIP (cross-linking and immunoprecipitation) method to determine if PQBP1 directly 
binds its targets in vivo (Ule et al. 2003). Live HeLa cells were exposed to UV light to 
crosslink RNA-protein complexes, and then PQBP1 was immunopurified from cell 
lysates (Figure 3-3A). RT-PCR quantification of Bcl-x and 9 other target mRNAs (Figure 
3-1D) showed no enrichment in PQBP1 IPs compared to an irrelevant IgG control. These 
results suggest that PQBP1 does not bind AS target mRNAs directly with the caveat that 
it may fail to be effectively cross-linked under the conditions where other known splicing 
factors are observed to bind. 
PQBP1, on the other hand, affects the association of the spliceosome factor 
SF3B1 with a target pre-mRNA. Among the proteins that are associated with PQBP1 are 
the splicing factor 3B (SF3B) protein complex members (Table 3-1), which form part of 
the U2 small nuclear ribonucleoprotein (U2 snRNP). The function of the SF3B complex 
is critical for the assembly of the spliceosome complex A as well as the successful 
execution of the splicing reaction (Wahl et al. 2009). Furthermore, subunit 1 of the SF3B 
complex—SF3B1—was reported to regulate the AS of Bcl-x through direct interaction 
with a cis-element in the Bcl-x mRNA (Massiello et al. 2006). And we observed that 
CLIP with SF3B1 showed a 40 fold enrichment of Bcl-x binding over an IgG control 
(Figure 3-3D, blue column over Bcl-x).  
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Figure 3-3: SF3B1 function is affected by PQBP1. 
(A) Western blot of PQBP1 CLIP together with an irrelevant IgG control, probed with PQBP1 
antibody. PQBP1 was not detected in depleted supernatants or the IgG pulldown, indicating 
efficient and specific antibody binding of PQBP1. 
(B) Western blot of SF3B1 CLIP from PQBP1 KD samples and samples treated with siRNA 
targeting firefly luciferase mRNA as control. Shown are total cell lysates of control (lane 1) and 
PQBP1 KD (lane 2) HeLa cells probed with antibodies indicated on the left side. 
(C) Western blot of SF3B1 CLIP from PQBP1 KD samples and samples treated with siRNA 
targeting firefly luciferase mRNA as control. Lane 1 and 2 are the IgG controls; Lane 3 and 4 are 
SF3B1 CLIP stained by SF3B1 antibody for control and PQBP1 KD samples. 
(D) Quantification of Bcl-x and Mcl1 mRNA enrichment in SF3B1-RNA complex as from SF3B1 
CLIP in control and PQBP1 KD samples respectively by RT-PCR. Data values normalized to the 
IgG control and mean of three independent measurements +/- SD are shown. 
 (E) Proposed model mechanism of PQBP1 AS regulation. A schematic of part of a hypothetical 
mRNA is shown. Orange rectangles are exons and the black line is the intron. “GU” marks the 5’ 
splice site, “A” the branch site recognized by the U2 snRNP with help from components like 
SF3B1 and “AG” the 3’ splice site. Dashed double green lines indicate the association between 
PQBP1 and SF3B1. Through an association with SF3B1 and other splicing factors, PQBP1 
influences the recruitment of U2 snRNP to specific target sites, thus affecting splicing decisions 
on a subset of mRNAs. Loss or mutations of PQBP1 interrupt the splicing factor association and 
the recognition of specific splice sites. See Discussion.  
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Figure 3-3 (Continued). 
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To test if the recognition of Bcl-x by SF3B1 is influenced by PQBP1, we knocked 
down PQBP1 in HeLa cells and re-analyzed the enrichment of Bcl-x in the SF3B1-RNA 
complex (Figure 3-3B,C). PQBP1 depletion led to an 8-fold decrease of Bcl-x mRNA 
levels in SF3B1 CLIP compared to a control knockdown (Figure 3-3D), although the 
level of SF3B1 protein remained unchanged (Figure 3-3B) and the steady state level of 
Bcl-x mRNA did not change upon PQBP1 KD (Supplemental Figure S3-2).  
To further test if PQBP1’s impact on SF3B1-RNA recognition is specific to the 
targets of PQBP1, we analyzed the mRNA of Mcl1 in the SF3B1-RNA complex. Like 
Bcl-X, Mcl1 is a mammalian apoptosis regulator and has two splicing isoforms, anti-
apoptotic Mcl1-L and pro-apoptotic Mcl1-S (Akgul et al. 2004). However, while 
knockdown of SF3B1 significantly shifted the splicing of Mcl1 towards Mcl1-S (Moore 
et al. 2010), PQBP1 knockdown had little affect (Figure 3-1D; Moore et al. 2010). We 
therefore hypothesized that the knockdown of PQBP1 should have relatively minor 
influence on Mcl1 mRNA enrichment in the SF3B1-RNA complex. Indeed, CLIP data 
showed only a 1.4 fold decrease of Mcl1 mRNA enrichment in the SF3B1-RNA complex 
in PQBP1 KD sample compared to control (Figure 3-3D). Additionally, the decrease was 
mostly likely due to Mcl1 mRNA steady state level change of 1.5-fold (Supplemental 
Figure S3-2). Therefore, PQBP1 influenced the recognition of SF3B1 to one mRNA 
whose AS is affected by PQBP1, but not for an mRNA where AS was regulated by 
SF3B1 but not PQBP1. These results do not rule out possibilities that PQBP1 may affect 
mRNA AS through other interactions, or that other splicing factors may assist in the 
process.  
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Loss of PQBP1 causes defects in neurite outgrowth 
Previous work found that PQBP1 is most highly expressed in the central nervous 
system of embryonic or newborn rodents, with the peak around birth (Qi et al. 2005). 
Considering the tissue-specific expression pattern of PQBP1 as well as its disease 
association, we examined the role of PQBP1 in AS modulation in embryonic rodent 
neurons. 
PQBP1 is highly expressed in embryonic mouse cortical and hippocampal 
neurons as shown by Western blots (Figure 3-4A). In addition, PQBP1 localizes 
predominantly in the nucleus of neurons (Figure 3-4B, upper panels), as shown 
previously in other cell types (Waragai et al. 1999; Komuro et al. 1999; Kalscheuer et al. 
2003). A closer examination demonstrated that PQBP1 co-localizes with SC35—a 
splicing factor in nuclear speckles, a nuclear domain enriched for splicing regulatory 
factors (Figure 3-4B, lower panels; Supplemental Figure S3-3A; Spector and Lamond, 
2011). 
To understand the importance of PQBP1 in neuron development, we knocked 
down PQBP1 in mouse embryonic primary cortical neurons with shRNAs delivered by 
lentivirus (Figure 3-4C). Neurons were first examined by immunostaining of the 
microtubule-associated protein 2 (MAP2), a marker for dendrites. Interestingly, upon 
PQBP1 KD the number of projections and length of neurites were decreased and the 
connection between neurons degenerated considerably (Figure 3-4D). A second shRNA 
against PQBP1 led to a similar defect in neurite morphology (Supplemental Figure S3-
3B,C). To determine if this defect is simply due to cell apoptosis, we compared the 
number of DAPI-stained intact nuclei after fixation as well as the percentage of  
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Figure 3-4. PQBP1 affects dendritic outgrowth and branching in mouse cortical 
neurons. 
(A) Western blot of PQBP1 expression in mouse embryonic cortical and hippocampal neurons, 
compared to endogenous β-actin expression. 
(B) IF staining of mouse embryonic primary cortical neurons (the four upper panels) and rat 
embryonic primary cortical neurons (the three lower panels). Neurons were fixed and stained with 
antibodies or dyes listed on top of each panel. See also Figure S3-3A. 
(C) Western blot of mouse embryonic cortical neurons infected with virus from a non-targeting 
control shRNA or a PQBP1-targeting shRNA. See also Figure S3-3B. 
(D) IF staining of mouse primary embryonic cortical neurons 5 days after infection with virus 
from a non-targeting control shRNA or a PQBP1-targeting shRNA. Green: MAP2 staining; blue: 
DAPI staining. See also Figure S3-3C. 
(E) Comparison of the number of intact nuclei between neuron samples 5 days after infection 
with virus from a non-targeting control shRNA or a PQBP1-targeting shRNA. Neurons were 
fixed and stained with DAPI. Healthy and intact nuclei were counted for each sample. Mean of 
eight independent measurements +/- SD are shown. Difference in the number of intact nuclei 
between control and PQBP1 KD samples was analyzed by 1-way ANOVA test. n.s.: not 
significant 
(F) Comparison of the percentage of Annexin-V–stained neurons between samples infected with 
virus from a non-targeting control shRNA or a PQBP1-targeting shRNA. The number of neurons 
with Annexin V staining and the percentage of Annexin-V–positive neurons were calculated and 
normalized to neuron samples that were not treated by virus. Y-axis depicts the fold of the 
percentage of Annexin-V–positive neurons in control or PQBP1 KD samples to samples that 
were untreated. Neurons on day 3 and day 6 after infection/plating were studied. Mean of six 
independent measurements +/- SD are shown. Difference in the percentage of Annexin-V–
positive neurons between control and PQBP1 KD samples was analyzed by 1-way ANOVA test. 
n.s.: not significant 
(G) IF of individual neurons that were transiently transfected with either a non-targeting control 
shRNA or a PQBP1-targeting shRNA together with a GFP-vector. Neurons were grown on a 
layer of feeder glial cells and were examined 5 days after transfection. 
(H) Sholl analysis of dendritic branching for neurons transiently transfected with a non-targeting 
control shRNA or PQBP1-targeting shRNA together with a GFP-vector. Concentric circles were 
drawn at intervals of 5 µm. The number of dendritic branch intersections with each concentric 
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circle was counted (mean ± S.E., n=16-17). The x-axis depicts the distance of the concentric 
circle from the neuron soma center and the y-axis depicts the number of intersections the 
corresponding circle encounters with dendrites.  
 
 
 
Figure 3-4 (Continued). 
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Annexin-V–stained cells between control and PQBP1 KD neurons (Figure 3-4E,F). No 
significant differences were observed, indicating that the defects observed from PQBP1 
KD are not from neuron apoptosis.  
PQBP1 KD neurons showed substantially diminished dendrite branching and 
dendrite length (Figure 3-4G,H). To quantify the changes in neurite outgrowth, we 
transiently transfected neurons with a non-targeting control shRNA or a PQBP1-targeting 
shRNA together with a GFP vector (Figure 3-4G). Sholl analysis was then performed on 
neurons that were GFP-highlighted for control and PQBP1 KD (Figure 3-4H; Sholl, 
1953). 
To confirm that the dendritic outgrowth defect observed was a direct effect of 
PQBP1 KD, we examined whether the defect could be rescued by re-expressing WT 
PQBP1 in comparison to the disease-associated PQBP1 mutants. shRNA-resistant, 
FLAG-HA-tagged cDNAs encoding human PQBP1, ΔAG and Y65C were co-expressed 
in mouse cortical neurons with shRNAs targeting endogenous mouse PQBP1 (Figure 3-
5A; Supplemental Figure S3-3D). Western blots confirmed the knockdown of 
endogenous mouse PQBP1 and the concomitant expression of exogenous dual-tagged 
human PQBP1 and variants (Figure 3-5B). Total PQBP1 expression in all three rescue 
samples was compatible with the level of PQBP1 in the control sample, with the 
exception of ΔAG, which reached only 68% of the control (Figure 3-5B). To 
quantitatively compare neurite outgrowth between mutant PQBP1 and WT rescue, we 
transfected mouse cortical neurons with the rescue constructs (Figure 3-5C) and 
performed Sholl analysis after five days. A significant restoration of dendrite density and 
length was observed in WT PQBP1 rescued neurons, while ΔAG and Y65C showed less 
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improvement (Figure 3-5D,E,F). In the case of ΔAG, it is possible that insufficient 
expression of ΔAG may contribute to the deficiency of rescue.  
Combining the results above, we conclude that PQBP1 is important in 
maintaining neurite projection and outgrowth in neuron development. Moreover, 
deviation in neurite structure may be part of the defects brought about by the disease-
associated mutants of PQBP1.  
 
Coupling of neuron projection and PQBP1 function 
Dendrite structure is the crucial basis for neuron network formation and 
information processing. To clarify the molecular function of PQBP1 in maintaining 
neurite outgrowth, we systematically profiled the AS targets of PQBP1 in mouse 
embryonic cortical neurons by RNA-seq.  
We considered RNA-seq reads that were directly mapped over splice junctions as 
the most straightforward evidence to quantify the splicing changes. For each splice 
junction, a 5’ initiation site (5’ IS) is defined as the final nucleotide position of the 
upstream exon, and the 3’ end site (3’ ES) is defined as the first nucleotide position of the 
downstream exon (Figure 3-6A). An AS event is then defined as a set of junctions that 
share the same 5’ IS or the same 3’ ES, with each junction in the set referred to as a sub-
AS-junction (Figure 3-6A). This definition covers all 6 primary AS patterns except for 
intron retention, which was not considered in our analysis (Figure 4-2; Black 2003). An 
AS event under an experimental condition is represented by the distribution of read 
counts mapped to each sub-AS-junction within the AS event—i.e., the ‘usage’ of each 
sub-AS-junction under that condition. We developed methods to identify AS events that  
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Figure 3-5: WT PQBP1 but not the mutants rescues the neuron morphological 
defects 
(A) Schematic of the pLKO.1-derived lentiviral constructs used to generate viruses for the rescue 
experiments. See also Figure S3-3D. 
(B) Western blot of neuron samples that were infected with virus from an unmodified PQBP1-
targeting shRNA, a non-targeting control shRNA, or PQBP1-targeting shRNA constructs co-
expressing exogenous WT PQBP1, ∆AG or Y65C. Antibodies used are listed on the right. 
Quantification of total PQBP1 level for each sample compared to control is shown below each 
lane.  
(C) IF of individual neurons that were transiently transfected with PQBP1-targeting shRNA 
constructs co-expressing exogenous WT PQBP1, ∆AG or Y65C together with a GFP-vector. 
Neurons were grown on a layer of feeder glial cells. 
(D-F) Sholl analysis of dendritic branching for neurons that were transiently transfected with a 
non-targeting control shRNA, an unmodified PQBP1-targeting shRNA, or PQBP1-targeting 
shRNA constructs co-expressing WT PQBP1 (D), ∆AG (E) or Y65C (F) (mean ± S.E., n=10-17). 
 
 
 
 
 
 
 
 
 
 
101 
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experienced significant differential ‘usage’ of any sub-AS-junction between control and 
PQBP1 KD conditions (for details, see Chapter 4), and defined these AS events as AS 
targets of PQBP1. In total, 457 targets were identified in the process (Figure 4-3; 
Supplemental Table S4-1).  
To validate PQBP1 targets identified by RNA-seq, we picked 10 candidate targets 
together with two candidate non-targets from the analysis and designed primers to 
amplify each splicing isoform of each gene. We then compared the ratio of the isoform 
expression levels by RT-PCR for control and PQBP1 KD samples. All 10 identified 
targets exhibited significant AS shift upon PQBP1 KD while the two non-targets showed 
no discernible changes (Figure 3-6B). This result demonstrated the sensitivity and 
specificity of our computational method to identify AS targets of PQBP1.  
The PQBP1 AS targets showed tissue-specific functional enrichment, with strong 
Gene Ontology (GO) enrichments for neuron projection development/morphogenesis, 
dendrite development and axonogenesis (Figure 3-6C; Supplemental Table S3-1), versus 
genes that were expressed in mouse embryonic cortical neurons profiled from the RNA-
seq data. This observation was in accordance with the neurite outgrowth defect observed 
when PQBP1 was knocked down (Figure 3-4D,G,H). Targets of PQBP1 also showed 
strong enrichment in RNA splicing, synaptic transmission, chromatin modification, cell-
cell signaling, phosphate metabolic process, neurotransmitter transport and ADP-
ribosylation factor (ARF) protein signal transduction (Figure 3-6C; Supplemental Table 
S3-1). The GO term enrichment profile for PQBP1’s AS targets is specific compared to 
high-throughput studies on other proteins in neurons, especially RNA splicing, chromatin 
modification, dendrite development related functions, and ARF signal transduction (Ule  
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Figure 3-6: PQBP1’s AS targets in mouse embryonic cortical neurons. 
(A) A schematic of a defined AS event and quantification of splicing changes. A hypothetical 
alternatively spliced mRNA is shown, with light rectangles representing exons and black lines 
between exons representing introns. The middle exon is the alternatively spliced exon. 5’ IS is the 
start of a splicing junction and 3’ ES the end of the junction. The AS event shown here includes 
two sub-AS-junctions that share the same 5’ IS. Light dashed short lines mark RNA-seq reads 
that are mapped to sub-AS-junction-1 and dark solid short lines mark reads mapped to sub-AS-
junction-2. The distribution of reads mapped to the two sub-AS-junctions was used for AS 
quantification in our analysis. See also Chapter 4. 
(B) RT-PCR validation of 10 randomly picked AS events identified as PQBP1 targets and 2 
randomly picked AS events identified as non-PQBP1-targets in the computational analysis. Abat1 
and Icmt were predicted non–PQBP1-targets. The y-axis depicts the ratio between isoform 1 and 
isoform 2. Dlgap4, Tmod3, Adam15 and Dclk1 follow the y-axis on the right side while the rest 
follow the y-axis on the left side. Mean of three independent measurements +/- SD are shown. 
Differences between control and PQBP1 KD samples were analyzed by 1-way ANOVA test. ∗: 
statistically significant with p-value<0.05; ∗∗: statistically significant with p-value<0.01; n.s.: not 
significant. 
(C) GO term functional enrichment of AS targets of PQBP1. Statistics were calculated with all 
genes that are expressed in mouse embryonic cortical neurons (profiled from RNA-seq data) as 
the background. The GO term enrichment profile here is specific compared to RNA-seq studies 
for other proteins in neurons (see text). X-axis is the corrected p-value (fdr) in negative log for 
enrichment. See also Supplemental Table S3-1. 
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Figure 3-6 (Continued). 
RNA splicing
Cell-cell signaling
Synaptic transmission
Chromatin modification
Transmission of nerve impulse
Neuron projection development
Neuron differentiation
Neurotransmitter secretion
Regulation of ARF protein signal transduction
Phosphate metabolic process
Axonogenesis
Cellular component 
organization at cellular level
Dendrite development
Neuron projection morphogenesis
significance, -log (fdr)
0 2 4 6
A B
C
sub_AS_junction_1
sub_AS_junction_2
5' IS
5' IS
3' ES
3' ES
an AS event
Control
PQBP1 KD
0
2
4
6
8
10
12
0
1
2
3
Ab
at1Icm
t
Nc
am
1
Sn
ap2
5
Nrc
am
Ag
ap3Cd
h5
Sn
ca
Dlg
ap4
Tm
od3
Ad
am
15
Dc
lk1
n.s.n.s.
iso
fo
rm
 1
/ is
of
or
m
 2
 
 
 
 
105 
et al. 2005; Gehman et al. 2011; Charizanis et al. 2012). Bcl-x AS is not conserved from 
human to mouse, and was not identified as a target in this analysis. Among the 14 AS 
targets identified in HeLa cells that were related to apoptosis control (Figure 3-1D), only 
the mRNA of BCLAF1 was recognized as an AS target of PQBP1 in mouse neurons, 
indicating the tissue specificity of PQBP1’s regulation in AS.  
Considering the physical and potential functional association of PQBP1 and 
SF3B1, we also knocked down SF3B1 in mouse cortical neurons and examined the AS of 
the 10 verified targets of PQBP1 (Supplemental Figure S3-4A). Interestingly, all 10 
targets also showed a significant AS shift upon SF3B1 KD (Supplemental Figure S3-4).  
Among the top hits of PQBP1 AS targets was NCAM-140, a major isoform of 
Neural Cell Adhesion Molecules 1 (Ncam1) (Figure 3-6B). Specifically, a 30nt-exon 
between exon 7 and 8 is alternatively spliced in NCAM-140 and is designated VASE 
(Variable Alternatively Spliced Exon) (Figure 3-7A). The VASE-excluding isoform of 
NCAM-140 (VASE –) promotes neurite outgrowth while the VASE-including isoform 
(VASE +) inhibits neurite outgrowth (Doherty et al. 1992). The embryonic brain mainly 
expresses VASE – with gradual ascendancy until final dominance of VASE + expression 
toward adulthood, except in regions such as the olfactory bulb where reformation of 
synapses and turnover of neurons continue (Small and Akeson 1990). Thus, the AS of 
VASE in NCAM-140 is a critical switch for neuronal plasticity. To confirm PQBP1’s 
affect on VASE, we designed primers flanking the VASE exon and examined VASE + 
and VASE – isoforms by RT-PCR and electrophoresis (Figure 3-7A). VASE + was 
increased upon PQBP1 KD, while VASE – decreased (Figure 3-7B), resulting in a 
significant decrease in the ratio of VASE –/VASE + expression in response to PQBP1 
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shRNA versus a control hairpin (Figure 3-6B, Ncam1). These results were confirmed 
with a second shRNA targeting PQBP1 (Supplemental Figure S3-5). 
As a further confirmation that PQBP1 impacts the AS of NCAM-140, we 
examined AS of NCAM-140 after PQBP1 KD in neurons co-expressing the WT PQBP1, 
ΔAG and Y65C constructs from Fig. 5A. Interestingly, neurons rescued with WT PQBP1 
restored the ratio of VASE –/VASE + to levels observed in control samples (Figure 3-
7C). In contrast, ΔAG and Y65C were less effective in correcting the VASE –/VASE + 
ratio (Figure 3-7C).  
To test whether NCAM-140 is one of the PQBP1 targets responsible for the 
defects observed in cells lacking PQBP1, we examined the effect of restoring the ratio of 
VASE – and VASE +. We co-expressed VASE – under the hPGK promoter in the 
lentiviral shRNA vector as described above (Figure 3-5A). Knockdown of PQBP1 was 
verified by western blot (Figure 3-7D) and the change in the ratio of VASE –/VASE + by 
RT-PCR (Figure 3-7E). Neurons were transfected with the rescue construct (Figure 3-7F) 
and Sholl analysis on transfected neurons displayed a significant recovery from the 
neurite outgrowth defect caused by PQBP1 KD (Figure 3-7G). These results confirm the 
role of PQBP1 in the AS of NCAM-140 and modulating neurite outgrowth. 
 
DISCUSSION 
In this work, we have shown that the disease-associated factor PQBP1 plays a 
role in the AS of mRNAs. We demonstrated that PQBP1 associates with core 
spliceosome components and has a protein association network enriched for other 
splicing factors. Following downregulation of PQBP1, we observed aberrant splicing  
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Figure 3-7: PQBP1-modulated AS of NCAM-140 influences neurite outgrowth. 
(A) A schematic of alternatively spliced region of NCAM-140. Green rectangles are exons and 
black lines are introns. The gray rectangle marks the Variable Alternatively Spliced Exon 
(VASE). Arrowheads are primers designed for RT-PCR and electrophoresis. 
(B) NCAM-140 VASE splicing isoforms for neuron samples infected with virus from a non-
targeting control shRNA or a PQBP1-targeting shRNA were analyzed by RT-PCR and gel 
electrophoresis. See also Supplemental Figure S3-5. 
 (C) RT-PCR quantification for VASE – and VASE +. The ratio of the two isoform levels are 
compared among neurons infected with virus from a non-targeting control shRNA, an unmodified 
PQBP1-targeting shRNA, or PQBP1-targeting shRNA constructs co-expressing exogenous WT 
PQBP1, ∆AG or Y65C. Mean of three independent measurements +/- SD are shown. Differences 
between samples were analyzed by 1-way ANOVA test. ∗∗: statistically significant with p-
value<0.01 
(D) Western blot of neurons infected with virus from a non-targeting shRNA, an unmodified 
PQBP1-targeting shRNA, a PQBP1-targeting shRNA construct co-expressing exogenous WT 
PQBP1, or a PQBP1-targeting shRNA construct co-expressing exogenous VASE – to restore the 
ratio of VASE –/VASE +. 
(E) RT-PCR quantification for VASE – and VASE + expression levels of neurons infected with 
virus from a non-targeting shRNA, an unmodified PQBP1-targeting shRNA, or a PQBP1-
targeting shRNA construct co-expressing exogenous VASE – to restore the ratio of VASE –
/VASE +. Mean of three independent measurements +/- SD are shown. Differences between 
samples were analyzed by 1-way ANOVA test. ∗∗: statistically significant with p-value<0.01. 
(F) IF of individual neurons that were transiently transfected with a PQBP1-targeting shRNA 
construct co-expressing exogenous VASE – to restore the ratio of VASE –/VASE + together with 
a GFP vector. Neurons were grown on a layer of feeder glial cells. 
(G) Sholl analysis of dendritic branching for individual neurons that were transiently transfected 
with a non-targeting control shRNA, an unmodified PQBP1-targeting shRNA, or a PQBP1-
targeting shRNA construct co-expressing exogenous VASE – to restore the ratio of VASE –
/VASE + (mean ± S.E., n=15-17). 
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Figure 3-7 (Continued). 
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profiles for many mRNAs in both human cells and primary mouse cortical neurons. 
Specifically in neurons, mRNA profiling showed preferential misregulation of AS in 
factors that are important for neurite outgrowth, which is defective upon PQBP1 
depletion. Collectively, we show that PQBP1 has a role in AS, and indicates aberrant AS 
as a possible mechanism underlying the symptoms of neurological disorders associated 
with PQBP1.   
 
PQBP1 affects alternative splicing 
Our work presents several lines of evidence that PQBP1 affects AS of many pre-
mRNAs. Previous work has indicated an association of PQBP1 with mRNA processing 
factors (Waragai et al. 1999; Okazawa et al. 2002; Komuro et al. 1999; Waragai et al. 
2000). We discovered that PQBP1 co-localizes with SC35 in nuclear speckles (Figure 3-
4B; Supplemental Figure S3-3A), which are nuclear subdomains enriched for many 
splicing regulatory factors (Spector and Lamond 2011). Moreover, profiling of PQBP1-
associated proteins revealed a set of factors highly enriched in splicing regulators and 
spliceosome components (Figure 3-2E; Table 3-1). Among these binding partners, we 
also identified WBP11, a previously reported interactor of PQBP1 (Table 3-1; Komuro et 
al. 1999). These results support PQBP1’s connection with the splicing machinery.  
 
PQBP1 affects U2 snRNP component SF3B1 function 
We observed that PQBP1 did not associate with functional AS target mRNAs in 
vivo in CLIP experiments suggesting it does not bind directly to the AS targets identified 
in HeLa cells (Figure 3-3A) consistent with its apparent lack of known RNA-binding 
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domains (Figure 3-2A). SF3B1, which was previously shown to directly bind substrate 
mRNAs and affect Bcl-x AS (Gozani et al. 1998; Massiello et al. 2006) and was herein 
identified in PQBP1 affinity purifications (Table 3-1), constituted a prime candidate to 
work together with PQBP1. Consistent with this hypothesis, depletion of PQBP1 
decreased SF3B1’s association with Bcl-x mRNA (Figure 3-3D). In contrast, the binding 
of SF3B1 to Mcl1, a target of SF3B1 (but not of PQBP1) was not affected by the 
knockdown of PQBP1 (Figure 3-3D). These findings suggest that PQBP1 affects the 
association of SF3B1 with a distinct subset of substrate mRNAs. Further, we found that a 
subset of PQBP1 targets affected in their splicing was similarly influenced by the 
knockdown of SF3B1 (Supplemental Figure S3-4). SF3B1 is a central component of the 
U2 snRNP. Recruitment of U2 snRNP to the intronic branchpoint sequence (BPS) is a 
key step in the assembly of the spliceosomal A complex, and thus the selection of splice 
sites (Wahl et al. 2009). We propose a model whereby through an association with 
SF3B1, PQBP1 influences the recruitment of U2 snRNP to specific target sites, thus 
affecting splicing decisions on a subset of mRNAs (Figure 3-3E). The precise mechanism 
by which this occurs remains to be explored. 
 
PQBP1 affects AS of mRNAs in neurons 
Depletion of PQBP1 causes a decrease in outgrowth and branching of dendrites in 
mouse primary cortical neurons (Figure 3-4G,H; Supplemental Figure S3-3B,C). This 
morphological defect was not apoptosis-related (Figure 3-4E,F). Qualitatively, dendrites 
close to the nucleus appeared more affected than distal dendrites by knockdown of 
PQBP1 (Figure 3-4H; 3-5D). The defect in neurite morphology caused by loss of PQBP1 
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could be rescued by re-expression of WT PQBP1 (Figure 3-5C,D), confirming the 
correlation between neurite deformity and the loss of PQBP1 expression. Transcriptome-
wide profiling revealed that PQBP1’s AS targets were enriched for factors regulating 
neuron projection development (Figure 3-6C).  
To further investigate the affect of PQBP1 on neurons, we focused on the VASE-
associated isoforms of NCAM-140 encoded by Ncam1, which has been implicated in 
neurite outgrowth and development. Ncam1 contains five immunoglobulin-like (Ig) 
domains involved in homophilic binding of Ncam1 either in cis or trans that in turn 
controls cell-cell interactions and the induction of neurite outgrowth (Walsh and Doherty 
1997). The AS of VASE determines the inclusion or exclusion of the fourth Ig domain 
and alters the homophilic binding of NCAM-140 (Lahrtz et al. 1997). The VASE – 
isoform of NCAM-140 stimulates — while VASE + inhibits — neurite outgrowth 
(Doherty et al. 1992; Saffell et al. 1994; Liu et al. 1993).  
We found that the ratio of VASE –/VASE + expression corresponded to the level 
of functional PQBP1 and neurite outgrowth (Figure 3-4D; 3-5C ;3-7C,E,F). Moreover, 
restoration of the proper ratio of VASE –/VASE + ‘rescued’ the abnormal neurite 
outgrowth associated with the knockdown of PQBP1 (Figure 3-7F,G). These results 
identified NCAM-140 as a critical target connecting PQBP1-mediated AS to the cellular 
process of neurite projection and outgrowth. However, the ability of enforced VASE –
/VASE + expression to rescue the neurite outgrowth defect caused by PQBP1 
downregulation does not exclude the possibility that other PQBP1 targets contribute to 
this phenotype. For example, PQBP1 AS targets are also enriched in ARF-related 
proteins (Figure 3-6C). The members of the ARF family of small GTPases were 
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previously reported to affect dendritic branching and spine formation (Hernández-Deviez 
et al. 2002; Moore et al. 2007).   
 
A possible role for PQBP1 in neurological disorders 
Clinical genetics identified mutations in PQBP1 as the direct cause for 
Renpenning Syndrome, a representative XLMR disorder characterized by microcephaly, 
short stature, multiple body malformations, and mental retardation (Kalscheuer et al. 
2003; Stevenson et al. 2005). We examined the function of two disease-associated 
PQBP1 variants—a truncated protein resulting from a ΔAG deletion, and a point 
mutation containing a Y65C mutation in the WW domain. We discovered that the 
disease-associated PQBP1 mutants had deficiencies in splicing-related functions. Our 
proteomics profiling indicates that the association between splicing-related factors and 
WT PQBP1 was lost or altered in the Y65C and ΔAG mutants, respectively (Table 3-1). 
These results indicate that the association of PQBP1 with splicing factors is important for 
its function. In line with their compromised association with the splicing machinery, 
neither ΔAG nor Y65C restored the AS of NCAM-140 VASE when PQBP1 was knocked 
down in mouse primary neurons (Figure 3-7C). Furthermore, both mutants were also 
unable to rescue the defects in neurite outgrowth upon depletion of PQBP1 (Figure 3-
5E,F). Defects in dendritic development are consistently found in many other mental 
retardation disorders, including Fragile-X mental retardation and Rett Syndrome (Parrish 
et al. 2007). Our results suggest that disease-associated PQBP1 variants are deficient in 
maintaining the proper function of PQBP1 in AS. Moreover, aberrant splicing of specific 
AS targets may contribute to the disease symptoms in PQBP1-related mental retardation 
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disorders. 
 
In summary, we propose that PQBP1, a protein related to neurological diseases, 
affects AS through association with the core splicing complex. Aberrant AS of specific 
targets resulting from misregulation of PQBP1 mutants may be one of the causes of 
PQBP1-related neurological disorders.  
 
MATERIALS AND METHODS 
Plasmids, cell culture, and siRNA transfection 
Details of plasmid and stable cell-line constructions are included in Supplemental 
Materials and Methods. HeLa and 293T cell lines (ATCC) were grown in standard 
conditions. siRNAs were transfected with Hiperfect (Qiagen) at a final concentration of 
40nM. siRNAs were siGENOME siRNAs (Thermo scientific) for PQBP1 and firefly 
luciferase. Transfections were optimized to reach 85% or more protein depletion 72 hours 
post-transfection, as determined by Western blotting.  
 
Mouse cortical culture, plasmid transfection and lentivirus infection 
Mouse embryonic cortical neurons were prepared and seeded as in Kim et al. 
2010. For direct neuron transfection, MISSION® shRNA lentivirus constructs for PQBP1 
(Sigma) and a non-targeting shRNA vector (Addgene Plasmid 1864) were transfected 
into neurons on the day of seeding with Lipofectamine2000 (Invitrogen). For lentiviral 
infection of neurons, 293T cells were transfected with shRNA constructs and packaging 
vectors. Lentivirus-containing supernatants were collected 48 hours post-transfection. 
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Neurons were then incubated with the supernatants for 6 hours on the day of seeding. 
Infection was optimized to reach 60% or more protein depletion 72 hours post-infection, 
as determined by Western blotting.  
 
RNA extraction and RT-PCR 
Cellular RNA was extracted by RNeasy Mini Kit (Qiagen). 1.5-4 µg RNAs were 
reverse-transcribed by Superscript First-Strand Synthesis System (Invitrogen). Bcl-x and 
NCAM-140 VASE splicing isoforms were analyzed by RT-PCR through primers 
flanking the alternatively spliced region. A linear range for cDNA input was determined 
by running a two fold dilution series of 28 cycle PCR reactions. Products were run on 5% 
Tris-Borate-EDTA gels (Biorad), stained with SYBR gold stain (Invitrogen) and 
quantified with Image J software (NIH). Triplicate samples in the linear range were run 
to determine isoform ratios. Real-time PCR primers were designed with the software 
Primer3 (SourceForge) and verified by electrophoresis to generate single, correctly sized 
products. PCR reactions were prepared with SYBR GREEN master mix (Applied 
Biosystems), run on a Mastercycler® ep realplex (Eppendorf) and quantified by the 
ΔΔC(t) method. Primer sets are listed in Supplemental Table S3-2. 
 
Tandem affinity Immunopurification 
FLAG-HA tagged PQBP1 and the Y65C and ΔAG mutants were purified from 
HeLa cell extracts by tandem affinity purification and visualized by silver stain as 
recently described (Adelmant et al. 2012). Specific details are provided in Supplemental 
Materials and Methods. 
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Sample preparation and mass spectrometry analysis 
Sample preparation and LC-MS/MS analysis were done with slight modifications 
to a recently described method (Rozenblatt-Rosen et al. 2012). Specific details are 
provided in Supplemental Materials and Methods.    
 
Western blotting 
Cellular proteins were extracted with 1xRIPA buffer (IX PBS, 1% Triton X-100, 
0.5% sodium deoxycholate, 0.1% SDS, protease inhibitors). 10-30 µg of proteins were 
loaded onto each lane of a NuPAGE 4-12% Bis-Tris gel. Proteins were transferred onto 
PVDF membranes and probed with the following primary antibodies diluted in 1X PBST 
with 5% non-fat milk: α-PQBP1 (Santa Cruz); α-FLAG (Sigma); α-HA (Roche); α-actin 
(Chemicon); α-SF3B1 (MBL). 
 
CLIP 
HeLa cells were cross-linked at 4000 mJ/cm2 with a UV Stratelinker (Stratgene) 
and suspended in 1X RIPA buffer supplemented with protease inhibitors, 10mM DTT 
and 0.4U/µl RNAseOUT (Invitrogen). Lysates were treated briefly with RQ1 RNAse-
free DNAse (Promega) and cleared by centrifugation. Dynal beads (Invitrogen) that were 
pre-coupled with 10µg of antibody or non-relevant IgG were incubated with the 
supernatants and rocked at 4°C for 4 hours. Beads were then washed 3 times with the 
lysis buffer plus 300mM NaCl and twice with 1X PNK buffer (50 mM Tris-Cl pH 7.4, 10 
mM MgCl2, 0.5% NP-40). RNA-protein complexes were eluted and treated with 
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Protease K (Ambion) and RNAs were extracted by acid phenol/chloroform. Reverse 
transcription was performed with a 1:1 mix of oligo-dT and random hexamers and 
cDNAs were analyzed by real-time PCR.  
 
Immunofluorescence 
Neurons were fixed with 4% paraformaldehyde and 2% sucrose/PBS for 8 
minutes. Cells were then washed 3 times with 1X PBS and treated with 1X GDB (Gelatin 
Dilution Buffer) buffer (0.3% triton, 0.1% gelatin) for 15 minutes. Cells were then 
incubated with antibodies, stained with DAPI and imaged on a Nikon Ti Inverted 
Fluorescence Microscope. For co-staining, we swapped the fluorophores on secondary 
antibodies to confirm there was no bleed-through in the fluorescence channels.  
 
Annexin V staining 
Neurons were incubated with FITC-conjugated Annexin V (BioLegend) diluted 
1:50 in media at 37 °C for half an hour. Neurons were then directly imaged alive on a 
Nikon Ti Inverted Fluorescence microscope.  
 
GO functional analysis 
GO term enrichments for proteins associated with PQBP1 in HeLa cells were 
determined with DAVID Bioinformatics Database (Huang et al. 2009; Dennis et al. 
2003). Functional GO enrichments of PQBP1 AS targets in neurons were determined 
with GoMiner™ software (Zeeberg et al. 2003). 
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ABSTRACT 
Alternative splicing (AS) is widely recognized as a major source of biological 
diversity and regulation in eukaryotes. >90% of mammalian genes undergo AS and 
present tissue- and development stage-specific AS profiles. These characteristics make it 
necessary to study AS at a global level. High-throughput transcriptome sequencing 
(RNA-seq) is a powerful method to examine AS at a genome-wide scale. However, the 
diversity of AS patterns presents computational challenges to quantify AS from RNA-seq 
data. Currently, several methods are applied in AS quantification and differential AS 
analysis, such as Cuffdiff, MISO and DEXSeq. These methods use RNA-seq reads 
mapped to a full splicing transcript, or key AS regions of a transcript, or exons of a gene. 
Most of these methods rely on a priori knowledge of the genomic annotations of exons 
and cannot be applied in examining tissue-specific novel AS events. These methods also 
lack sensitivity necessary to detect changes in AS events that involve short alternatively 
spliced exons. Here, we present a new method to analyze global AS profiles under 
different conditions based on RNA-seq reads mapped to splice junctions only. Our 
method does not depend on current genomic annotation and presents a thorough and 
sensitive comparison of AS patterns between conditions. When applied to quantify global 
AS changes upon depletion of PQBP1 in mouse cortical neurons, our method identified 
many AS targets of PQBP1 that were later experimentally validated. Interestingly, some 
experimentally verified targets, such as Ncam1 that has an alternatively spliced exon of 
30bp could only be recognized by our method but not other software. These results 
showed the specificity and sensitivity of our junction-based AS quantification method.   
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INTRODUCTION 
RNA-seq as a powerful tool to investigate AS on a global scale 
Alternative splicing (AS) is a major source of biological diversity in eukaryotes. 
Greater than 90% of mammalian genes encode pre-mRNAs that undergo AS and generate 
more than one transcript (Wang et al. 2008; Pan et al. 2008) using one or more of the 
following seven basic AS patterns: cassette exon inclusion/exclusion, mutually exclusive 
exon usage, alternative 5’ splice site usage, alternative 3’ splice site usage, alternative 
promoter site usage, alternative poly-A site usage and intron retention (Black 2003; 
Figure 1-2). In addition to adding great diversity to the transcriptome in multicellular 
eukaryotes, AS also plays critical regulatory roles in biological processes, and in many 
cases acts as the crucial determinant for cell fate and identity. The regulation of AS is 
carried out by a wide range of RNA-binding proteins (RBPs) that associate with cis-
elements embedded in precursor messenger RNA (pre-mRNA) sequences (Black 2003). 
AS regulation is further incorporated into cellular signaling pathways and responds 
dynamically to environmental cues (Moore et al. 2008; Wahl et al. 2009).  
One of the major challenges in studying AS is to systematically quantify and 
compare global AS changes under different conditions. Indeed, the disturbance of 
specific AS regulators can lead to aberrant global AS changes that are closely associated 
with human diseases (Ule et al. 2005; Gehman et al. 2011; Charizanis et al. 2012). Such 
changes in global AS patterns can only be recognized by comparing genome-wide AS 
profiles between the healthy and abnormal states. High-throughput transcriptome 
sequencing (RNA-seq) is a powerful means of investigating AS at the genome-wide 
scale. However, the diversity of AS patterns and complex hierarchical AS regulation 
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bring forward computational challenges to quantify global AS changes from RNA-seq 
data. 
 
Current bioinformatics tools to quantify AS 
 RNA-seq on a biological sample generates a massive amount of short reads 
(length varying from 50bp to 200bp) that represent the whole transcriptome and can be 
used to quantify the expression levels of different mRNA transcripts from each gene. The 
common practice for RNA-seq–based differential analysis is to first define a 
quantification unit, such as a gene or a specific transcript from a gene. The read counts of 
each quantification unit can then be collected and compared between conditions using 
statistical tools (Pepke et al. 2009). Various software packages have been developed to 
analyze differential gene expression patterns from RNA-seq data between conditions by 
comparing the collective count of reads that map to any mRNA isoforms from a given 
gene (Garber et al. 2011). Analyzing the AS changes of a gene’s mRNAs, however, is a 
more complicated problem. The major issue lies in the proper definition of the 
quantification unit that represents the AS patterns of a gene’s pre-mRNAs. So far, only a 
few bioinformatics tools have been developed for differential AS analysis with various 
definitions of the quantification unit. In general, these quantification units can be 
summarized into two categories.  
The first category uses a full splicing isoform or the key AS region of a splicing 
isoform as the quantification unit for AS (Figure 4-1A; Mortazavi et al. 2008; Wang et al. 
2008). Tools in this category include Cuffdiff (Trapnell et al. 2010; Trapnell et al. 2013) 
and MISO (Katz Y et al. 2010). This definition of quantification unit depends on a priori  
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Figure 4-1: Bioinformatics models for AS quantification. 
(A) A schematic of AS quantification from RNA-seq data is shown for a hypothetical 
alternatively spliced pre-mRNA. Green rectangles represent exons and black lines between exons 
are introns. For models that use the whole splicing isoform or key AS region of that isoform as 
the quantification unit of AS, black short lines mark reads that are mapped to the full isoform.  
(B) For models that use exons as the quantification unit of AS, blue short lines mark reads that 
are mapped to each exon of the pre-mRNA for exon usage quantification between conditions.  
(C) For our method that use splice junction as the quantification unit, red short lines mark reads 
that are mapped to each splice junction of the mRNA. 
(D) A schematic of a defined AS event and quantification model of AS in our method. The 
middle exon is the alternatively spliced exon. 5’ IS is the start of a splicing junction and 3’ ES the 
end of the junction. The AS event shown here includes two sub-AS-junctions that share the same 
5’ IS. Red short lines mark RNA-seq reads mapped to sub-AS-junction-1 and purple short lines 
mark reads mapped to sub-AS-junction-2. The distribution of reads mapped to the two sub-AS-
junctions was used for differential analysis of AS in our analysis. 
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Figure 4-1 (Continued). 
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knowledge of all the mRNA isoforms/AS patterns of a gene. There are two ways to get 
priori knowledge of these mRNA isoforms and AS patterns across the genome. One is to 
use current genomic annotation (Wang et al. 2008; Katz et al. 2010) to extract 
information about all known splicing patterns or mRNA isoforms of a gene. However, 
this approach has major problems: novel AS events will not be considered. The current 
annotations of organism transcriptomes are far from complete, as high-throughput studies 
constantly identify novel AS events in different samples (Mortazavi et al. 2008). Novel 
and especially tissue-specific AS events are in many cases crucial, since various studies 
have shown that functional AS decisions are highly dynamic and are usually made in a 
tissue- and developmental stage-specific manner (Wang et al. 2008; Mortazavi et al. 
2008). The other way is to reconstruct the transcriptome of a specific biological sample 
from the RNA-seq data so that information about mRNA splicing isoforms of all genes 
can be collected. Although this approach is able to include novel splicing isoforms, 
reconstruction of the transcriptome from massive amount of short reads is itself a 
computationally challenging problem (Garber et al. 2011). Many genes in higher 
organisms produce more than 10 or even thousands of isoforms and have a combination 
of multiple basic AS patterns, especially in complex tissues such as the brain (Nilsen and 
Graveley 2010). As a result, even with the most powerful computational tools, it is 
difficult to decipher every transcript of a given gene simply from the sequencing data. 
The other shortcoming of this approach is the lack of the sensitivity necessary for 
analyzing changes brought by small alternatively spliced exons/exonic regions. In 
general, the length of a transcript (several thousand bp) is much larger than that of an 
alternatively spliced exon (10 to a few hundred bp), so a full-length transcript can attract 
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far more reads than a short alternatively spliced exon. As a result, especially in long 
transcripts, changes in read count of a transcript contributed by an AS event that involves 
small alternatively spliced exons are relatively hard to detect.  
The second category of AS quantification tools define the quantification unit 
based on exon usage (Figure 4-1B). Usage, defined as the number of reads mapped to 
each exon of the gene, can be calculated and compared among different conditions. Tools 
of this category include DEXSeq (Anders and Huber 2010). The detection of differential 
exon usage under specific conditions indicates changes in the exclusion or inclusion of 
exons, and thus AS patterns of that gene (Anders and Huber 2010). This exon-based 
approach also relies on a priori knowledge of an annotated genome and has the same 
problem as discussed in the first category. In addition, this method is not sensitive enough 
to detect differential usage of short exons (some exons can be as short as 20bp), 
especially if the gene under investigation has many other long exons. The reason is that a 
short exon cannot attract many read counts in the first place, especially when the exon 
length is shorter than the read length. The changes in read count from AS of that exon 
will be small compared to the read counts from other exons.  
In fact, the most straightforward means of measuring AS changes is to examine 
the number of reads that are directly mapped to different AS junctions (Figure 4-1C). 
However, this approach has not been applied to quantify global AS changes from RNA-
seq data. 
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Biological variability and differential analysis 
Variability among biological replicates is crucial for generating valid statistics in 
differential analysis (Hansen et al. 2011). Due to costs and technical difficulties, only a 
small number of replicates are performed in RNA-seq experiments, usually not enough to 
estimate biological variability among samples through standard approaches (Garber et al. 
2011). As a result, the majority of current computational methods for global AS 
differential analysis exclude biological variability in their statistics and can only compare 
one sample out of several replicates in each condition in a pairwise manner (Anders et al. 
2012; Wang et al. 2008; Katz et al. 2010). Interestingly, methods to infer biological 
variability from a small number of replicates have been developed for sequencing 
technologies (Robinson and Smyth 2007; Robinson and Smyth 2008), and have started to 
be implemented for differential analysis using RNA-seq, such as software packages Edge 
R, DESeq and DEXSeq (Robinson et al. 2010; Anders and Huber 2010; Anders et al. 
2012). These methods have been tested in practice for differential gene expression 
analysis and have proven to be effective in modeling and incorporating biological 
variability for generating reliable statistics (Becker et al. 2011; Hah et al. 2011; Ross-
Innes et al. 2012).  
We hereby present a computational method that use only reads directly mapped 
over splice junctions to compare differential AS profiles from RNA-seq data. Applying 
this method, we identified 457 AS events that experience significant changes upon 
PQBP1 depletion in mouse embryonic cortical neurons. Subsequent experimental 
validation on the computationally predicted AS targets of PQBP1 demonstrates the high 
specificity and sensitivity of our method. 
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RESULTS 
Description of the junction-based method 
We considered RNA-seq reads that are directly mapped over splice junctions as 
the quantification unit for splicing changes (Figure 4-1C). In fact, before RNA-seq, exon 
junction microarrays that bear probes straddling selected splice junctions have been used 
for AS quantification (Johnson et al. 2003). Computational methods comparing AS 
profiles using exon junction arrays gave reliable results on differential analysis (Ule et al. 
2005). For each splice junction we define the 5’ initiation site (5’ IS) of the junction as 
the final nucleotide position of the upstream exon and the 3’ end site (3’ ES) as the first 
nucleotide position of the downstream exon (Figure 4-1D). An AS event is thus defined 
as a set of splice junctions that share the same 5’ IS or the same 3’ ES, with each junction 
in the set referred to as a sub-AS-junction (Figure 4-1D). This definition of AS covers all 
6 primary AS patterns except for intron retention, which was not considered in our 
analysis (Figure 4-2; Black 2003). The splicing pattern of an AS event under a certain 
condition is represented by the distribution of read counts mapped respectively to each 
sub-AS-junction within the AS event—i.e., the ‘usage’ of each sub-AS-junction under 
that condition. 
We take a two-step approach to retrieve read counts on splice junctions. RNA-seq 
reads represent the transcriptome, i.e. the processed transcripts where introns are already 
removed. Thus the reads that are from exonic regions can be mapped directly back to the 
genome, while reads that straddle splice junctions cannot. Our first step is to identify all 
the splice junctions and the junction sequences. Reads are mapped to the genome using 
Tophat, an alignment program that maps short RNA-seq reads to the genome and  
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Figure 4-2: Definition of AS events in our method covers basic AS patterns. 
 
 
identifies exon-exon junctions without a priori knowledge of the exon annotation 
(Trapnell et al. 2009). Tophat recognizes splice junctions by first directly mapping fully 
mappable reads to the genome to define “exon islands”. After that, reads that straddle 
splice junctions and are thus not directly mappable in the first step are systematically 
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segmented and each segment is mapped separately to different exon islands, so as to 
discover separate exons or exonic regions that are straddled by these reads, i.e. the splice 
junction (Trapell et al. 2009). In this way, Tophat provides a thorough scan for not only 
known splice junctions, but also novel junctions in the specific sample. After junction 
identification, we generate a junction sequence database by extracting exonic sequences 
upstream and downstream of each junction. The second step is to collect read counts on 
each identified splice junction. We combine the mouse genome sequence and the junction 
sequence database together and use Bowtie, a short read alignment program (Langmead 
et al. 2009) to map all the reads to the combined sequence database, this time without 
read segmentation. In this way, reads that are from exonic regions can be directly mapped 
to the genome and reads that span a splice junction can be directly mapped to the profiled 
junction sequences, and read counts for each splice junction are achieved. 
To analyze the differential ‘usage’ of each sub-AS-junction within an AS event 
between conditions, we apply a modified version of the method DEXSeq (Anders et al. 
2012). DEXSeq was originally developed to analyze differential exon usage within a 
gene under different conditions. Dependent on prior knowledge of genome annotation, 
DEXSeq utilizes biological variability among replicates to generate robust statistical tests 
directly from raw read counts (Robinson and Smyth 2007; Anders and Huber 2010; 
Anders et al. 2012). We adapted this method to analyze the differential ‘usage’ of each 
sub-AS-junction in an AS event between different conditions. Since our statistical tools 
are adapted from DEXSeq, we incorporated the variability among biological replicates in 
our analysis. 
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Application of the junction-based method 
As an application of this method, we compared global AS profiles between 
control and PQBP1-knockdown (PQBP1 KD) mouse cortical neuron samples as 
described in Chapter 3. RNA samples from three non-targeting shRNA treated replicates 
and two PQBP1 KD replicates were extracted and sequenced. Each sample under each 
condition received 55-120 million paired-end 50bp reads.  
Reads were mapped to the mouse genome (GRCm38/mm10) using Tophat and a 
total of 141,493 splice junctions were identified from the mouse embryonic cortical 
neuron samples (Figure 4-3). A junction sequence database was then established by 
extracting exonic sequences upstream and downstream of each junction from the UCSC 
genome browser (Karolchik et al. 2004); the exact junction length varied from 46bp to 
98bp, depending on the Tophat report for the span of the junction. We used Bowtie2 to 
map all the reads to the combined sequence database of the mouse genome and the splice 
junction sequence database (Figure 4-3). For each sample, ~80% of reads were mapped 
uniquely and for multi-hit reads we picked the top-scored mapping site, so that ~98% of 
reads mapped to the combined genome and junction database. 
We prepared Perl scripts to profile AS events and the corresponding sub-AS-
junctions from the splice junction database identified by Tophat, as defined previously. 
The read counts on each sub-AS-junction were extracted respectively with Samtools (Li 
et al. 2009). Perl scripts were written to adapt the R package of DEXSeq (Anders et al. 
2012; Gentleman et al. 2004) to analyze the differential usage of sub-AS-junctions within 
an AS event, comparing control and PQBP1 KD samples. To make the analysis more 
stringent, only sub-AS-junctions with one or more mapped reads from all five control and  
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Figure 4-3: Flow chart of the computational analysis to identify AS targets of 
PQBP1 from RNA-seq data. 
 
 
PQBP1 KD samples were considered. A sub-AS junction that received less than ten reads 
adding up from all five samples was excluded from statistical tests, as suggested by 
DEXSeq (Anders et al. 2012). From 141,493 junctions identified by Tophat, our profiling 
resulted in 14,532 AS events involving 31,044 sub-AS-junctions, distributed among 5996 
genes (Figure 4-3). From there, 585 AS events were identified to exhibit significant 
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changes in usage of sub-AS-junctions upon PQBP1 KD with a p-value cutoff at 0.05, 
covering 457 genes (Supplemental Table S4-1; Figure 4-3). 
 
Validation of the junction-based method 
To validate our method, we randomly picked ten computationally predicted 
PQBP1 AS targets and two predicted non-targets, and analyzed the splicing of each 
candidate by RT-PCR (Figure 3-6B). All ten predicted targets showed significant changes 
in AS and the predicted non-targets did not (Figure 3-6B), indicating the specificity and 
sensitivity of our junction-based method to analyze differential AS between different 
conditions.  
 
DISCUSSION 
In this work, we described a new junction-based computational method to 
efficiently analyze differential global AS from RNA-seq data. We used RNA-seq reads 
that are directly mapped over splice junctions as the quantification unit and defined the 
distribution of read counts among sub-AS-junctions within an AS event as the AS pattern 
of that event. We also applied statistical methods that incorporate variability among 
biological replicates to justly analyze the differential usage of sub-AS-junctions of an AS 
event under different conditions. We applied this method in evaluating genome-wide AS 
changes in neurons upon PQBP1 depletion and validated our results experimentally. 
Broadly, our method provides a thorough and reliable way to quantify global AS changes 
between different conditions and can be applied to many aspects of AS studies such as 
identifying genome-wide AS targets of a splicing regulator.  
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Read distribution among splicing junctions as a rational quantification unit for AS  
The number of reads that map over a splice junction is a direct and quantitative 
reflection of how much that splice site is selected during the process of pre-mRNA AS. 
Although it is difficult to reconstruct every transcript that a gene generates from RNA-
seq data, there has been significant progress in designing algorithms that identify splice 
junctions of the transcriptome (Trapnell et al. 2009; Au et al. 2010; Wang et al. 2010). 
Tophat is among the most well developed and widely used algorithms within this 
category (Trapnell et al. 2009). In our method, Tophat provides a relatively complete 
profiling of all the splice junctions as the basis for achieving accurate read counts for 
each junction.  
Our method defines an AS event as a set of sub-AS-junctions that share the same 
5’ IS or 3’ ES and describe AS pattern of this event as the distribution of reads among 
sub-AS-junctions within that AS event. This definition conveys similar ideas as Ule et al. 
2005 with exon junction microarrays in which each AS event is examined between 
different samples by comparing the hybridization intensity of probes representing each 
sub-AS-junction. In Ule et al., 49 computationally predicted AS events that experienced 
the most significant changes upon Nova1 knockout were tested by RT-PCR and all 49 
were validated (Ule et al. 2005). In our case, all 10 randomly picked predicted PQBP1 
AS targets and 2 non-targets were also verified by RT-PCR. These results indicate the 
high specificity and sensitivity of our model for AS quantification using read distribution 
among sub-AS-junctions. 
 
 
 
 
140 
  Moreover, our method adapts DEXSeq to model biological variability and 
incorporate it into statistical testing for significant changes in sub-AS-junction usages 
within AS events between conditions. In this way we avoided discrepancies that may be 
brought up by pairwise comparisons among samples under different conditions. 
 
A thorough and sensitive detection of global AS changes 
Our method can detect changes in AS events that are tissue-specific and have not 
been annotated before. For example, we computationally predicted and experimentally 
validated an important AS target of PQBP1 using our method—the splicing of the VASE 
(Variably Alternatively Spliced Exon) exon in Ncam1 between exon 7 and 8 (Figure 3-
7A; 3-6B). The VASE-excluding isoform of Ncam1 (VASE –) promotes neurite 
outgrowth while the VASE-including isoform (VASE +) inhibits neurite outgrowth 
(Doherty et al. 1992). Thus, Ncam1 is an important component among PQBP1’s AS 
targets that functionally relates the role of PQBP1 in AS regulation to the phenotypic 
activity of neurite outgrowth (See chapter 3). Although reported before in the literature, 
the VASE exon is not included in the current mouse genome annotation (Figure 4-4). As 
a result, computational methods such as MISO and DEXSeq that depend on priori 
knowledge of annotated genomes will not be able to identify Ncam1 as PQBP1’s AS 
target. On the other hand, methods that perform differential AS analysis by reconstructing 
the transcriptome from RNA-seq such as Cuffdiff (Trapnell et al. 2010; Trapnell et al. 
2013) could not identify the AS of VASE in Ncam1 either (data not shown). One possible 
reason could be the difficulty of correctly reconstructing all the AS transcripts of Ncam1 
from RNA-seq reads.  
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Figure 4-4: RNA-seq reads mapped to junctions between exon7 and VASE, and 
VASE and exon 8 in mouse gene Ncam1 from control and PQBP1 KD samples. 
Genomic structure of mouse Ncam1 in shown. Blue rectangles are exons and lines 
between exons are introns, with arrowheads on introns showing the direction of 
transcription. Genomic structure on top is from the Refseq database, while the one on the 
bottom is the Ncam1 genomic structure in mouse brain inferred from RNA-seq data. 
VASE exon (pink rectangle) is not included in Refseq but is discovered from RNAseq 
data. The middle two lanes show the reads count from control and PQBP1 KD samples 
on splicing junctions. Each red arc between exons represents reads mapped to the 
corresponding splice junction. The height and thickness of an arc show the relative depth 
of read counts mapped to that junction. In PQBP1 KD sample, the arcs connecting exon 7 
and VASE and VASE and exon 8 are significantly increased in comparison to the control 
sample, depicting an increase in the generation of VASE + isoform. This figure is 
generated by the Integrative Genomics Viewer (Thorvaldsdóttir et al. 2013; Robinson et 
al. 2011).  
 
 
Our method also shows better sensitivity in detecting AS changes than other 
algorithms. The lengths of splicing junctions identified from Tophat are approximately 
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quick to detect. Take Ncam1 as an example again. The VASE exon is only 30bp long 
while the length of an Ncam1 transcript is around 6kb. If using the transcript as the 
quantification unit, the read count from the inclusion or exclusion of VASE can hardly 
cause noticeable changes in the total amount of reads received by an Ncam1 transcript. 
This may be another reason that Cuffdiff could not identify Ncam1 as an AS target of 
PQBP1. As for exon-based AS differential analysis methods such as the original 
DEXSeq, even adding the annotation for VASE could not improve the prediction result 
of DEXSeq on Ncam1. It is again possible that the short VASE exon compared to other 
exons has a small number of reads mapped to it in the first place, and that the change in 
read count caused by the AS of VASE is too weak to be detected.   
In contrast, when using reads mapped to the splicing junctions as the 
quantification unit, a significant difference in VASE splicing is observed immediately 
between the control and PQBP1 KD samples (Figure 4-4). These facts again illustrate the 
sensitivity of our junction-based method in performing differential AS analysis between 
different conditions. 
  
MATERIALS AND METHODS 
RNA-seq sample preparation  
We used the PrepX mRNA IntegenX kit (Illumina) to prepare library 
constructions from total RNA. The detailed protocol can be tracked through the link 
provided below: 
http://www.genome.med.harvard.edu/documents/illumina/IntegenX_Apollo324_mRNA_
Seq_Protocol_10012012.pdf  
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Samples were then run on Illumina HiSeq 2000. The reported sequencing data has been 
deposited in NCBI’s Gene Expression Omnibus (Edgar et al. 2002) and is accessible 
through GEO series accession number GSE44402. 
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ABSTRACT  
Alternative splicing (AS) of mRNA is a major source of biological diversity and 
regulation in eukaryotes. Despite its rapidity and flexibility as a regulatory mechanism, 
AS remains under-utilized in synthetic biology. The eukaryotic AS regulatory network 
contains multiple standard network motifs including positive and negative feedback 
loops. In many cases, AS functions as a switch modulating critical biological functions, 
such as cell fate and identity determination during development in multicellular 
eukaryotes. AS allows cells to respond to environmental cues at the post-transcriptional 
level, often more rapidly than through transcriptional regulation alone. Here, we 
demonstrate a synthetic splicing-based circuit in mammalian cells—based on the 
autoregulatory feedback loop from the splicing regulation of Sex-Lethal (Sxl), the 
Drosophila sex determination master gene—that confers memory of extracellular stimuli. 
We show that, as in Drosophila, Sxl regulates the splicing of its own mRNA in 
mammalian cells. Furthermore, through quantitative modeling and experimental data, we 
show that this positive feedback loop can serve as a crucial element in synthetic devices 
to rapidly respond to and retain memory of transient exposure to stimuli in mammalian 
cells. Our splicing-based memory device explores the potential of AS regulatory 
networks in synthetic circuit design and will contribute to the study of long-term effects 
of transient stimuli on cells as well as our knowledge of post-transcriptional regulation in 
biology. 
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INTRODUCTION 
In biological systems, it is common that transient stimuli lead to long-term effects, 
especially in cellular decision-making and cell fate determination. As an example, the 
NOTCH signaling pathway regulates the maintenance of neural progenitor cells as well 
as their differentiation into neurons and glia (Gaiano and Fishell 2002). A brief 
inactivation of NOTCH is adequate to shift a series of downstream molecular events and 
cause progenitor cells to commit to permanent differentiation (Nelson et al. 2007). The 
importance of transient stimuli in long-term cell dynamics is also prominent in human 
diseases. For instance, hypoxia is associated with many pathological conditions including 
cancer, and acute or chronic hypoxia can bring different biological effects in tumor cells 
(Bristow and Hill 2008).  
Cellular decision-making dependent on transient stimuli arises from bistability, 
the phenomenon of the existence of two stable states of a network that are switchable in 
the presence of appropriate stimuli (Strogatz 1994). In certain cases, bistability shows 
irreversibility, as in the case of cells permanently committing to a specific fate or state 
upon receiving a transient signal (Thomas and Kaufman 2001). In other words, cells keep 
the ‘memory’ of this signal, change the gene expression profile accordingly, and self-
perpetuate this expression profile. Irreversibility in bistability is usually achieved by 
strong positive feedback loops in the regulatory network (Xiong and Ferrell 2003).       
With traditional approaches, it is difficult to identify cells that have been 
influenced by past transient stimuli. Synthetic biology on the other hand, provides tools 
to design and engineer circuits that confer cellular ‘memory’ of a past transient signal 
into a readout that is experimentally detectable (Ajo-Franklin et al. 2007). The protracted 
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cellular response to a transient signal in the past can then be studied by tracking the cells 
that carry markers of memory. Currently, synthetic bistable circuits are mostly based on 
feedback loops adapted from transcriptional regulatory networks (Gardner et al. 2000; 
Atkinson et al. 2003; Kramer et al. 2004; Vilaboa et al. 2005; Ajo-Franklin et al. 2007; 
Ingolia and Murray 2007; Burrill and Silver 2011; Burrill et al. 2012). In addition, most 
of these circuits are implemented in prokaryotes, as the establishment of bistability and 
memory in eukaryotes, especially in mammalian cells, has proved to be more difficult 
(Ingolia and Murray 2007; Burrill et al. 2012). The few transcription-based synthetic 
memory circuits built in eukaryotes show heterogeneous performance on memory 
retention in the population (Burrill and Silver 2011; Burrill et al. 2012). It has been 
proposed that this phenomenon is due to the kinetic features of transcriptional regulation, 
especially the time scale of transcription activation compared to that of other cellular 
activities such as cell division (Burrill and Silver 2011).  
Alternative splicing (AS) is a crucial component in biological regulatory 
networks. AS regulatory network is part of post-transcriptional regulation and allows 
cells to respond to environmental cues more rapidly than through mechanisms at the 
transcriptional level alone. In addition, AS regulatory network is composed of multiple 
standard network motifs including negative and positive feedback loops, and often 
functions as the major determinant of cell fate.   
Perhaps the most striking example of AS determining cell fate comes from the 
splicing of Sex-lethal (Sxl) encoding the master regulator for Drosophila sex 
determination (Figure 5-1). The primary determinant of fly sex is the ratio between the 
number of X chromosomes and the number of sets of autosomes (X:A) in the cell. In  
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Figure 5-1: Alternative splicing regulation of Sxl and sex determination in 
Drosophila.  
A schematic of the AS of Drosophila Sxl is shown. Gray rectangles are exons and black lines 
between exons are introns; the dark rectangle marks the alternatively spliced exon 3; arrows show 
translation start sites; stop signs show premature termination codons. In male flies where the ratio 
of number of X chromosome to sets of autosomes (X:A) is 0.5, Sxl follows the default splicing 
pattern to include exon 3 that contains a stop codon, leading to transcript degradation. In female 
flies where X:A is 1, Sxl is spliced to skip exon 3 and generates mature Sxl proteins. Sxl is itself a 
splicing regulator and enhances the female-specific pattern to keep a steady production of Sxl 
proteins. Sxl affects the functions of a cascade of downstream genes and thereby regulates 
female-specific phenotype determination processes such as somatic sex determination, germ line 
sex determination and dosage compensation. 
 
male flies where the X:A ratio is 0.5, the splicing of Sxl includes exon 3 that contains a 
premature termination codon. Thus the male-specific Sxl transcripts are degraded through 
nonsense-mediated mRNA decay (NMD) and do not produce Sxl protein. In contrast, in 
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female flies where the X:A ratio is 1, an alteration in the splicing of Sxl is initiated early 
in embryogenesis to skip exon 3 and leads to the expression of full-length Sxl protein. 
This protein is itself a splicing factor that auto-regulates the splicing of Sxl to maintain 
the female-specific isoform, resulting in a steady production of Sxl protein. Besides its 
own pre-mRNA, Sxl also regulates the splicing of pre-mRNAs of transformer (tra) and 
male-specific lethal-2 (msl-2), and modulate the functions of a cascade of downstream 
regulators for male- or female-specific phenotypes including somatic sex determination, 
germ-line sex determination and dosage compensation (Figure 5-1; Baker 1989; Penalva 
and Sánchez, 2003). Through this mechanism, throughout a fly’s life cells maintain the 
memory of sex information via the positive feedback loop of Sxl regulating the AS of its 
own pre-mRNA. Considering the homogenous establishment of sex memory in every fly 
cell throughout development and the fast cell cycle (8 minutes on average for embryonic 
cells) in fly cells, it is possible that the AS regulation of Sxl possesses unique kinetic 
features that allow fast and uniform action. 
With a diverse collection of regulatory network motifs and rapid response to 
signals, AS is currently underutilized in synthetic circuit design. Here, we present a 
synthetic mammalian memory circuit that utilizes the AS regulation of Sxl to confer 
memory of transient doxycycline (dox) exposure. We show that the self-regulation of 
splicing of Sxl is preserved in mammalian cells, as in Drosophila, and that the auto-
regulatory loop of Sxl splicing regulation can serve as a functional module of a synthetic 
circuit to rapidly confer memory of extracellular signals. We further performed 
quantitative stochastic modeling of the memory circuit for rational device optimization 
and integration into mammalian cells. Collectively, our study explores the potential of AS 
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regulatory network applications in synthetic devices and contributes to the understanding 
of post-transcriptional regulation in biology.     
 
RESULTS 
Splicing of Drosophila Sxl is preserved in mammalian cells 
We found that splicing of Drosophila Sxl is preserved in mammalian cells (Figure 
5-2A,B,C,D). To test if the expression of Sxl is harmful to mammalian cells, we first 
transfected U2OS cells with GFP-tagged mature Sxl. No noticeable negative effect on 
U2OS cells was observed. In addition, Sxl localizes in the nucleus of U2OS cells as in 
flies (Figure 5-2A).  
The default Sxl splicing pattern in male flies includes exon 3 with a stop codon, 
which leads to transcript degradation. Only the expression of functional Sxl protein itself 
can shift the splicing of Sxl to the female-specific isoform that excludes exon 3. To 
determine whether the AS regulation of Sxl is preserved in mammalian cells, we co-
transfected U2OS cells with a Sxl AS plasmid—a plasmid that contains CMV-driven Sxl 
fused to GFP with alternatively spliced exon 3 and adjacent introns (Figure 5-2B)—and 
an mCherry-tagged mature Sxl. As a control, we co-transfected the Sxl AS plasmid with a 
plasmid that expresses mCherry by itself (Figure 5-2B). Cells were then analyzed by flow 
cytometry (Figure 5-2B,C) and Western blotting (Figure 5-3D) for GFP-tagged Sxl 
expression. A significant increase in GFP-tagged Sxl was detected in the co-transfection 
of the Sxl AS plasmid with the mCherry-tagged Sxl in comparison to with mCherry alone 
(Figure 5-2B,C,D). These results illustrate that the splicing pattern of Sxl is the same in  
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Figure 5-2: Splicing of Sxl in mammalian cells. 
(A) Fluorescence microscopy examination of U2OS cells transfected with GFP-tagged Sxl, in 
comparison to transfection with just GFP. 
(B) A schematic of a Sxl AS plasmid is shown. Grey rectangles are exons; dark rectangle marks 
the alternatively spliced exon 3 and its adjacent intronic sequences are represented by black lines. 
Arrow shows translation start site and stop sign shows the premature termination codon. Sxl in 
this plasmid is fused to GFP, represented by a green rectangle. The inclusion or exclusion of exon 
3 in Sxl splicing determines whether functional GFP-tagged Sxl can be generated. U2OS cells 
were co-transfected with the Sxl AS plasmid and mCherry-tagged mature Sxl, or the Sxl AS 
plasmid and mCherry. Cells were analyzed by flow cytometry. For each chart, X-axis is the 
intensity of the GFP fluorescence, and Y-axis is the intensity of the mCherry fluorescence. 
Percentage of cells falling into each quadrant (Q1, Q2, Q3, Q4) is listed.  
(C) Quantification of the GFP fluorescence intensity of U2OS cells in Q2 (cells co-expressing 
GFP- and mCherry-tagged Sxl) as in (B). 
(D) Western blot of U2OS cells that were co-transfected with the Sxl AS plasmid and mCherry-
tagged mature Sxl, or the Sxl AS plasmid and mCherry, probed with GFP antibody. Size markers 
are listed on the left. 
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Figure 5-2 (Continued). 
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mammalian cells as in Drosophila and that the positive feedback loop of Sxl protein 
regulating its own pre-mRNA’s splicing is preserved in mammalian cells. 
 
Design of a splicing-based memory circuit 
We designed a splicing-based memory circuit as shown in Figure 5-3A. For the 
trigger, the mature female-specific Sxl was cloned in C-terminal fusion with mCherry, 
driven by a dox-sensitive promoter T-REx. The T-REx promoter is repressed by the 
binding of Tet repressor that is previously integrated and continuously expressed in the 
specific U2OS cell lines we use (Blacklow Laboratory). When dox is present Tet 
repressor is removed from the promoter allowing expression of mCherry-tagged Sxl (Yao 
et al. 1998). For the reporter, the alternatively spliced exon 3 of Sxl, together with the 
adjacent introns and other constitutive exons (exon 1, 2, 4, 5, 6, 7 and 8) were cloned in 
C-terminal fusion with GFP, driven by a CMV promoter (Figure 5-3A). Without dox, the 
trigger does not produce any functional mCherry-tagged Sxl protein (Figure 5-3B). The 
Sxl transcripts generated from the CMV promoter of the reporter thus follow the splicing 
pattern in male flies that includes exon 3 and the premature termination codon. This leads 
to transcript degradation and no production of GFP-tagged Sxl proteins (Figure 5-3B). 
Upon dox exposure, the mCherry-tagged Sxl protein generated from the trigger will alter 
the splicing of Sxl transcripts from the reporter to exclude exon 3 and produce functional 
GFP-tagged Sxl proteins (Figure 5-3C). Sxl will in turn auto-regulate the splicing of its 
own pre-mRNA from the reporter and enhance the altered splicing pattern for continuous 
production of GFP-tagged Sxl, even after the trigger is turned off (Figure 5-3C). The GFP  
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Figure 5-3: Design of the splicing-based memory circuit and predicted responses. 
(A) A schematic of the design of the Sxl splicing-based memory circuit. Grey rectangles are 
exons and dark rectangles marks the alternatively spliced exon 3 in Sxl. Black lines on either side 
of exon 3 represent the adjacent intronic sequences. Arrows show translation start site and stop 
signs show premature termination codons. The trigger is under the dox-sensitive promoter T-Rex. 
The reporter is driven by a CMV promoter. 
(B) Device response without dox exposure. With no dox, the trigger does not express functional 
mCherry-tagged Sxl and the reporter follows the default male splicing pattern. No GFP-tagged 
Sxl protein is generated and no fluorescence signal is detected. 
(C) Device response upon dox exposure. With dox, the trigger is activated and expresses 
mCherry-tagged mature Sxl protein, which in turn shifts the splicing of the reporter to exclude 
exon 3. GFP-tagged mature Sxl protein is generated from the reporter and self-enhances the 
reporter Sxl transcript to follow the female-specific splicing pattern. 
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Figure 5-3 (Continued). 
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fluorescence signal here serves as a marker for memory of a transient dox exposure in the 
past.       
 
Integration of the splicing-based memory circuit in U2OS cells  
Stable integration of the memory circuit into mammalian cells is necessary for 
evaluation of the device’s ability to maintain memory over time. By disassembling a 
circuit into several plasmids and randomly integrating them separately into the cells, 
stable cell lines are generated containing a varying number of copies of each circuit part 
in different positions of the genome. We first made U2OS cell lines that stably carry the 
proposed memory device by random integration of the trigger and reporter constructs on 
separate plasmids. The trigger plasmid expresses puromycin resistance and the reporter 
plasmid expresses hygromycin B resistance (Figure 5-4A). U2OS cells were co-
transfected with the trigger and reporter plasmids and were dual-selected by puromycin 
and hygromycin B for cell clones that stably integrated both the trigger and the reporter 
of the device as a whole. Different cell clones were picked after the dual selection and 
each was examined for the device response. 
 The resulting stable U2OS cell line showed prompt activation of the trigger to 
dox exposure and rapid response from the reporter to the trigger (Figure 5-4B,C). U2OS 
cells were exposed to dox for 19 hours and examined for the fluorescence signal from the 
trigger and reporter by microscope. We observed that the trigger expressed high level of 
mCherry-tagged Sxl upon dox induction and the reporter generated GFP-tagged Sxl due 
to the activation of the trigger (Figure 5-4B). To validate that the reporter responds to the 
trigger by AS of Sxl, we designed RT-PCR primers flanking the alternatively spliced  
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Figure 5-4: Analysis of U2OS cells that stably integrated the memory circuit 
through random integration. 
(A) Trigger and reporter constructs used for generating stable cell lines that carry the device. 
Arrowheads show RT-PCR primers used to analyze the splicing of the reporter Sxl transcript. 
(B) Trigger response (by DsRed for mCherry) and reporter activities (by FITC for GFP) are 
detected 19 hours post dox induction (19 hpi) in U2OS cells by fluorescence microscope. 
(C) RT-PCR analysis of Sxl transcripts generated from the reporter before and after dox 
induction. A significant shift from the isoform that contains exon 3 (bands in the right panel) to 
isoform that excludes exon 3 (bands in the left panel) is observed. Exon 3 is around 170 bp long 
so a band shift of 170 bp is expected. 
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Figure 5-4 (Continued). 
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exon 3 (spanning to GFP for exclusive reporter Sxl transcripts; see Figure 5-4A). A 
significant shift in the splicing of reporter transcripts was observed from the exon 3-
inclusive male-specific isoform to the exon 3-exclusive female-specific isoform upon the 
exposure to dox (Figure 5-4C). In the future, this stable cell line will be tracked for many 
days after removal of dox to observe memory of dox exposure.   
 
Rational optimization of device design and genomic integration in U2OS cells 
To optimize the long-term maintenance of memory, it is critical to investigate the 
dynamics of the splicing-based memory circuit to optimize the balance between the 
kinetics of trigger activation and the positive feedback loop of the reporter. Random 
integration of the device does not allow control of copy number and ratio of 
trigger/reporter constructs, or the integration location in the genome, making it difficult to 
evaluate and optimize the design of the device. We believe that a combination of more 
controlled genome integration methods and computational modeling will contribute to 
systematically optimizing the design and performance of the splicing-based memory 
device. Experimentally, there are many methods to integrate a plasmid carrying the whole 
device into specific locations in the mammalian genome with controlled copy numbers, 
such as recombinase-based site-directed integration of transgenes or transposon-mediated 
transgenesis (Oumard et al. 2006; Turan and Bode 2011; Wilson et al. 2007). 
Mathematical modeling of the synthetic circuit will provide information about the steps 
in the system that are critical for establishing a memory response.  
We designed the device to be carried by one single plasmid, containing both the 
trigger and the reporter. The performance of the device is tunable through three variables: 
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the copy number of the trigger within the device plasmid, the copy number of the reporter 
within the plasmid, and the copy number of the whole device-carrying plasmid integrated 
in the mammalian genome (Figure 5-5). By varying theses three variables, we can 
systematically generate different designs of the device experimentally.  
 
 
 
 
 
 
 
Figure 5-5: Systematic designs for controlled integration of the splicing-based device 
into mammalian cells.  
The trigger and reporter will be carried by a single plasmid where the copy number of each part is 
tunable (m copies of trigger and n copies of the reporter; each copy will be separated by an 
insulator sequence). Depending on the experimental integration methods used, the copy number 
of the whole plasmid integrated can be tuned as well.  
 
To rationally evaluate and predict the performance of the device with different 
designs, we applied stochastic modeling using the Gillespie algorithm (Gillespie 1977) to 
examine the dynamics of the device. Specifically, a preliminary model was built with 
simplifications described as follows: 
I. The trigger activation upon dox exposure is described here in two steps: (a) A linear 
increase of mCherry-fused Sxl mRNA with exposure time, complemented by the 
degradation of the mRNA. (b) The translation of trigger Sxl mRNA to Sxl proteins. 
The trigger activation, based on the experimental testing, can be further modified to 
GFPSXLT-REx 4 5 6 7 8321CMVinsulator sequencemCherry
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detailed dox-based transcription activation, modeling the binding between dox and 
the Tet repressor, and the Tet repressor and the promoter. Currently, we allow 10 
hours of dox exposure to activate the trigger. 
II. It is estimated that a stably integrated CMV promoter generates on average 114 
copies of a transcript in a single HEK-293 cell at an investigated time point (Yunger 
et al. 2010). Considering the strength of the CMV promoter, we define the reporter 
as generating a static pool of 114 Sxl transcripts at any moment. If needed, this 
simplification could be modified to model the detailed transcription activation of 
the CMV promoter over time when cell division is taken into account.  
III. Although it is still not fully understood how Sxl regulates the splicing of exon 3 of 
its own transcript, it has been observed that Sxl binds to several poly-U sites 
upstream and downstream of exon 3 (Wang and Bell 1994; Kanaar et al. 1995). It 
has been suggested that splicing of exon 3 is the synergistic result of Sxl proteins 
that are bound to the auxiliary sites near exon 3 (Sakamoto et al. 1992; Wang and 
Bell 1994; Penalva et al. 1996). Additionally, it is believed that Sxl proteins 
cooperatively bind to the auxiliary sites in the Sxl pre-mRNA forming homodimers 
(Sakamoto et al. 1992; Wang and Bell 1994; Samuels et al. 1998). It has been 
suggested that these Sxl dimers are critical for carrying out the splicing decision 
(Louis et al. 2003). Combining the information above, we modeled the regulation of 
splicing of exon 3 by Sxl proteins via assuming Sxl proteins bind cooperatively to a 
pre-mRNA and forms dimers, as described in Louis et al. 2003. For simplicity, we 
only consider Sxl dimers from one binding site in the modeling but ignore the 
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synergistic effect from multiple Sxl dimers from many binding sites (Louis et al. 
2003).    
We then built a preliminary model of the splicing-based synthetic memory circuit 
based on the descriptions above, supposing that there is one copy of the trigger and one 
copy of the reporter integrated in the genome. Model variables are explained in Table 5-
1. Major reactions of the model are shown as equations (1)-(13). Equations (1)-(2) depict 
trigger activation upon dox exposure; (3)-(5) depict the splicing activation of the reporter 
upon trigger activation; (6)-(9) depict the splicing-based positive feedback loop of the 
reporter. The parameter values used in this model are listed in Supplementary Table S5-1 
(Louis et al. 2003). The initial value of each variable is set to zero except for  
Sreporter−mRNA , 
which is set to 114. 
Table 5-1. Model variables 
Model variables Definition 
S  Sxl 
Dox  Exposure to dox 
Strigger−mRNA  The mCherry fused Sxl transcript produced from the trigger 
Strigger−protein  The mCherry-tagged Sxl protein produced from the trigger 
 
Sreporter−mRNA  The default non-functional exon 3-included Sxl transcript produced from the reporter 
 
Sreporter−mRNA i Strigger−protein  The intermediate product in splicing: an mCherry-tagged Sxl protein bound to an exon 3-included reporter Sxl transcript 
 
Sreporter−mRNA i S2trigger−protein  The intermediate product in splicing: two mCherry-tagged Sxl proteins bound to an exon 3-included reporter Sxl 
transcript as homodimers 
Sreporter−mRNA  The GFP-fused exon 3-excluded Sxl transcript produced from 
the reporter  
Sreporter−protein  The GFP-tagged Sxl protein produced from the reporter 
 
Sreporter−mRNA i Sreporter−protein  The intermediate product in splicing: a GFP-tagged Sxl protein bound to an exon 3-included reporter Sxl transcript 
 
Sreporter−mRNA i S2reporter−protein  The intermediate product in splicing: two GFP-tagged Sxl proteins bound to an exon 3-included reporter Sxl transcript 
as homodimers  
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(1) 
(2) 
(3) 
(4) 
(5) 
(6) 
(7) 
(8) 
(9) 
(10) 
(11)  
(12) 
(13) 
 
With these initial settings of the model, the memory of transient dox exposure can 
be established successfully (Figure 5-6A). We then perturbed the parameters of the model 
as well as the initial values of  
Sreporter−mRNA  in order to investigate their effects on model 
performance. The results from these perturbations can determine whether a specific 
kinetic step of the circuit is essential for the performance of the device and contribute to 
the optimization of the device design.  Interestingly, although this is a preliminary model, 
it helped us to reveal interesting insights. For example, we found that memory 
establishment in the model is very sensitive to the capacity of the reporter to generate Sxl 
transcripts, i.e. the pool of Sxl transcripts generated by the reporter that can be converted 
to functional female-specific isoforms and produce Sxl proteins (Figure 5-6B,C). In 
contrast, the rate of trigger Sxl production does not affect the model’s performance on 
memory retention as much (data not shown). Suppose the number of transcripts generated  
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Figure 5-6: Stochastic modeling prediction of device performance when the 
production level of reporter Sxl transcripts is perturbed. 
(A) Device performance predicted by stochastic modeling when the reporter can generate 114 
copies of Sxl transcript. Memory of dox exposure is established. Left panel shows trigger and 
reporter Sxl protein productions and right panel shows functional Sxl mRNA (exon 3-excluded) 
productions from the trigger and reporter. X-axis depicts hours after dox induction and Y-axis 
shows number of molecules. Dox is removed after 10 hours. 
(B) Device performance predicted by stochastic modeling when the reporter can generate 57 
copies of Sxl transcript. Memory of dox exposure is still retained. 
(C) Device performance predicted by stochastic modeling when the reporter can generate 28 
copies of Sxl transcript. Memory of dox exposure is no longer retained. 
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Figure 5-6 (Continued). 
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from a CMV promoter is fixed, the amount of reporter Sxl transcripts is positively 
correlated to the copy number of the reporter in the device. Thus, it is crucial to 
experimentally measure the basal transcription level of the CMV promoter in our reporter 
and optimize the ratio of trigger/reporter constructs in the device based on that. 
 
DISCUSSION 
Preserved AS regulation of Drosophila Sxl in mammalian cells 
One surprising discovery of our study is that the self-regulation of splicing of 
Drosophila Sxl is preserved in mammalian cells, although mammalian cells do not have 
the gene Sxl nor its homolog and sex determination in mammals is profoundly different 
from flies. The expression of Sxl protein does not seem to have negative effects on 
mammalian cells (Figure 5-2A). As in Drosophila, Sxl transcripts containing exon 3 and 
surrounding intronic sequences per default generate the exon 3-inclusive male-specific 
isoform in mammalian cells (Figure 5-2B,D), and only the expression of a mature Sxl 
protein can alter the AS to generate the exon 3-exclusive, female-specific isoform (Figure 
5-2B,C,D).  
Although the mechanism of Sxl regulating the splicing of exon 3 is not fully 
understood, many factors have been identified to be involved in this process, including 
Spf45, snf, fl(2)d, and vir (Lallena et al. 2002; Salz and Flickinger 1996; Granadino et al. 
1990; Hilfiker et al. 1995). All these factors are splicing regulators and unlike Sxl, have 
homologs in mammalian cells. Thus the machinery for Sxl to regulate its own pre-mRNA 
splicing is preserved in mammalian cells. This could explain why we observe that 
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splicing of Drosophila Sxl is recapitulated in mammalian cells. The observation that 
overexpression of Drosophila Sxl in U2OS cells does not lead to a phenotype could be 
explained by the high specificity of AS regulation by Sxl (Penalva and Sánchez 2003). So 
far, only Sxl itself, tra and msl-2 in Drosophila have been experimentally validated as AS 
targets of Sxl. The splicing regulation of Sxl on these factors is involved in Drosophila 
sex determination, dosage compensation and germ line sex determination, the specific 
mechanisms of which are not implicated outside the genus Drosophila (Penalva and 
Sánchez 2003). As a result, the expression of foreign Sxl does not significantly affect 
mammalian cells.    
 
The potential of applying Sxl auto-regulatory feedback loop in synthetic memory circuits 
Our Sxl splicing-based memory device showed prompt response of the trigger to 
dox exposure and subsequent activation of the reporter from the trigger when stably 
integrated (Figure 5-4B,C). Although we have not been able to confirm whether stable 
establishment of memory can be achieved after removal of dox, the experimental results 
indicate the possibility of using the positive feedback loop of Sxl auto-splicing-regulation 
in memory devices.    
Due to the absolute bistability in the splicing pattern of Sxl and the fast regulation 
of its own transcript, the auto-regulatory loop of Sxl splicing regulation has great 
potential for use in synthetic memory devices. Unlike most AS events, the splicing of Sxl 
presents a 100% switch between the two male/female AS isoforms (Penalva and Sánchez 
2003). This demonstrates a tight control between the two states represented by the 
expression of the two splicing isoforms and low leakage in each state. In addition, 
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although AS is a posttranscriptional regulatory mechanism, many splicing events are 
coupled with transcription, in which the speed of RNA polymerase II and other activities 
affecting transcription can affect splicing (Pandya-Jones and Black, 2009; Listerman et 
al. 2006). However, it is shown that the regulation of Sxl on the splicing of exon 3 is 
uncoupled from transcription (Vargas et al. 2011). This means that Sxl AS is likely 
regulated under a fast time scale like other post-transcriptional regulations. This feature is 
important for building memory devices in mammalian cells as the device needs to 
respond to a transient trigger exposure and balance with the time scale of cell division.   
 
The interplay of computational modeling and experimental testing in rational synthetic 
device design  
The optimization of synthetic devices requires an efficient system to rationally 
test and evaluate the design of circuits. The combination of mathematical modeling and 
controlled genome integration methods provide such an approach.  
Information about the circuit dynamics can be obtained from modeling and used 
to guide the design of the device (Figure 5-6; Figure 5-5). Conversely, the comparison 
between the prediction of the model and the experimental performance of the device will 
improve the modeling and increase the prediction capability of the model. We believe 
that close interplay between computational modeling and experimental testing will 
improve our understanding of the optimization of splicing-based synthetic devices, as 
well as the dynamics of the AS regulatory network and its potential in building synthetic 
devices.   
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MATERIALS AND METHODS 
Plasmids, cell culture and stable cell line making 
Female Sxl transcript was cloned from cDNA made from female flies. RNA from 
10 females flies was extracted with Trizol (Invitrogen) and 5 µg were reverse transcribed 
with Superscript III (Invitrogen) and oligo-dT. Genomic regions of Sxl (exon 3 and 
adjacent intronic sequences) were PCR-amplified from Drosophila genomic DNA. 
Minigene constructs were cloned in T-Rex vector (Silver laboratory), EGFP-N1 and 
mCherry-N1 vector (Clontech).  
U2OS cell lines (Backlow laboratory) were grown in standard conditions. Plasmid 
transfection was performed with LipofectAMINE 2000 (Invitrogen). To generate a staple 
cell line carrying the memory device through random integration, U2OS cells were co-
transfected with the trigger and reporter constructs and co-selected with puromycin and 
hygromycin B 48 hr post-transfection. Resistant colonies were isolated with cloning 
cylinders (Millipore) and expanded. 
 
RNA extraction and RT-PCR 
U2OS cellular RNA was extracted by RNeasy Mini Kit (Qiagen). 1.5-3 µg RNAs 
were reverse-transcribed by Superscript First-Strand Synthesis System (Invitrogen). Sxl 
splicing isoforms were analyzed by RT-PCR through primers flanking the alternatively 
spliced region. A linear range for cDNA input was determined by running a two fold 
dilution series of 28 cycle PCR reactions. Products were run on 5% Tris-Borate-EDTA 
gels (Biorad), stained with SYBR gold stain (Invitrogen) and quantified with Image J 
software (NIH). Triplicate samples in the linear range were run to determine isoform 
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ratios. Real-time PCR primers were designed with the software Primer3 (SourceForge) 
and verified by electrophoresis to generate single, correctly sized products.  
 
Western blotting 
Cellular proteins were extracted with 1xRIPA buffer (IX PBS, 1% Triton X-100, 
0.5% sodium deoxycholate, 0.1% SDS, protease inhibitors). 10-30 µg of proteins were 
loaded onto each lane of a NuPAGE 4-12% Bis-Tris gel. Proteins were transferred onto 
PVDF membranes and probed with GFP antibody (Aves labs) diluted in 1X PBST with 
5% non-fat milk. 
 
Flow cytometry 
Cells were fixed with 4% paraformaldehype in 1X PBS and resuspended in 1X 
PBS. Cells were then loaded onto an LSRII (BD Biosciences) with 488 nm (DsRed) and 
568 nm (FITC) lasers. Unexposed U2OS cells were used to set up levels for basal 
fluorophore expression. Data were analyzed with FlowJo.  
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SUMMARY
Alternative splicing is a vast source of biological
regulation and diversity that is misregulated in can-
cer and other diseases. To investigate global control
of alternative splicing in human cells, we analyzed
splicing of mRNAs encoding Bcl2 family apoptosis
factors in a genome-wide siRNA screen. The screen
identifiedmany regulators ofBcl-x andMcl1 splicing,
notably an extensive network of cell-cycle factors
linked to aurora kinase A. Drugs or siRNAs that
induce mitotic arrest promote proapoptotic splicing
of Bcl-x, Mcl1, and caspase-9 and alter splicing of
other apoptotic transcripts. This response precedes
mitotic arrest, indicating coordinated upregulation
of prodeath splice variants that promotes apoptosis
in arrested cells. These shifts correspond to post-
translational turnover of splicing regulator ASF/SF2,
which directly binds and regulates these target
mRNAs and globally regulates apoptosis. Broadly,
our results reveal an alternative splicing network
linking cell-cycle control to apoptosis.
INTRODUCTION
Nearly all human precursor messenger RNAs (pre-mRNAs)
undergo alternative splicing (AS), with tremendous variation
and specificity across tissues, development, and disease (Pan
et al., 2008). This vast complexity is a formidable challenge to
experimental and informatic analysis of AS and its physiological
roles (Blencowe, 2006). One emergent concept is that function-
ally coherent transcript populations, termed RNA ‘‘regulons,’’
are coregulated by dedicated RNA-binding proteins (RBPs) to
promote specific biological functions (Keene, 2007). These
RBPs, notably SR proteins and hnRNPs, ‘‘decode’’ transcript
cis elements and control stepwise assembly of spliceosomal
snRNPs: U1 at the 50 splice -site (ss), then U2 near the 30 ss,
and finally U5/4/6 (Wahl et al., 2009; Black, 2003). Splicing
control is integrated with signal transduction pathways, pro-
moting dynamic, context-driven regulation. Collectively, these
features produce robust cell- and tissue-specific signatures of
exon use that shape many aspects of cell fate (Moore and Silver,
2008). Exon signatures are radically transformed in tumors, but
the causes and consequences are unknown.
In this study, we examine AS of Bcl2 family apoptosis regula-
tors Bcl-x and Mcl1. Bcl2-like proteins contain up to four Bcl2-
homology (BH) domains (BH1–4) (Hardwick and Youle, 2009).
Factors possessing all four BH domains, including Bcl2, Bcl-xL,
and Mcl1L, antagonize apoptosis by preventing mitochondrial
outer membrane permeablization (MOMP), thus sequestering
proapoptotic factors in mitochondria. Factors lacking one or
more BH domain, including Bid, BAD, and BAX, are proapoptotic
and promote MOMP. A finely tuned balance of pro- and antia-
poptotic Bcl2-like factors therefore controls mitochondrial integ-
rity and hence downstream steps in apoptosis such as apopto-
some formation and caspase activation (Wang and Youle, 2009).
Remarkably,Bcl-x,Mcl1, and some otherBcl2 familymRNAs are
alternatively spliced to yield both long (L) antiapoptotic and short
(S) proapoptotic forms. For Bcl-x, use of an alternative 50 ss in
exon 2 excludes the BH1 and BH2 domains (Akgul et al.,
2004). For Mcl1, exon 2 skipping excludes the BH1 and BH2
domains and eliminates the downstream transmembrane
domain via frame shift.
Many cis-regulatory elements and trans-acting factors exert
combinatorial control of Bcl-x splicing. Most known regulators,
including Sam68, ASF/SF2, hnRNP F/H, SRp30c, and RBM25,
altered Bcl-x AS in vitro or when overexpressed in cell culture
(Cloutier et al., 2008; Zhou et al., 2008; Paronetto et al., 2007;
Garneau et al., 2005). In addition, in RNA interference (RNAi)-
based loss-of-function assays, depletion of Sam68 and
hnRNPA1 favored Bcl-xL formation, while depletion of U2
snRNP component SF3B1/SAP155 favored Bcl-xS (Paronetto
et al., 2007; Massiello et al., 2006). Comparably little is known
of Mcl1 splicing regulation.
Beyond Bcl2-like factors, caspases, ‘‘death receptors,’’
ligands and various adaptors are regulated by AS, suggesting
broad roles in controlling apoptosis (Schwerk and Schulze-
Osthoff, 2005). Many apoptosis regulators, including Bcl2-like
proteins, are proto-oncogenes that contribute to apoptosis
resistance in cancer (Letai, 2008; Fesik, 2005). Modulation of
apoptotic factors by targeting the splicing machinery is thus an
attractive strategy to facilitate tumor cell death. Furthermore,
while the divergent functions of Bcl-x and Mcl1 isoforms in
apoptosis are well established, the physiological contexts and
upstream regulation of their expression are poorly defined.
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These unanswered questions illustrate a pervasive challenge in
defining physiological contexts of AS regulation, because
strategies for systematic evaluation of upstream regulation are
limited.
Genome-scale screening of RNA regulatory events is compli-
cated by the difficulty of visualizing RNAs in vivo, and the tech-
nical infeasibility of high-throughput measurements by RT-PCR
and other methods. Splicing-sensitive fluorescent reporters are
an alternative strategy that produce a robust, visual output suit-
able for screening efforts (Stoilov et al., 2008; Warzecha, et al.,
2009; Orengo et al., 2006). Here, we present high-throughput
assays that recapitulate physiological regulation of Bcl-x and
Mcl1 AS. In a whole-genome siRNA screen, we identified new
factors that regulate the balance of anti- and proapoptotic splice
isoforms, with striking enrichment for cell-cycle factors. These
results define functional interactions between the cell cycle
and splicingmachineries in human cells thatmanifest in a coordi-
nated program of AS controlling apoptosis.
RESULTS
Reporter Assays for Bcl-x andMcl1 Alternative Splicing
To develop splicing assays for high-throughput analysis, we de-
signed splicing-sensitive reporters for the Bcl2 family apoptosis
regulators Bcl-x and Mcl1. 50 untranslated region (UTR), open
reading frame (ORF), and intervening intron sequences for Bcl-x
and Mcl1 were cloned in C-terminal fusions with Venus (yellow)
and mCherry (red) complementary DNAs (cDNAs), respectively
(Figure 1A). In HeLa cells, these constructs expressed long and
short spliced mRNAs at ratios similar to endogenous mRNAs
(Figure 1B). To render constructs splicing-sensitive, premature
termination codons (PTCs) were introduced in alternative exon
regions exclusive to long splice forms. As expected, PTCs elim-
inated expression of long protein variants, but short forms were
retained (Figure 1C).
To produce screen assay cell lines, splicing reporters were
stably transfected into HeLa cells alongwith a constitutivemCer-
ulean fluorescent protein (CFP) construct. All constructs used
the human EF1a promoter, which contains a 50 UTR intron,
allowing dual measurements of minigene splicing and a constitu-
tively spliced CFP reporter under identical control. To test the
Bcl-x reporter line, we verified that siRNA-depletion of known
regulator SF3B1 increased Bcl-xS-Venus expression relative to
a non-targeting control (Figure 1D, left panels) (Massiello et al.,
2006). Immunoblotting confirmed efficient siRNA knockdown
of SF3B1, and upregulation of Bcl-xS-Venus reporter protein
(Figure 1E). RT-PCR confirmed upregulation of the Bcl-xS-
Venus mRNA (Figure 1F). Finally, RT-PCR analysis of endoge-
nous Bcl-x transcript in HeLa cells verified that SF3B1 knock-
down shifted splicing toward Bcl-xS, demonstrating congruous
regulation of minigene and endogenous splicing (Figure 1G,
upper panel).
We had no a priori knowledge of Mcl1 regulators, but SF3B1
knockdown also upregulated Mcl1S-mCherry in the splicing
assay, establishing a positive assay control (Figure 1D, right
panels). Analysis of endogenous Mcl1 verified this shift toward
Mcl1S (Figure 1G, lower panel).
High-Throughput siRNA Screens for Alternative
Splicing Regulators
To identify regulators ofBcl-x AS, >21,000 siRNA pools targeting
known and predicted human genes were screened for upregula-
tion of the Bcl-x reporter (Figure 2A). Three hundred and sixty-
nine positive hits were identified with a Support Vector Machine
(SVM) model that determined reproducibility (i.e., ‘‘confidence’’)
across triplicates and signal ‘‘strength’’ relative to positive and
negative control siRNAs (Figure 2B, and Figure S1 and Table S1
available online). Hits had strong gene ontology (GO) enrich-
ments for mRNA splicing/processing, protein kinase signaling,
cytoskeleton association, and cell-cycle functions (Figure 2C).
Importantly, the screen blindly recovered positive control
SF3B1 and several of its interactors.
For validation, hits were retested in the screen assay with
four individual siRNAs from deconvoluted SMARTpools. Two
hundred and seventy-four of 369 factors validated with at least
one siRNA, and 160 validated with two or more (Figure 2A and
Table S2). In the primary and validation screens, Bcl-x-Venus
expression correlated significantly with cell death (Figures S2A
and S2C). Venus showed no systematic correlation to CFP,
indicating that nonspecific promoter effects were not a major
source of positives (Figures S2B and S2F). In the validation
screen, apoptosis was tracked by Annexin-V-Cy5 staining and
showed strong coupling to proapoptotic Bcl-x splicing and cell
death (Figures S2D and S2E). Functional enrichments, notably
splicing and cell-cycle regulation, were similar between vali-
dated hits and the primary screen (Figure 2C). Subsequent anal-
yses focused on ‘‘high-confidence’’ factors validated with two
or more siRNAs. We focused specifically on aurora kinase A
(AURKA) and other mitotic regulators because of their strong
functional enrichment and their novelty in the context of splicing
regulation.
Physiological function for screen hits was confirmed by
analysis of endogenous Bcl-x AS in HeLa cells. siRNAs against
19 factors were tested, and 16 (!85%) significantly shifted
Bcl-x splicing toward Bcl-xS (Figure S3A). The magnitude of
these shifts matched or exceeded fold changes that promote
apoptosis in various cell types, indicating physiological signifi-
cance (Mercatante et al., 2002; Taylor et al., 1999). As further
indication of this significance, AURKA knockdown strongly
shifted endogenous Bcl-x protein toward Bcl-xS (Figure S3B).
This shift was larger than the corresponding mRNA shift, sug-
gesting an amplification effect during translation. Regulation of
endogenous Bcl-x by AURKA and other hits also confirmed in
MCF7 (breast adenocarcinoma) and PANC1 (pancreatic carci-
noma) cells (Figure S3C). These lines differ markedly in steady
state AURKA levels, with MCF7 (like HeLa) expressing high
levels, and PANC1 levels closer to ‘‘normal’’ tissue (Ross et al.,
2000). Thus, splicing regulation by AURKA inhibition was not
restricted to HeLa cells and occurred irrespective of steady state
AURKA levels.
Apoptosis Suppression Defines Direct Regulators
of Bcl-x Alternative Splicing
In screening experiments, proapoptotic Bcl-x splicing correlated
to apoptosis induction and increased cell death (Figure S2).
However, screen hits are likely to include both direct regulators
626 Cell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc.
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of Bcl-x splicing and factors that influence splicing indirectly via
upstream activation of proapoptotic pathways (Figure 3A). To
define systematically the relationship of screen hits to apoptosis,
we retested all 274 validated regulators inBcl-x reporter cells en-
gineered to overexpress Bcl2. Bcl2 overexpression suppresses
mitochondrial permeablization and hence canonical apoptosis
progression (Kroemer, 1997). Importantly, Bcl2 directly antago-
nizes the function of Bcl-xS, so this strategy also suppresses
potential downstream effects of Bcl-xS-Venus produced by
the reporter construct. We predicted that Bcl2 overexpression
would attenuate the effects of proapoptotic siRNAs that alter
Bcl-x splicing as part of a general proapoptotic response, but
not siRNAs that target more direct regulators of splicing.
Supporting the latter prediction, depletion of direct regulator
SF3B1 increased reporter expression despite Bcl2 overexpres-
sion (Figure 3B).
Thirty-three percent of 160 high-confidence Bcl-x regulators
were totally suppressed by Bcl2 overexpression (Table S3). For
example, Bcl2 suppressed both cell death and changes in
Bcl-x splicing in response to depleting mRNA export factors
NXF1 or NUPL2 (Figure 3C). By contrast, 67% of factors,
including AURKA, showed partial or no suppression of proapop-
totic Bcl-x splicing, despite the fact that cell counts showed effi-
cient suppression of cell death. Thus, AURKA, not previously
implicated in splicing regulation, functioned independently of
Bcl2, whereas mRNA export factors, which directly interact
Figure 1. Bcl-x and Mcl1 Alternative
Splicing Reporters
(A) Bcl-x andMcl1minigene splicing reporters are
schematized. Green rectangles are exons, with
dark gray as alternative regions. Black lines depict
introns. Large arrows denote translation start
sites, and arrowheads show primer sets used
for qPCR. Inserted PTCs, exclusive to long (L) iso-
forms, are shown by red ‘‘stop signs.’’
(B) Minigene constructs are spliced like endoge-
nous mRNAs. Splice isoforms from minigene- or
mock-transfected (endogenous) HeLa cells were
analyzed by RT-PCR with primer sets from (A).
Because of high transient minigene expression,
cDNA from minigene samples was diluted 1:105
relative to mock (endogenous). At this dilution,
endogenous mRNAs do not contribute to prod-
ucts in the ‘‘minigene’’ lanes.
(C) A PTC introduced to the alternative exon region
eliminated Bcl-xL-Venus but not Bcl-xS-Venus
protein expression. HeLa cells were transfected
with Bcl-x-Venus (PTC-) or Bcl-x-Venus-PTC
(PTC+) constructs, and lysates were analyzed by
western with indicated antibodies. Migration of
isoforms is indicated to the left of images (last
two lanes overexposed to show Bcl-xS-Venus).
(D) SF3B1 knockdown activated proapoptotic
splicing of Bcl-x and Mcl1 reporters. Stable
reporter lines were transfected with SF3B1 or non-
targeting siRNA pools and imaged in the indicated
channels. SF3B1 knockdown increased minigene
expression versus controls in both cases. SF3B1
depletion also decreased CFP modestly, possibly
reflecting a role in splicing the EF1a intron. Subse-
quent experiments showed this effect on CFP
expression was restricted to SF3B1 (see Figures
S2B and S2F).
(E) Upregulation of Bcl-xS bySF3B1 depletion was
confirmed by western analysis. Lysates from cells
treated as in (D) were analyzed with antibodies
indicated to the left of images. SF3B1 knockdown
depleted SF3B1 and increased Bcl-xS-Venus
relative to controls.
(F) Results in (D) and (E) were verified at the RNA
level by RT-PCR. Migration of Bcl-xS, Bcl-xL (PTC
causes nonsense-mediated decay), and GAPDH
(loading control) are indicated to left of the images.
(G) Results in (D), (E), and (F) model the regulation of endogenous Bcl-x andMcl1mRNAs. Unmodified HeLa cells were transfected with SF3B1 or control siRNAs.
RT-PCR analysis confirmed that SF3B1 knockdown favored short, proapoptotic forms. S/L ratios are quantified to the right of the images; values are the means of
three independent measurements ± SD, normalized to controls.
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with the spliceosome, were suppressed. Overall, most mRNA-
splicing and cell-cycle regulators showed no or partial sup-
pression (Figure 3D). Suppressed factors were enriched for
functions in transcription, while signaling factors spanned both
categories.
Discovery ofMcl1 Alternative Splicing Regulators
To explore functional coordination of apoptotic AS events, we
determined all Bcl-x regulators that also control functionally
analogous AS of Mcl1. Fifty-two of 160 ‘‘high-confidence’’
factors regulated both events, and we validated a subset on
endogenous Mcl1 (Figure 4A, Figure S4, and Table S4). Cell-
cycle functions were enriched for factors that coregulated
Bcl-x and Mcl1, but not factors that regulated only Bcl-x
(Figure 4A). Similarly, common regulators were disproportion-
ately enriched for splicing functions versus those that only regu-
lated Bcl-x. This result indicates extensive coregulation of Bcl-x
and Mcl1 by cell-cycle and splicing factors. In contrast, tran-
scription regulators were enriched only forBcl-x. Figure 4B sche-
matizes hits in the Bcl-x andMcl1 screens with known or postu-
lated functions in mRNA metabolism. Hits included ‘‘core’’
spliceosome components in Sm ring domains and snRNPs, as
well as hnRNP and SR proteins. Interestingly, factors acting
late in spliceosome assembly, including U5 snRNP components
and factors previously linked to cell-cycle regulation (e.g.,
CDC40, CDC5L), scored positively for both Bcl-x and Mcl1
(Makarova et al. 2004).
As an unbiased analysis of Mcl1 AS, we tested siRNA pools
for >700 human kinases and phosphatases in theMcl1 screening
assay. Common regulators for Bcl-x and Mcl1 included cell-
Figure 2. Whole-Genome siRNA Screen for
Regulators of Bcl-x Alternative Splicing
(A) Screening, analysis, and hit selection are sche-
matized. Of 369 primary hits, 274 revalidated. The
pie chart indicates how many of 274 validated hits
reconfirmed with one, two, three, or four siRNAs.
One hundred and sixty ‘‘high-confidence’’ hits
validated with two or more siRNAs (see the
Extended Experimental Procedures for complete
analysis methods).
(B) SVM probability scores are plotted for the
whole-genome siRNA screen, with confidence
on the x axis and strength on the y axis. The blue
region shows the SVM cutoff for hit selection
(see Figures S1, S2, and S3 and Tables S1 and
S2 for detailed analysis and validation).
(C) GO functional enrichments from primary, reva-
lidated (one ormore siRNAs), and high-confidence
(two or more siRNAs) hits are shown, plotted by
relative statistical significance.
See also Figures S1, S2, and S3 and Tables S1
and S2.
cycle kinases AURKA, PLK1, and WEE1
(Figure 4C and Table S5). Further, BUB1
scored strongly for Bcl-x and weakly
positive for Mcl1, though the latter did
not surpass the confidence threshold.
Conversely, CDK1 (CDC2) was strongly
positive for Mcl1, and weakly so for Bcl-x. These data indepen-
dently confirm Mcl1 AS regulation by cell-cycle disruption.
Coupling of Cell-Cycle Control and Alternative Splicing
The screen identified many cell-cycle factors, including cancer
therapy targets AURKA, PLK1, and survivin (BIRC5). Protein
interaction network analysis of screen hits revealed AURKA-
centered interactions spanning the cell cycle, spliceosome,
and tumor suppressors (Figure 5A). As independent validation
of this regulation, nocodazole, an inhibitor of microtubule
polymerization, and aurora kinase inhibitors ZM447439 and
VX-680 strongly induced Bcl-xS formation in a dose-dependent
manner (Figure 5B). By contrast, the broad-spectrum kinase
inhibitor staurosporine induced apoptosis but not Bcl-xS forma-
tion, demonstrating specific regulation by cell-cycle inhibitors.
ZM447439 and VX-680 inhibit the three mammalian aurora
kinases AURKA, AURKB, and germline-restricted AURKC. How-
ever, ZM447439 is !20-fold more potent toward AURKB than
AURKA in vitro, while VX-680 is !30-fold more potent against
AURKA (Ditchfield et al., 2005; Harrington et al., 2004). Since
Bcl-x splicing regulation in screening assays was AURKA
specific, VX-680 was used subsequently because of its higher
specificity for AURKA. Importantly, nocodazole and VX-680
treatment also shifted endogenous Bcl-x and Mcl1 splicing
(Figure S5).
In flow cytometry experiments, aurora inhibitors induced
mitotic arrest concomitant with upregulation of theBcl-x reporter
(Figure 5C). Bcl-xS-Venus levels in actively cycling G2/M cells
were slightly higher than in G1, but the difference was not signif-
icant compared to arrested cells (Figure 5D). In addition, S phase
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arrest by double-thymidine block did not affect Bcl-xS-Venus
levels, so the splicing response was specific to mitotic arrest
(Figure 5E). Since transcription and splicing are primarily
silenced in M phase (Shin and Manley, 2002), we considered
two possibilities: (1) splicing changes preceded arrest or (2)
a subset of cells underwent an abnormal division prior to full
arrest, leading to a proapoptotic stress response. To test the
latter scenario, cells were synchronized by double-thymidine
block, released, and treated with VX-680. Venus fluorescence
was measured 16 hr after thymidine release, thus ruling out an
intervening mitotic cycle. Figure 5F shows the splicing response
to VX-680 in synchronized cells was comparable to asynchro-
nous cells. Apoptosis induction by staurosporine caused no
splicing response, regardless of synchronization. These results
show that stimuli that activate G2/M and spindle checkpoints
trigger proapoptotic Bcl-x splicing, but the response precedes
actual arrest.
Downstream Mechanisms of Splicing Regulation
To identify direct splicing regulators downstream of cell-cycle
inhibition, we examined expression of splicing factors upon
AURKA knockdown, focusing on strong screen hits or factors
previously linked to Bcl-x splicing (Figure S6A). Among these
factors, only ASF/SF2 (SFRS1)—an SR protein previously linked
to cell-cycle regulation and a strong hit in the primary screen—
showed specific downregulation upon AURKA knockdown
(Figure 6A) (Li et al., 2005). Inhibition of AURKA with VX-680
also resulted in dose-responsive downregulation of ASF/SF2
(Figure 6B).
ASF/SF2 mRNA was not significantly reduced upon AURKA
inhibition, ruling out transcriptional downregulation or effects
on RNA stability (Figure S6B). However, VX-680 treatment
reduced exogenous green fluorescent protein (GFP)-tagged
ASF/SF2 in a manner similar to endogenous ASF/SF2, indicating
posttranslational turnover as the main source of ASF/SF2 deple-
tion (Figure 6C). AURKA inhibition also induced ASF/SF2 down-
regulation in apoptosis-resistant cells that overexpress Bcl2
(Figure S6C). Therefore, this regulatory pathway functions in
cells where apoptosis is suppressed, consistent with our finding
that AURKA knockdown shifts Bcl-x splicing when apoptosis is
suppressed (Figure 3C).
To determine whether Bcl-x is a direct target of ASF/SF2, we
used the CLIPmethod (ultraviolet [UV] crosslinking and immuno-
precipitation) to analyze RNAs bound directly by ASF/SF2
in vivo. RNP complexes were covalently crosslinked in living
cells by UV exposure, and ASF/SF2-RNA complexes were
immunopurified (Figure 6D). RT-PCR analysis showed significant
enrichment of Bcl-x mRNA in ASF/SF2-RNA immunoprecipita-
tions (IPs) versus an irrelevant IgG control, along with Mcl1 and
previously known target TPX2 (Figure 6E) (Sanford et al., 2009).
Figure 3. Apoptosis Inhibition by Bcl2 Suppressed a Subset of Bcl-x Regulators
(A) Screen hits (lightning bolts) may affectBcl-xAS bymany potential mechanisms. Regulationmay be direct, such as (1) direct suppression ofBcl-xS formation or
(2) facilitation ofBcl-xL. Indirect or downstream regulators may (3) promote cell survival pathways or (4) suppress proapoptotic pathways. We predicted that Bcl2
overexpression would suppress the splicing regulatory effect of siRNAs targeting indirect mechanisms, but not direct regulators.
(B) Bcl2 overexpression did not suppress the effect of SF3B1 depletion, consistent with direct regulation of Bcl-x splicing.
(C) Bcl2 suppressed the effect of siRNAs against mRNA export factors NXF1 and NUPL2, but not AURKA, on Bcl-x splicing (compare Venus images between
‘‘wild-type’’ and ‘‘Bcl2 overexpression’’). By contrast, Bcl2 suppressed cell death in all cases (compare DAPI images).
(D) Thirty-three percent of hits were suppressed by Bcl2 overexpression, while 67% showed partial to no suppression. GO functional enrichments within these
subsets are shown with p values (see Table S3).
See also Table S3.
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APAF1 and TNFSF13 mRNAs were detectable in input but not
ASF/SF2 IPs, demonstrating that crosslinking was specific.
Our data show direct regulation of Bcl-x and Mcl1 splicing by
ASF/SF2 and downregulation of ASF/SF2 by AURKA inhibition.
To test whether ASF/SF2 functions downstream of AURKA inhi-
bition, we examined whether exogenous ASF/SF2 expression
could ‘‘rescue’’ the splicing response to AURKA inhibition.
Bcl-x reporter cells were transfected with mCherry-tagged
constructs expressing wild-type (WT) ASF/SF2 or a variant lack-
ing the second RNA recognition motif (DRRM2) domain. After
VX-680 treatment, the Bcl-x splicing response in cells express-
ing ASF/SF2-WT was reduced!50% relative to cells expressing
DRRM2 or mCherry alone (Figure 6F). CLIP of exogenous GFP-
tagged ASF/SF2 constructs confirmed deficient recognition of
endogenous Bcl-x mRNA by the DRRM2 mutant (Figure 6G)
(Ca´ceres et al., 1997). Therefore, enforced ASF/SF2 expression
rescued the effect of AURKA inhibition on Bcl-x splicing, and
rescue was dependent on intact splicing regulatory function.
ASF/SF2 regulates apoptosis globally in response to cell-cycle
inhibition. Consistent with previous reports, siRNA depletion of
ASF/SF2 activates markers of apoptosis (e.g., Annexin-V stain-
ing, DNA fragmentation, and caspase cleavage) (data not shown)
(Li et al., 2005; Karni et al., 2007). To analyze apoptosis regula-
tion by ASF/SF2 in the context of cell-cycle disruption, we
depleted ASF/SF2 by RNAi and analyzed apoptosis markers
upon AURKA inhibition with VX-680. ASF/SF2 depletion
enhanced caspase activation and Annexin-V staining relative
to a nontargeting siRNA control (Figures 7A and 7B). In addition,
we compared the effects of ASF/SF2 depletion to the depletion
of two splicing factors (SRPK1 and SNRP70) that had no signif-
icant effect on endogenous Bcl-x splicing and a third factor
(Sam68) that has antagonistic effects to ASF/SF2 on Bcl-x
splicing (Figure S3A and Table S1) (Paronetto et al., 2007).
ASF/SF2 depletion sensitized cells to VX-680-induced apoptosis
relative to SRPK1, SNRP70, or Sam68 depletion. In contrast,
ASF/SF2 depletion did not enhance staurosporine-induced
apoptosis relative to SRPK1, SNRP70, or Sam68 depletion
(Figure S6D). We could not reliably analyze the effects of en-
forced ASF/SF2 expression on apoptotic markers because over-
expression was toxic in the time frame required for this analysis.
In sum, ASF/SF2 loss-of-function triggers apoptosis and specif-
ically sensitizes cells to apoptosis induced by AURKA inhibition.
To examine broader functions of AS in this apoptotic
response, we analyzed caspase-9 (CASP9) and caspase-2
(CASP2) mRNAs, which produce short (S), antiapoptotic, or
long (L), proapoptotic isoforms (Schwerk and Schulze-Osthoff,
2005). Depletion of ASF/SF2 and AURKA favored proapoptotic
CASP9 splicing (Figure 7C) (Massiello and Chalfant, 2006). In
addition, ASF/SF2 depletion favored proapoptotic CASP2
splicing, although AURKA knockdown had no significant effect.
We extended our analysis to additional factors with diverse
apoptotic functions and AS patterns, including exon skipping,
alternative 50 ss use, and intron retention. Splice isoforms were
measured with an isoform-sensitive qPCR strategy upon
Figure 4. Coordinated Regulation of Bcl-x and Mcl1 Alternative
Splicing
(A) Bcl-x screen hits were tested forMcl1 regulation to identify common regu-
lators. High-confidence hits are depicted as a Venn diagram, with GO enrich-
ments listed with p values in the subsets where they were most significantly
enriched (see Figure S4 and Table S4).
(B) Spliceosome-associated proteins (SAPs) that were Bcl-x screen hits are
shownwith established physical interactions and functional roles. Blue ellipses
represent known RNP or protein complexes; pink ellipses contain functionally
or structurally related factors. Low-confidence hits are italicized. Factors in
gray rectangle have unknown roles in splicing but were identified in proteomic
analyses or are similar to known splicing factors (Chen et al., 2007). Factors are
marked as follows: *, high-confidence hit forMcl1; underlined, phosphorylated
in mitosis; +, putative AURKA target; x, putative CDK1 target; and #, putative
PLK1 target (Dephoure et al., 2008).
(C) Hits from a kinase/phosphatase screen for Mcl1 splicing regulation are
shown, with corresponding Bcl-x regulators. A cutoff of p < 10"5 in three repli-
cates, or p < 10"7 in two replicates was applied (see Table S5). Cell cycle
factors are underlined.
See also Figure S4 and Tables S4 and S5.
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knockdown of various screen hits, revealing widespread
changes in splicing upon silencing of cell-cycle regulators
(Figures 7D). This approach is only semiquantitative, so we
focused on identifying biologically robust events by Z score anal-
ysis of four independent experiments (Figures S7A and S7B).
Hierarchical clustering of knockdown profiles revealed overlap-
ping regulation by cell-cycle kinases AURKA, CDC2, and
BUB1. In addition, splicing factor profiles grouped by validated
spliceosomal interactions; the U2 snRNP factors SF3B1 and
SF3A1 overlapped significantly, as did U5 factors PRPF6 and
U5-200K. Interestingly, ASF/SF2 targets clustered with AURKA
and kinetochore component NDC80, suggesting overlapping
regulation in this specific set of mRNAs. As confirmation of direct
regulation, binding of ASF/SF2 to selected targets CASP9,
CASP2, ATG4, and BMF was established by CLIP (Figure S7D).
DISCUSSION
Genome-wide Identification of Alternative Splicing
Regulators in Human Cells
We developed a strategy for systematic, high-throughput anal-
ysis of AS regulation in human cells. Our siRNA screens identi-
fied many spliceosomal regulators of Bcl-x and Mcl1 splicing,
as well as functional connections to cell-cycle control, cytoskel-
eton dynamics, and signal transduction (Figure 2C). Strong func-
tional enrichment for known splicing factors was an encouraging
indication of specificity. In addition, a high validation rate of
screen hits on endogenous AS indicated faithful modeling of
physiological regulation in our reporter assays (Figure S3).
Broadly, our efforts expand the catalog of factors linking
mRNA metabolism and apoptosis and provide a platform for
Figure 5. Alternative Splicing Regulation Is Coupled to Cell-Cycle Control
(A) Screen hits span an AURKA-centered protein interaction network. Circles (‘‘nodes’’) depict proteins, connected by lines (‘‘edges’’) representing validated
protein-protein interactions. A maximum of two nonhit bridges was permitted to connect hits to AURKA, as described in the Extended Experimental Procedures.
(B) Drugs disrupting the cell-cycle promote proapoptotic Bcl-x AS. Bcl-x reporter cells were treated with nocodazole, aurora inhibitors VX-680 or ZM447439, or
staurosporine for 18 hr. 3-fold dilution series were tested with the following maximum concentrations: 200 nM nocodazole, 10 mMVX-680, 30 mMZM447439, and
33 nM staurosporine. Percent-Venus-positive values for drug treatments were normalized to DMSO treatments; plotted values reflect means of 8–12 measure-
ments ± SD. Nocodazole, VX-680, and ZM447439, but not staurosporine, caused significant proapoptotic shifts in Bcl-x splicing (p < 0.001). LD50 ranges derived
from cell counts are shown below the x axis. Wells with >33 nM staurosporine had >95% death, so they were not quantified (see Figure S5).
(C) Aurora inhibitors induced mitotic arrest coupled with proapoptotic Bcl-x splicing. Bcl-x reporter cells were treated with 3 mM VX-680, 10 mM ZM447439, or
DMSO, stained with propidium iodide, and analyzed for DNA content and Venus fluorescence by flow cytometry.
(D) Asynchronous, actively cycling cells from (C) show little to no Bcl-x splicing fluctuations relative to arrested cells.
(E) S phase arrest by double thymidine block did not alter Bcl-x splicing, indicating specificity for mitotic arrest. Cells were analyzed as in (C).
(F) Bcl-x splicing regulation precedes mitotic arrest. Asynchronous or thymidine-synchronized cells from (E) were treated with the indicated inhibitors or DMSO.
Cells were analyzed by automated microscopy 16 hr after thymidine release, precluding an intervening round of mitosis for synchronized cells. The response in
presynchronized cells confirms a splicing shift upstream of mitotic arrest.
See also Figure S5.
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future high-throughput analyses of mRNA processing in living
cells.
Screen hits spanned essential processes, such as transcrip-
tion, cell division, and prosurvival signaling, with extensive
mechanistic links to apoptosis, implicating splicing regulation
in diverse proapoptotic pathways. The strong correlation of
Bcl-xS formation with apoptosis induction and cell death further
support a physiological function for splicing regulation in
apoptosis (Figure S2). To investigate the functional connection
between splicing regulation and apoptosis, we retested factors
in cells rendered resistant to apoptosis by exogenous Bcl2
expression (Figure 3). Surprisingly, cell-cycle factors, like most
spliceosomal factors, were generally not affected by Bcl2
expression. Therefore, functional coupling of cell-cycle disrup-
tion to proapoptotic splicing remained intact in cells in which
the canonical apoptosis pathway was suppressed. This finding
suggests that coordinated, proapoptotic splicing could be
exploited to target apoptosis-resistant cell populations, such
as tumors.
Our screening experiments also revealed functional coordina-
tion of proapoptotic splicing events. Fifty-two of 160 ‘‘high-confi-
dence’’ Bcl-x regulators affected functionally analogous splicing
of Mcl1, and common regulators were disproportionately
enriched for splicing and cell-cycle functions (Figure 4A). Over-
lapping spliceosomal regulators of Bcl-x and Mcl1 included
‘‘alternative splicing factors’’ (e.g., hnRNPs and SR proteins)
and ‘‘core’’ spliceosome components spanning most steps in
spliceosome assembly (Figure 4B). Interestingly, U5 snRNP
Figure 6. ASF/SF2 Regulates Splicing
Downstream of AURKA
(A) siRNA depletion of AURKA downregulated
ASF/SF2. Cells were transfected with two different
siRNAs for AURKA or AURKB, or control siRNAs.
Lysates were analyzed by western analysis for
indicated factors. No other splicing factors mea-
sured in these samples showed significant
changes (Figure S6A), indicating specificity for
ASF/SF2.
(B) VX-680 treatment downregulated ASF/SF2 in
a dose-dependent manner.
(C) ASF/SF2 is downregulated posttranslationally
upon AURKA inhibition (see also Figure S6B).
HeLa cells were transfected with a GFP-ASF/SF2
construct, and then treated with VX-680 or
DMSO. Western analysis showed that VX-680
downregulated exogenous ASF/SF2, indicating
posttranslational turnover. ASF/SF2 downregula-
tion also occurred in apoptosis-resistant cells
overexpressing Bcl2 (see Figure S6C).
(D) Visualization of ASF/SF2-RNA complexes by
CLIP is shown. RNP complexes were UV cross-
linked in live HeLa cells, ASF/SF2 was immuno-
purified, and RNA was end labeled with g-32P-
ATP. Complexes were run on SDS-PAGE and
visualized by autoradiography. Noncrosslinked
ASF/SF2 (UV! lane) was also labeled, as
observed in Sanford et al. (2009).
(E) ASF/SF2 directly bindsBcl-x andMcl1mRNAs.
RT-PCR analysis of ASF/SF2-bound RNAs
showed significant enrichment of Bcl-x, Mcl1,
and known target TPX2 versus an irrelevant IgG
control. Values are the means of three indepen-
dent measurements ± SD.
(F) Exogenous expression of ASF/SF2 attenuated
the effect of AURKA inhibition on Bcl-x splicing.
Bcl-x reporter cells were transfected with
mCherry-tagged ASF/SF2, a mutant lacking the
second RRM domain (DRRM2), or mCherry alone.
Eighteen hours after transfection, cells were
treated with 3 mm VX-680 or DMSO for 24 hr.
The fraction of Venus-positive cells among mCherry-positive cells was determined by automated microscopy. VX-680-treated samples were background cor-
rected by subtraction of values from DMSO treatment. Values are the means of three separate measurements ± SD, expressed relative to the mCherry-trans-
fected control. ASF/SF2-WT attenuated theBcl-x response to VX-680 by"50% versusDRRM2. CFP expressionwas not affected, indicating specific attenuation
of Bcl-x splicing.
(G) ASF/SF2-DRRM2 shows deficient association with Bcl-x and Mcl1 mRNAs. CLIP analysis of exogenous, GFP-tagged ASF/SF2-WT or -DRRM2 was per-
formed with a-GFP antisera. Values are the means of three independent measurements ± SD.
See also Figure S6.
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and associated factors that function late in spliceosome
assembly affected splice-site choice for Bcl-x, Mcl1, and other
mRNAs (Figures 4B, 7C, and 7D). Current mechanistic models
support splice-site pairing early in spliceosome assembly upon
U2 snRNP recruitment (Dassah et al., 2009). Our findings
suggest that perturbations of late steps in spliceosome func-
tion may promote remodeling of splice-site choice downstream
of the rate-limiting steps that normally determine splicing
decisions.
Cell-Cycle Disruption Coupled to Proapoptotic
Alternative Splicing
Our screen for AS regulators identified factors involved in mitotic
spindle assembly, kinetochore and centromere dynamics,
microtubule transport, centrosome duplication and dynamics,
and cell division (Figure 5A). Well-characterized pharmacolog-
ical inhibitors, notably for AURKA, confirmed functional coupling
of cell-cycle and splicing regulation (Figure 5B and Figure S5).
In flow cytometry experiments, proapoptotic Bcl-x splicing was
coupled to mitotic arrest, but not S phase arrest or G2/M in
actively cycling cells (Figures 5C–5E). Since prevailing evidence
supports suppression of transcription and splicing in mitosis, it is
unlikely that the observed response initiates in mitotically ar-
rested cells (Shin and Manley, 2002). Moreover, when cells
were presynchronized to preclude an intervening cell division,
VX-680 still induced a robust splicing response (Figure 5F).
Therefore, this splicing regulation precedes mitotic arrest,
indicating accumulation of prodeath factors in anticipation of
G2/M and/or mitotic spindle checkpoints. Since cell-cycle
disruption also promoted a proapoptotic switch in CASP9
splicing and altered splicing of other apoptotic regulators, this
regulation likely extends to many coregulated mRNAs (Figures
7C and 7D).
Many previous studies have linked cell-cycle and splicing
regulation, reaching back to the seminal isolation of cell-division
cycle (CDC) loci in S. cerevisiae that encode spliceosome
components, including factors (CDC5L and CDC40) identified
here. Recent genetic and proteomic analyses of mitotic spindle
assembly have reasserted the notion that the cell-cycle and
splicing machineries are intertwined, but functional conse-
quences have not been established (Bjo¨rklund et al., 2006, Rines
et al., 2008). We observe coordinated proapoptotic splicing
upon inhibition of key cell-cycle factors, but preceding mitotic
arrest, indicating anticipatory upregulation of prodeath factors
that may subsequently propagate apoptosis in arrested cells.
Since arrested cells cannot mount de novo transcriptional and
Figure 7. An Apoptotic Alternative Splicing
Program Linked to Cell-Cycle Control
(A) ASF/SF2 downregulation triggers apoptosis
and sensitizes cells to apoptosis induction by
AURKA inhibition. HeLa cells were transfected
with indicated siRNAs, incubated to allow factor
depletion, and then treated with varying concen-
trations of VX-680. Apoptosis was measured via
cleavage of a fluorescent caspase-3 substrate.
Depletion of ASF/SF2, but not SRPK1, SNRP70,
or Sam68, sensitized cells to VX-680-induced
apoptosis. This selective sensitization by ASF/
SF2 depletion was not observed for staurospor-
ine-induced apoptosis (see Figure S6D). Data
reflect the means of three independent transfec-
tions ± SD.
(B) Analysis in (A) was repeated with Annexin-V
staining used as the apoptosis marker.
(C) CASP9 and CASP2 AS were analyzed in HeLa
cells by qPCR after transfection with the indicated
siRNAs. Relative levels of proapoptotic isoform (L)
normalized to negative controls are shown. Values
are the means of three independent measure-
ments ± SD.
(D) Results of AS profiling by real-time qPCR are
shown in a heat-map of Z scores averaged across
four biological replicates, along with unsupervised
hierarchical clustering (see Figure S7 for an
expanded view and validation of these data).
(E) A model of cell-cycle arrest coupled to apo-
ptosis via AS is shown. We propose anticipatory,
proapoptotic splicing decisions in interphase that
later promote apoptosis in arrested cells. Light-
ning bolts represent siRNAs, drugs, or other
stimuli that disrupt the cell cycle and promote
proapoptotic splicing of Bcl-x, Mcl1, CASP9, and
other targets.
See also Figures S6 and S7.
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splicing responses, this finding suggests a genetic mechanism
for cell-cycle checkpoint response.
ASF/SF2 Regulates an Apoptotic Splicing Network
We present evidence that ASF/SF2 downregulation mediates
a proapoptotic splicing response to cell-cycle disruption.
ASF/SF2 was a hit in the Bcl-x andMcl1 screens, and its overex-
pression was previously shown to favor Bcl-xL formation (Paro-
netto et al., 2007). AURKA inhibition triggered posttranslational
turnover of ASF/SF2, but not other SR proteins or splicing factors
identified in the screen (Figures 6A–6C and Figure S6A). In addi-
tion, ASF/SF2 directly binds Bcl-x and Mcl1 mRNAs, and its
enforced expression attenuated the effect of AURKA inhibition
on Bcl-x splicing (Figures 6D–6G).
ASF/SF2 regulation extends beyond Bcl-x to global regulation
of apoptosis (Li et al., 2005). ASF/SF2 depletion, but not deple-
tion of several splicing factors that were not validated screen
hits, sensitized cells to apoptosis induction by AURKA inhibition
(Figures 7A and 7B). In contrast, ASF/SF2 depletion did not
specifically enhance apoptosis in response to staurosporine
(Figure S6D). ASF/SF2-mediated splicing regulation extended
to other functional targets, including CASP9, which underwent
a proapoptotic splicing shift upon depletion of AURKA and
ASF/SF2 (Figure 7C). Our analysis of some 25 additional AS
targets revealed overlapping effects of AURKA and ASF/SF2
inhibition (Figure 7D). The fact that some mRNAs (e.g., CASP2)
did not respond identically to AURKA and ASF/SF2 knockdown
may reflect differential effects of targeting upstream versus
direct regulators of splicing, or the activity of additional, uniden-
tified splicing regulators. Nonetheless, these experiments
strongly indicate that ASF/SF2 downregulation globally shifts
alternative splicing patterns to promote apoptosis upon disrup-
tion of the cell cycle.
Alternative Splicing in a Global Context
Our data link coordinated proapoptotic splicing to activated cell-
cycle checkpoints (Figure 7E). These findings are relevant to
basic mechanisms of apoptosis in arrested cells, which are
poorly defined, and the exploitation of these pathways in cancer
therapy. Aberrant expression of AURKA and other prodivision
factors promotes spindle checkpoint abrogation, chromosomal
instability, and aneuploidy in tumors (Lapenna and Giordano,
2009). Our findings indicate that AURKA activation may also
propagate oncogenesis by promoting antiapoptotic splicing of
crucial cell-death regulators. Conversely, AURKA inhibition
elicits parallel upregulation of prodeath variants, which may
contribute to its demonstrated efficacy as a cancer drug target.
Importantly, this regulation remains intact in apoptosis-resistant
cells, suggesting functional and potential therapeutic relevance
in tumors.
ASF/SF2 downregulation triggers proapoptotic splicing and
promotes apoptosis. Importantly, ASF/SF2 is a proto-oncogene
in its own right, and its depletion is linked to genome instability
and G2/M arrest (Karni et al., 2007; Li and Manley, 2005). Our
data highlight RNA targets that may contribute to its transform-
ing properties. Taken together, these findings suggest that
ASF/SF2 has multiple, synergistic functions in controlling cell
arrest and apoptosis, underscoring its role as a central regulator
of mRNA metabolism in cancer. Finally, it bears reiterating that
our systematic screening approach was the original source of
these biological insights, as well as many new regulators and
functional connections not expounded here. We believe future
screening efforts will be instrumental in defining global roles for
AS in physiological and disease contexts.
EXPERIMENTAL PROCEDURES
siRNA Screening
Cells were transfected in triplicate in 384-well plates with >21,000 siRNA
SMARTpools (Thermo-Fisher) for known and predicted human genes.
Seventy-two hours later, cells were fixed, DAPI stained, and imaged on the
Image Xpress Micro microscope (Molecular Devices). Cell counts (DAPI),
percent of Venus-positive cells, and average per-cell CFP signal were deter-
mined with MetaXpress software. Wells were then assigned probabilistic
‘‘strength’’ and ‘‘confidence’’ scores in the Venus channel using a support
vector machine (SVM) model trained on positive and negative control data
(Figure S1, Table S1, and the Extended Experimental Procedures). For inde-
pendent verification, plate-wide, median-normalized Z scores were also tabu-
lated. Wells with SVM strength scores with false discovery rate (FDR) <10, or
z > 2.6 were inspected visually.
Three hundred and sixty-nine positives were retested in a validation screen
with four siRNAs from deconvoluted SMARTpools. siRNAs >2 standard devi-
ations (SDs) above negative controls in the Venus channel were deemed posi-
tive (Table S2). Bcl2-overexpression and Mcl1 screens were performed and
analyzed as for the validation screen (Tables S3 and S4).
RNA Extraction and RT-qPCR
Cellular RNA was extracted with Trizol (Invitrogen) reagent, and 2.5–5 mg were
reverse transcribed with Superscript III (Invitrogen) and oligo-dT. Bcl-x, Mcl1,
CASP9, and CASP2 isoforms were analyzed by qPCR with primers flanking
alternative exon sequences. For each product, a linear range of cDNA input
was determined empirically by running of a 2-fold dilution series in 26–28 cycle
reactions. Products were run on 5% TBE-PAGE gels, stained with Sybr-Gold
(Invitrogen), and quantified with QuantityOne software (Biorad).
Real-time qPCR primer sets were designed with Primer3 webware and
tested by electrophoresis to verify correctly sized products (Table S6). Reac-
tions were prepared with Sybr-Green PCR mix (ABI), run on the ABI 7900HT
system, and quantified by a DDC(t) method. Amplicons from alternative
regions were first normalized to a constitutive amplicon from the same tran-
script. To correct for differential primer efficiencies, data were then normalized
to negative controls. Z scores were tabulated across four independent exper-
iments and clustered with Eisen Cluster 2.0.
Splicing Assays with Drug Treatments
Sources for inhibitors are in the Extended Experimental Procedures. Cells
were treated in 96-well plates for 18–24 hr and analyzed by automated micros-
copy. For flow cytometry, cells were fixed in 3% PFA/1X PBS then 70%
ethanol, permeablized in 1X PBS/0.1% Triton X-100, and stained with
20 mg/ml propidium iodide. DNA content and Venus fluorescence were
analyzed on the LSRII system (BD Biosciences).
Western Blotting
Proteins were extracted in RIPA buffer (IX PBS, 1%Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, protease inhibitors) and quantified by Protein Dye-
Binding Assay (Biorad). Ten to fifty micrograms of total protein were run on
4%–12% Bis-Tris polyacrylamide gels (Invitrogen), transferred to PVDF
membranes, and probed with antibodies listed in Supplemental Data.
CLIP
UV crosslinking and RNP purification/visualization were performed as
described (Sanford et al., 2009). For quantification, CLIP and input samples
were treated with Proteinase K (Ambion), and RNA was extracted, reverse
transcribed, and analyzed by real-time qPCR.
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Apoptosis Assays
Annexin-V-Cy5 (Abcam) staining was quantified by automated microscopy.
Caspase activation was measured with the DEVD-Nucview 488 reagent
(Biotum), which stains nuclei specifically after it is cleaved by caspase-3. Cells
were incubated for 1 hr with 2.5 mM substrate, fixed, and analyzed by auto-
mated microscopy.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and six tables and can be found with this article online at doi:10.1016/
j.cell.2010.07.019.
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Alternative splicing (AS) is widely rec-
ognized as a major source for biological 
diversity and regulation. The contribu-
tion of AS to eukaryotic development and 
complexity is likely even greater than pre-
viously recognized, as a recent report dem-
onstrates that >90% of human genes are 
alternatively spliced.1 The regulation of AS 
is under the control of cis-elements residing 
in mRNA sequences and a large repertoire 
of RNA binding proteins (RNABPs).2 
AS regulation is further integrated with 
signal transduction and cell-specific cues 
that control RNABP dynamics and func-
tion.3 While many assays have revealed 
mechanisms for individual AS regulatory 
events, global understanding of AS regula-
tion is still at an early phase.3 Specifically, 
systematic identification of AS regulators, 
particularly those upstream of RNABPs, 
has been difficult via hypothesis-driven 
studies. Therefore, even in some of the 
best studied examples of AS it is unclear 
how AS is connected to other biological 
processes to carry out complex cellular 
functions.
We recently completed a whole-genome 
siRNA screen using a novel reporter strat-
egy to identify factors that regulate AS at 
all levels. As model AS events, we exam-
ined mRNAs for Bcl-x and Mcl1, Bcl-2 
family apoptosis regulators that pos-
sess two splice isoforms—anti-apoptotic 
Bclx-L and Mcl1-L, and pro-apoptotic 
Bclx-S and Mcl1-S.4 In the reporters, 
Venus and mCherry fluorescent protein 
cDNAs were fused to the 3' end of Bclx 
and Mcl1 genomic sequences, respectively. 
Premature termination codons (PTC) 
were then introduced to the alternatively 
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spliced regions exclusive in the long iso-
forms (Fig. 1A). Thus, Bclx-S and Mcl1-S 
could be detected as fluorescence fusion 
proteins, but the PTC prevented expres-
sion of fluorescene-tagged long isoforms. 
A genome-wide siRNA screen using the 
Bclx reporter revealed 160 factors, that 
when depleted, led to upregulation of pro-
apoptotic Bclx-S splicing. These factors 
were further tested for the Mcl1 reporter, 
identifying 52 factors that coordinately 
regulate AS. Surprisingly, knockdown 
of many cell cycle regulators, includ-
ing the potent oncogene aurora kinase A 
(AURKA), dramatically increased Bclx-S 
and Mcl1-S isoforms. Further analysis of 
factors downstream of AURKA linked 
the splicing changes to direct regulation 
by the splicing factor ASF/SF2 (SFRS1). 
Upon AUKRA inhibition, ASF/SF2 was 
degraded, causing a coordinated shift 
toward pro-apoptotic splicing in Bclx and 
other apoptosis-related splicing events.
Interestingly, pharmacological inhibi-
tion of AURKA by VX-680 (aurora kinase 
inhibitor) showed that accumulation of 
pro-apoptotic Bclx-S splicing was concom-
itant to mitotic arrest. However, in actively 
cycling G2/M cells, Bclx-S-Venus showed 
no increase. Also, Bclx-S upregulation was 
not detected during a double-thymidine 
block that caused S-phase arrest, indicat-
ing the specificity of the splicing response 
to mitotic arrest. Since the current view 
holds that splicing and transcriptional 
activity are mostly suppressed in mitosis,5 
we went on to ask if the splicing response 
preceded mitotic arrest, or whether it 
could represent a downstream effect of 
aberrant division in cells that were not yet 
arrested. Cells were synchronized with 
double-thymidine, released and treated 
with VX-680; Bclx-S upregulation was 
found to be comparable to asynchronized 
cells. Here, the venus-fluorescence was 
measured 16 hours post thymidine-release, 
preventing one intervening cell cycle. 
These data excluded the possibility that the 
splicing shift was caused by a subset of cells 
undergoing abnormal cell division before 
mitotic arrest. Thus, it can be concluded 
that the Bclx-S splicing response preceded 
mitotic arrest. Consequently, our investiga-
tion suggests that pro-death factors accu-
mulate prior to mitotic arrest. This finding 
provides novel mechanistic clues for how 
apoptosis occurs in arrested cells, and it is 
likely that this mechanism extends to other 
apoptosis regulators.
Aberrant AS is implicated in cancer,6 
but its specific functions are not well 
understood. In this screen, we found 
numerous factors that are themselves 
oncogenes or are frequently misregulated 
in cancer. Specifically, protein interac-
tion analysis on the top hits showed an 
AURKA-centered network spanning cell 
cycle regulators, spliceosome components 
and tumor suppressors. While aberrant 
regulation of AURKA is well known to 
induce spindle checkpoint abrogation, 
spindle assembly defects and chromo-
some instability in tumors,7 our data indi-
cate that AURKA can also contribute to 
oncogenesis by promoting anti-apoptotic 
splicing of crucial apoptosis regulators in 
malignant cells. Conversely, inhibition 
of AURKA leads to a dramatic elevation 
in pro-apoptotic splicing isoforms fol-
lowed by mitotic arrest. Since AURKA is 
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members, inducing apoptosis (Fig. 1B). 
Broadly, our screen revealed a novel func-
tional coupling of cell cycle control and 
AS, where these highly regulated processes 
are coordinated to regulate apoptosis.
*RNA regulon: ‘RNA regulon’ hypoth-
esis proposes that groups of function-
ally related mRNAs are coordinated and 
regulated by specific, shared RNABPs to 
quickly react to environmental cues.10
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functional connection between cell cycle 
and AS has not been emphasized in the lit-
erature. Our genome-scale exploration of 
apoptosis-related AS unexpectedly iden-
tified many cell cycle regulators, whose 
functions spanned multiple aspects of cell 
cycle control, including regulators of the 
G2/M transition, mitotic spindle assembly 
and microtubule transport. Importantly, 
downstream of the cell cycle regulators, we 
discovered an ASF/SF2 mediated ‘RNA 
regulon’* consisting of coordinated Bclx, 
Mcl1, caspase-9 and other apoptosis regu-
lator RNAs. Through this ‘RNA regu-
lon’, cells respond to upstream signals of 
cell cycle disruption and carry out a pro-
apoptotic AS splicing shift in the RNA 
a well-known target for anti-tumor thera-
pies, our findings may be useful for new 
insights in drug development and thera-
peutic targeting of AURKA.
Taken together, our screen revealed a 
novel physiological association between 
the cell cycle and AS. Interestingly, pre-
vious studies have hinted at a possible 
reciprocal link between cell cycle control 
and AS regulation. For example, many 
cell cycle regulators have been identi-
fied as spliceosome components, includ-
ing CDC40 and CDC5L, which were 
strong hits in our study. Moreover, recent 
large-scale screens identified splicing fac-
tors as affecting cell cycle progression and 
mitotic spindle integrity.8,9 However, a 
Figure 1. (A) Splicing reporters Bcl-x and Mcl1 are schematized. Green rectangles are exons, with gray areas depicting alternative spliced region. Black 
lines between rectangles are introns. Arrows denote translational start site. Inserted PTCs exclusive to long isoforms are shown by red “stop signs.” 
(B) A model of the functional coupling of cell cycle control and AS to apoptosis regulation from our genome-wide screen is shown.
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PQBP1, a factor linked to intellectual
disability, affects alternative splicing
associated with neurite outgrowth
Qingqing Wang,1 Michael J. Moore,2 Guillaume Adelmant,3,4,5 Jarrod A. Marto,3,4,5
and Pamela A. Silver1,6,7
1Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, USA; 2Laboratory of Molecular Neuro-
Oncology, The Rockefeller University, New York, New York 10065, USA; 3Department of Biological Chemistry and Molecular
Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA; 4Blais Proteomics Center, 5Department of Cancer
Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; 6Wyss Institute for Biologically Inspired Engineering,
Harvard University, Boston, Massachusetts 02115, USA
Polyglutamine-binding protein 1 (PQBP1) is a highly conserved protein associated with neurodegenerative
disorders. Here, we identify PQBP1 as an alternative messenger RNA (mRNA) splicing (AS) effector capable of
influencing splicing of multiple mRNA targets. PQBP1 is associated with many splicing factors, including the key
U2 small nuclear ribonucleoprotein (snRNP) component SF3B1 (subunit 1 of the splicing factor 3B [SF3B] protein
complex). Loss of functional PQBP1 reduced SF3B1 substrate mRNA association and led to significant changes
in AS patterns. Depletion of PQBP1 in primary mouse neurons reduced dendritic outgrowth and altered AS of
mRNAs enriched for functions in neuron projection development. Disease-linked PQBP1 mutants were deficient
in splicing factor associations and could not complement neurite outgrowth defects. Our results indicate that
PQBP1 can affect the AS of multiple mRNAs and indicate specific affected targets whose splice site determination
may contribute to the disease phenotype in PQBP1-linked neurological disorders.
[Keywords: PQBP1; alternative splicing; neurite outgrowth; neurological disorders]
Supplemental material is available for this article.
Received December 14, 2012; revised version accepted February 21, 2013.
Alternative splicing (AS) is a major source for biological
diversity and a crucial determinant of cell identity and
fate. To date, >90% of human precursor messenger RNAs
(pre-mRNAs) are reported to undergo AS, with immense
variation across tissue types and developmental stages
(Wang et al. 2008). The regulation of AS is carried out by
the interaction of RNA-binding proteins (RBPs), notably
hnRNPs and SR proteins, with cis-elements in the pre-
mRNAs (Black 2003). The dynamics of RBP cis-element
recognition are further modulated by a wide spectrum
of spliceosome-associated proteins and are responsive to
signal transduction networks (Varani and Nagai 1998;
Wahl et al. 2009). Tissue-specific AS regulation is espe-
cially prominent in the nervous system (Castle et al.
2008), where neurons must promptly respond to complex
stimuli and perform downstream functions with flexibil-
ity and precision (Dredge et al. 2001). Accordingly, neuron-
specific AS networks modulate such diverse functions,
including neurotransmission, receptor activity, and ion
channel function, and thus impact higher brain functions,
including cognition, coordination, and learning (Grabowski
and Black 2001).
Aberrant AS is a primary cause for many human dis-
eases (Wang and Cooper 2007). Diverse neurological
disorders are closely linked to aberrant splicing and can
be classified as cis-acting and trans-acting splicing defects
(Licatalosi and Darnell 2006). Cis-acting defects origi-
nate from mutations in the disease-associated gene that
change sequences important for the correct splicing
of the pre-mRNA. A representative example is fronto-
temporal dementia with Parkinsonism linked to chromo-
some 17, which arises frommutations causing missplicing
of the mRNA for the microtubule-associated protein tau
(Licatalosi and Darnell 2006). Trans-acting defects arise
from mutations or misregulation of splicing regulatory
factors. One example is retinitis pigmentosa, character-
ized by a progressive loss of rod photoreceptor cells,
which results from mutations in HPRP3, PRP31, and
PRPC8—factors crucial for the assembly and functioning
of U small nuclear ribonucleoproteins (snRNPs) in pre-
mRNA splicing (McKie et al. 2001; Vithana et al. 2001;
Chakarova et al. 2002). Although increasing numbers of
7Corresponding author
Email pamela_silver@hms.harvard.edu
Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.212308.112.
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splicing-related disorders have been identified, the mo-
lecular link between AS regulation and the disease pheno-
type remains to be elucidated.
Polyglutamine-binding protein 1 (PQBP1) is a highly
conserved protein with mutations associated with ;10
familial X-linked mental retardation (XLMR) diseases
(Kalscheuer et al. 2003; Stevenson et al. 2005). Patients
with these diseases share similar symptoms, such as
intellectual deficiency, microcephaly, and short stature
(Kalscheuer et al. 2003; Stevenson et al. 2005). Although
these diseases were separately discovered and originally
thought to be unrelated, they were recently grouped to-
gether as ‘‘Renpenning syndrome’’ because of the common
symptomatic manifestation and mutations in PQBP1
(Stevenson et al. 2005).
The molecular function of PQBP1 remains unclear.
PQBP1 is linked to transcription regulation based on its
interaction with RNA polymerase II and other transcrip-
tion factors (Waragai et al. 1999; Okazawa et al. 2002).
Recent studies also reported that PQBP1 was dynam-
ically associated with stress granules and interacted with
dynactin components, indicating a possible role for PQBP1
in RNA transport or cytoplasmic RNA processing (Kunde
et al. 2011). Also, PQBP1 has been implicated in pre-
mRNA splicing: PQBP1 interacts with known splicing
factors such as WBP11 and U5-15KD (Komuro et al. 1999;
Waragai et al. 2000) and is part of the early spliceosome
(Makarova et al. 2004). Consistent with this view, a dis-
ease-associated mutant of PQBP1 decreased splicing ef-
ficiency (Tapia et al. 2010).
We previously identified PQBP1 in a screen for factors
that affect the AS of the mRNA for Bcl-X, a mammalian
apoptosis regulator (Moore et al. 2010). Here, we show
that PQBP1 affects the AS of numerous other pre-mRNAs
in human cells. In addition, we used whole-transcriptome
sequencing to identify a global set of PQBP1 AS targets
in primary mouse neurons, which revealed that PQBP1
coordinates important neuronal functions and maintains
normal neurite development. Collectively, our findings
indicate that aberrant AS contributes to the disease
pathology of PQBP1-associated neurological disorders.
Results
PQBP1 affects the AS of mRNAs encoding apoptotic
factors
We previously identified PQBP1 as a potential effector for
Bcl-x splicing in HeLa cells in a genome-wide siRNA
screen using a fluorescence-based minigene assay (Fig.
1A; Moore et al. 2010). To verify the effect of PQBP1 on
the AS of Bcl-x, we examined the splicing of endogenous
Bcl-x after depletion of PQBP1 with two different siRNAs
(Fig. 1B) using RT–PCR primers flanking the alternatively
spliced region (Fig. 1A). As expected, depletion of PQBP1
favored a shift from the anti-apoptotic isoform Bcl-xL
toward the proapoptotic isoform Bcl-xS via increased use
of an alternative 59 splice site in the second exon (Fig.
1A,C; Supplemental Fig. S1A,B). These results confirmed
that PQBP1 affects the AS of Bcl-x in HeLa cells.
We now show that PQBP1 affects additional AS events.
We analyzed 31 mRNAs encoding apoptosis-related fac-
tors with annotated alternatively spliced isoforms. We
designed primers to amplify the alternatively spliced
exonic region and constitutive exonic region of each
mRNA, and the ratio of the two amplicons was compared
between the control and PQBP1 knockdown samples by
RT–PCR. Approximately half of these mRNAs showed
significant changes in AS when PQBP1 was knocked
down (Fig. 1D; Supplemental Fig. S1C). These results
provided further evidence that PQBP1 affects the AS of
many mRNAs.
Figure 1. AS targets of PQBP1 in HeLa cells. (A) Schematic of
Bcl-x. Light rectangles are exons, with dark color marking the
alternatively spliced region, and black lines are introns. Arrows
show translation start sites, and arrowheads mark quantitative
PCR primer sets. (B) Western blot of HeLa cell lysates where
PQBP1 is knocked down by siRNA. The control sample was
treated with a siRNA targeting firefly luciferase mRNA. An-
tibodies are listed on the right. Knockdown (KD) with two
different siRNAs is shown. (C) Gel analysis of RT–PCR of Bcl-x
splicing isoforms for control and PQBP1 knockdown samples
is shown (left panel) with quantification (right panel). Mean of
three independent measurements 6 SD are shown. Changes
were tested by one-way ANOVA. (**) Statistically significant
with P-value < 0.01. See also Supplemental Figure S1, A and B. (D)
Quantification of real-time PCR data on 14 mRNAs that showed
significant AS changes between control and PQBP1 knockdown
samples, with Mcl1 (not a target of PQBP1) as the negative
control. The Y-axis depicts the ratio between amplicons for
constitutive and alternative exonic regions; TPX-2 and CASP6
follow the Y-axis on the right side, while the rest follow the Y-axis
on the left side. Light columns show the ratio of two amplicons
from the control sample, and dark columns show the ratio of two
amplicons from the PQBP1 knockdown sample. Mean of three
independent measurements 6 SD are shown. The difference of
the ratio between control and PQBP1 knockdown samples was
analyzed by one-way ANOVA test. (*) Statistically significant
with P-value < 0.03; (**) statistically significant with P-value <
0.01; (n.s.) not significant. See also Supplemental Figure S1C.
Wang et al.
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PQBP1 is associated with splicing factors
To further clarify PQBP1’s role in AS regulation, we sys-
tematically determined the spectrum of proteins that are
associated with PQBP1. In addition, to understand the
aberrant function of disease-related PQBP1 mutants, we
compared the associated protein profile of wild-type PQBP1
and two mutant variants identified in Renpenning syn-
drome patients.
PQBP1 protein contains a WW domain, a polar amino
acid-rich domain, and aC-terminal domainwith a nuclear
localization signal (NLS) (Fig. 2A; Waragai et al. 1999).
The mutations in PQBP1 identified from Renpenning
syndrome patients can be classified into two categories:
frameshifting mutations in the AG dinucleotide hexamer
in the polar amino acid-rich domain and missense muta-
tions in the WW domain (Musante et al. 2010). Here, we
examined two representative disease-linked variants: one
with an AG dinucleotide deletion (DAG) in the polar
amino acid-rich domain, resulting in a truncated pro-
tein, and one with a point mutation (Y65C) in the WW
domain (Fig. 2A; Kalscheuer et al. 2003). PQBP1 local-
izes predominantly in the nucleus (Fig. 2B; Waragai et al.
1999; Komuro et al. 1999; Kalscheuer et al. 2003). In-
terestingly, both DAG and Y65C mutants localize to the
nucleus (Fig. 2B), although DAG loses a potential NLS
(Fig. 2A), indicating that there must be an additional
unidentified NLS or that it enters together with another
protein.
Proteins associated with wild-type PQBP1 were strongly
enriched for known or potential splicing factors and
spliceosome components (Fig. 2E; Supplemental Table
S1). HeLa cells expressing stably integrated Flag-HA-
tagged full-length PQBP1, DAG, or Y65C were generated
by stable integration of retroviral constructs and shown
by Western blotting to express exogenous proteins at
a level comparable with endogenous PQBP1 (Fig. 2C).
Tandem affinity purification with Flag and HA antibodies
followed by mass spectroscopy was performed to identify
PQBP1- or mutant-associated proteins (Fig. 2D; Supple-
mental Table S1). WBP11, a previously known PQBP1
interactor (Komuro et al. 1999), was detected in all three
replicate purifications of wild-type PQBP1, confirming
the validity of our approach (Supplemental Table S1).
U5-15KD, another proposed interactor of PQBP1 (Waragai
et al. 2000), was not identified, possibly because of cell
specificity or because the interaction is not strong enough
to be detected in our tandem affinity purification. DAG
showed significantly reduced splicing factor association
compared with wild-type PQBP1, while Y65C lost asso-
ciations with all splicing-related factors (Supplemental
Table S1). These results established an association, either
direct or indirect, of PQBP1 to the splicing machinery
and identified the WW domain as important for linking
PQBP1 to splicing complexes. This finding is consistent
with the idea that disease-linked mutations may disrupt
splicing-related functions of PQBP1.
PQBP1 influences SF3B1’s (subunit 1 of the splicing
factor 3B [SF3B] protein complex) recognition
of splicing sites
To explore the mechanism of PQBP1 in AS regulation, we
first examined whether PQBP1 directly binds pre-mRNAs
whose splicing it affects. Although previous studies
showed PQBP1 bound to polyrG resin in vitro (Komuro
et al. 1999), PQBP1 protein itself has no known RNA-
binding domains (Fig. 2A; Lunde et al. 2007). We used the
CLIP (cross-linking and immunoprecipitation) method to
determine whether PQBP1 directly binds its targets in
vivo (Ule et al. 2003). Live HeLa cells were exposed to UV
light to cross-linkRNA–protein complexes, and then PQBP1
was immunopurified from cell lysates (Fig. 3A). RT–PCR
quantification of Bcl-x and nine other target mRNAs
(Fig. 1D) showed no enrichment in PQBP1 immunopre-
cipitations compared with an irrelevant immunoglobulin
G (IgG) control. These results suggest that PQBP1 does
not bind AS target mRNAs directly, with the caveat
that it may fail to be effectively cross-linked under the
Figure 2. The spectrum of proteins associated with PQBP1 and
disease-linked mutants. (A) Schematics of the protein domain
organization of wild-type (WT) PQBP1 and two disease-linked
mutants. Boxes are protein domains, with names shown in the
center. (WW) WW domain; (CTD) C-terminal domain. Red
arrowheads show the mutation sites in the disease-linked
PQBP1 variants. (B) Immunofluorescence staining of HeLa cells
stably expressing Flag-HA-tagged wild-type PQBP1, DAG, or
Y65C. Cells were fixed and stained with antibodies or dyes
listed at the bottom of each panel column. (C) Western blot of
HeLa cell lines stably expressing empty Flag-HA vector, Flag-
HA-tagged wild-type PQBP1, Flag-HA-tagged DAG, and Flag-
HA-tagged Y65C. The antibodies used are indicated at the
bottom of each panel. (D) Silver staining of proteins copurified
with Flag-HA-tagged empty plasmid, Flag-HA-tagged wild-type
PQBP1, Flag-HA-tagged DAG, or Flag-HA-tagged Y65C. (E) GO
term enrichments of proteins that were pulled down with wild-
type PQBP1. Statistics were calculated with human genes as the
background. The X-axis is the corrected P-value (false discovery
rate [FDR]) in negative log for enrichment.
PQBP1 affects AS related to neurite outgrowth
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conditions where other known splicing factors are ob-
served to bind.
PQBP1, on the other hand, affects the association of
the spliceosome factor SF3B1 with a target pre-mRNA.
Among the proteins that are associated with PQBP1 are
SF3B protein complex members (Supplemental Table S1),
which form part of the U2 snRNP. The function of the
SF3B complex is critical for the assembly of the spliceo-
some complex A as well as the successful execution of the
splicing reaction (Wahl et al. 2009). Furthermore, SF3B1
was reported to regulate the AS of Bcl-x through direct in-
teraction with a cis-element in the Bcl-xmRNA (Massiello
et al. 2006), andwe observed that CLIP with SF3B1 showed
a 40-fold enrichment of Bcl-x binding over an IgG control
(Fig. 3D, blue column over Bcl-x).
To test whether the recognition of Bcl-x by SF3B1 is
influenced by PQBP1, we knocked down PQBP1 in HeLa
cells and reanalyzed the enrichment of Bcl-x in the
SF3B1–RNA complex (Fig. 3B,C). PQBP1 depletion led
to an eightfold decrease of Bcl-x mRNA levels in SF3B1
CLIP compared with a control knockdown (Fig. 3D), al-
though the level of SF3B1 protein remained unchanged
(Fig. 3B), and the steady-state level of Bcl-xmRNA did not
change upon PQBP1 knockdown (Supplemental Fig. S2).
To further test whether PQBP1’s impact on SF3B1–
RNA recognition is specific to the targets of PQBP1, we
analyzed themRNA ofMcl1 in the SF3B1–RNA complex.
Like Bcl-X, Mcl1 is a mammalian apoptosis regulator and
has two splicing isoforms: anti-apoptotic Mcl1-L and
proapoptotic Mcl1-S (Akgul et al. 2004). However, while
knockdown of SF3B1 significantly shifted the splicing of
Mcl1 toward Mcl1-S (Moore et al. 2010), PQBP1 knock-
down had little effect (Fig. 1D; Moore et al. 2010). We
therefore hypothesized that the knockdown of PQBP1
should have relatively minor influence on Mcl1 mRNA
enrichment in the SF3B1–RNA complex. Indeed, CLIP
data showed only a 1.4-fold decrease of Mcl1 mRNA
enrichment in the SF3B1–RNA complex in the PQBP1
knockdown sample compared with the control (Fig. 3D).
Additionally, the decrease was mostly likely due to a
Mcl1 mRNA steady-state level change of 1.5-fold (Sup-
plemental Fig. S2). Therefore, PQBP1 influenced the rec-
ognition of SF3B1 to one mRNA whose AS is affected by
PQBP1 but not for an mRNAwhere AS was regulated by
SF3B1 but not PQBP1. These results do not rule out
possibilities that PQBP1 may affect mRNA AS through
other interactions or that other splicing factors may assist
in the process.
Loss of PQBP1 causes defects in neurite outgrowth
Previous work found that PQBP1 is most highly expressed
in the CNS of embryonic or newborn rodents, with the
peak around birth (Qi et al. 2005). Considering the tissue-
specific expression pattern of PQBP1 as well as its disease
association, we examined the role of PQBP1 in AS mod-
ulation in embryonic rodent neurons.
PQBP1 is highly expressed in embryonicmouse cortical
and hippocampal neurons, as shown byWestern blots (Fig.
4A). In addition, PQBP1 localizes predominantly in the
nucleus of neurons (Fig. 4B, top panels), as shown pre-
viously in other cell types (Waragai et al. 1999; Komuro
et al. 1999; Kalscheuer et al. 2003). A closer examination
demonstrated that PQBP1 colocalizes with SC35—a splic-
ing factor in nuclear speckles, a nuclear domain enriched
for splicing regulatory factors (Fig. 4B, bottom panels;
Supplemental Fig. S3A; Spector and Lamond 2011).
Figure 3. SF3B1 function is affected by PQBP1. (A) Western
blot of PQBP1 CLIP together with an irrelevant IgG control,
probed with PQBP1 antibody. PQBP1 was not detected in
depleted supernatants or the IgG pull-down, indicating efficient
and specific antibody binding of PQBP1. (B) Western blot of
SF3B1 CLIP from PQBP1 knockdown (KD) samples and samples
treated with siRNA targeting firefly luciferase mRNA as con-
trol. Shown are total cell lysates of control (lane 1) and PQBP1
knockdown (lane 2) HeLa cells probed with antibodies indicated
at the left. (C) Western blot of SF3B1 CLIP from PQBP1
knockdown samples and samples treated with siRNA targeting
firefly luciferase mRNA as control. Lanes 1 and 2 are the IgG
controls, and lanes 3 and 4 are SF3B1 CLIP stained by SF3B1
antibody for control and PQBP1 knockdown samples. (D)
Quantification of Bcl-x and Mcl1 mRNA enrichment in the
SF3B1–RNA complex as from SF3B1 CLIP in control and PQBP1
knockdown samples, respectively, by RT–PCR. Data values
normalized to the IgG control and mean of three independent
measurements 6 SD are shown. (E) Proposed model mechanism
of PQBP1 AS regulation. A schematic of part of a hypothetical
mRNA is shown. Orange rectangles are exons, and the black
line is the intron. ‘‘GU’’ marks the 59 splice site, ‘‘A’’ marks the
branch site recognized by the U2 snRNP with help from
components like SF3B1, and ‘‘AG’’ marks the 39 splice site.
Green dashed double lines indicate the association between
PQBP1 and SF3B1. Through an association with SF3B1 and other
splicing factors, PQBP1 influences the recruitment of U2 snRNP
to specific target sites, thus affecting splicing decisions on a
subset of mRNAs. Loss or mutations of PQBP1 interrupt the
splicing factor association and the recognition of specific splice
sites. See the Discussion.
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To understand the importance of PQBP1 in neuron
development, we knocked down PQBP1 in mouse em-
bryonic primary cortical neurons with shRNAs delivered
by lentivirus (Fig. 4C). Neurons were first examined by
immunostaining of the microtubule-associated protein
2 (MAP2), a marker for dendrites. Interestingly, upon
PQBP1 knockdown, the number of projections and length
of neurites were decreased, and the connection between
neurons degenerated considerably (Fig. 4D). A second
shRNA against PQBP1 led to a similar defect in neurite
morphology (Supplemental Fig. S3B,C). To determine
whether this defect is simply due to cell apoptosis, we
compared the number of DAPI-stained intact nuclei after
fixation as well as the percentage of Annexin V-stained
cells between control and PQBP1 knockdown neurons
(Fig. 4E,F). No significant differences were observed, in-
dicating that the defects observed from PQBP1 knock-
down are not from neuron apoptosis.
PQBP1 knockdown neurons showed substantially di-
minished dendrite branching and dendrite length (Fig.
4G,H). To quantify the changes in neurite outgrowth, we
transiently transfected neurons with a nontargeting con-
trol shRNA or a PQBP1 targeting shRNA together with a
GFP vector (Fig. 4G). Sholl analysis was then performed
on neurons that were GFP-highlighted for control and
PQBP1 knockdown (Fig. 4H; Sholl 1953).
To confirm that the dendritic outgrowth defect observed
was a direct effect of PQBP1 knockdown, we examined
whether the defect could be rescued by re-expressing
wild-type PQBP1 in comparison with the disease-associ-
ated PQBP1 mutants. shRNA-resistant, Flag-HA-tagged
cDNAs encoding human PQBP1, DAG, and Y65C were
coexpressed in mouse cortical neurons with shRNAs
targeting endogenous mouse PQBP1 (Fig. 5A; Supplemen-
tal Fig. S3D). Western blots confirmed the knockdown of
endogenous mouse PQBP1 and the concomitant expres-
sion of exogenous dual-tagged human PQBP1 and vari-
ants (Fig. 5B). Total PQBP1 expression in all three rescue
samples was compatible with the level of PQBP1 in the
control sample, with the exception of DAG, which
reached only 68% of the control (Fig. 5B). To quantita-
tively compare neurite outgrowth betweenmutant PQBP1
and wild-type rescue, we transfected mouse cortical neu-
rons with the rescue constructs (Fig. 5C) and performed
Sholl analysis after 5 d. A significant restoration of dendrite
density and length was observed in wild-type PQBP1-
rescued neurons, while DAG and Y65C showed less
improvement (Fig. 5D,E,F). In the case of DAG, it is pos-
sible that insufficient expression of DAG may contribute
to the deficiency of rescue.
Combining the results above, we conclude that PQBP1
is important in maintaining neurite projection and out-
Figure 4. PQBP1 affects dendritic outgrowth and branching in
mouse cortical neurons. (A) Western blot of PQBP1 expression
in mouse embryonic cortical and hippocampal neurons, com-
pared with endogenous b-actin expression. (B) Immunofluores-
cence staining of mouse embryonic primary cortical neurons
(the four top panels) and rat embryonic primary cortical neurons
(the three bottom panels). Neurons were fixed and stained with
antibodies or dyes listed at the top of each panel. See also
Supplemental Figure S3A. (C) Western blot of mouse embryonic
cortical neurons infected with virus from a nontargeting control
shRNA or a PQBP1 targeting shRNA. See also Supplemental
Figure S3B. (D) Immunofluorescence staining of mouse primary
embryonic cortical neurons 5 d after infection with virus from
a nontargeting control shRNA or a PQBP1 targeting shRNA.
(Green) MAP2 staining; (blue) DAPI staining. See also Supple-
mental Figure S3C. (E) Comparison of the number of intact
nuclei between neuron samples 5 d after infection with virus
from a nontargeting control shRNA or a PQBP1 targeting
shRNA. Neurons were fixed and stained with DAPI. Healthy
and intact nuclei were counted for each sample. Mean of eight
independent measurements 6 SD is shown. The difference in
the number of intact nuclei between control and PQBP1
knockdown samples was analyzed by one-way ANOVA test.
(n.s.) Not significant. (F) Comparison of the percentage of
Annexin V-stained neurons between samples infected with virus
from a nontargeting control shRNA or a PQBP1 targeting
shRNA. The number of neurons with Annexin V staining and
the percentage of Annexin V-positive neurons were calculated
and normalized to neuron samples that were not treated by
virus. The Y-axis depicts the fold of the percentage of Annexin
V-positive neurons in control or PQBP1 knockdown samples to
samples that were untreated. Neurons on day 3 and day 6 after
infection/plating were studied. The mean of six independent
measurements 6 SD is shown. The difference in the percentage
of Annexin V-positive neurons between control and PQBP1
knockdown samples was analyzed by one-way ANOVA test.
(n.s.) Not significant. (G) Immunofluorescence of individual
neurons that were transiently transfected with either a non-
targeting control shRNA or a PQBP1 targeting shRNA together
with a GFP vector. Neurons were grown on a layer of feeder glial
cells and examined 5 d after transfection. (H) Sholl analysis of
dendritic branching for neurons transiently transfected with a
nontargeting control shRNA or PQBP1 targeting shRNA together
with a GFP vector. Concentric circles were drawn at intervals of 5
mm. The number of dendritic branch intersections with each
concentric circle was counted (mean 6 SE, n = 16–17). The X-axis
depicts the distance of the concentric circle from the neuron soma
center, and the Y-axis depicts the number of intersections the
corresponding circle encounters with dendrites.
PQBP1 affects AS related to neurite outgrowth
GENES & DEVELOPMENT 619
 Cold Spring Harbor Laboratory Press on May 7, 2013 - Published by genesdev.cshlp.orgDownloaded from 
 
 
 
 
203 
 
 
  
  
growth in neuron development. Moreover, deviation in
neurite structuremay be part of the defects brought about
by the disease-associated mutants of PQBP1.
Coupling of neuron projection and PQBP1 function
Dendrite structure is the crucial basis for neuron network
formation and information processing. To clarify the
molecular function of PQBP1 in maintaining neurite
outgrowth, we systematically profiled the AS targets of
PQBP1 in mouse embryonic cortical neurons by RNA
sequencing (RNA-seq).
We considered RNA-seq reads that were directlymapped
over splice junctions as the most straightforward evi-
dence to quantify the splicing changes. For each splice
junction, a 59 initiation site (59 IS) is defined as the final
nucleotide position of the upstream exon, and the 39 end
site (39 ES) is defined as the first nucleotide position of the
downstream exon (Fig. 6A). An AS event is then defined
as a set of junctions that share the same 59 IS or the same
39 ES, with each junction in the set referred to as a sub-AS
junction (Fig. 6A). This definition covers all six primary
AS patterns except for intron retention, which was not
considered in our analysis (Supplemental Fig. S4A; Black
2003). An AS event under an experimental condition is
represented by the distribution of read counts mapped
to each sub-AS junction within the AS event; i.e., the
‘‘usage’’ of each sub-AS junction under that condition. We
developed methods to identify AS events that experi-
enced significant differential ‘‘usage’’ of any sub-AS
junction between control and PQBP1 knockdown condi-
tions (for details, see the Supplemental Material) and
defined these AS events as AS targets of PQBP1. In total,
457 targets were identified in the process (Supplemental
Fig. S4B; Supplemental Table S2).
To validate PQBP1 targets identified by RNA-seq, we
picked 10 candidate targets together with two candidate
nontargets from the analysis and designed primers to
amplify each splicing isoform of each gene. We then com-
pared the ratio of the isoform expression levels by RT–PCR
for control and PQBP1 knockdown samples. All 10 identi-
fied targets exhibited significant AS shift upon PQBP1
knockdown, while the two nontargets showed no dis-
cernible changes (Fig. 6B). This result demonstrated the
sensitivity and specificity of our computational method
to identify AS targets of PQBP1.
The PQBP1 AS targets showed tissue-specific functional
enrichment, with strong gene ontology (GO) enrichments
for neuron projection development/morphogenesis, den-
drite development, and axonogenesis (Fig. 6C; Supple-
mental Table S4) versus genes that were expressed in
mouse embryonic cortical neurons profiled from the RNA-
seq data. This observation was in accordance with the
neurite outgrowth defect observed when PQBP1 was
knocked down (Fig. 4D,G,H). Targets of PQBP1 also
showed strong enrichment in RNA splicing, synaptic
transmission, chromatin modification, cell–cell signaling,
phosphate metabolic process, neurotransmitter transport,
and ADP-ribosylation factor (ARF) protein signal trans-
duction (Fig. 6C; Supplemental Table S4). The GO term
enrichment profile for PQBP1’s AS targets is specific
compared with high-throughput studies on other proteins
in neurons, especially RNA splicing, chromatin modifica-
tion, dendrite development-related functions, and ARF
signal transduction (Ule et al. 2005; Gehman et al. 2011;
Charizanis et al. 2012). Bcl-x AS is not conserved from
humans to mice and was not identified as a target in this
analysis. Among the 14 AS targets identified in HeLa cells
that were related to apoptosis control (Fig. 1D), only the
mRNA of BCLAF1 was recognized as an AS target of
Figure 5. Wild-type (WT) PQBP1 but not the mutants
rescues the neuron morphological defects. (A) Sche-
matic of the pLKO.1-derived lentiviral constructs used
to generate viruses for the rescue experiments. See also
Supplemental Figure S3D. (B) Western blot of neuron
samples that were infected with virus from an un-
modified PQBP1 targeting shRNA, a nontargeting con-
trol shRNA, or PQBP1 targeting shRNA constructs
coexpressing exogenous wild-type PQBP1, DAG, or
Y65C. Antibodies used are listed at the right. Quanti-
fication of total PQBP1 level for each sample compared
with control is shown below each lane. (C) Immuno-
fluorescence of individual neurons that were tran-
siently transfected with PQBP1 targeting shRNA
constructs coexpressing exogenous wild-type PQBP1,
DAG, or Y65C together with a GFP vector. Neurons
were grown on a layer of feeder glial cells. (D–F) Sholl
analysis of dendritic branching for neurons that were
transiently transfected with a nontargeting control
shRNA, an unmodified PQBP1 targeting shRNA, or
PQBP1 targeting shRNA constructs coexpressing wild-
type PQBP1 (D), DAG (E), or Y65C (F) (mean 6 SE; n =
10–17).
Wang et al.
620 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on May 7, 2013 - Published by genesdev.cshlp.orgDownloaded from 
 
 
 
 
204 
  
  
  
PQBP1 in mouse neurons, indicating the tissue specificity
of PQBP1’s regulation in AS.
Considering the physical and potential functional as-
sociation of PQBP1 and SF3B1, we also knocked down
SF3B1 in mouse cortical neurons and examined the AS of
the 10 verified targets of PQBP1 (Supplemental Fig. S5A).
Interestingly, all 10 targets also showed a significant AS
shift upon SF3B1 knockdown (Supplemental Fig. S5B).
Among the top hits of PQBP1 AS targets was NCAM-
140, a major isoform of neural cell adhesion molecules 1
(Ncam1) (Fig. 6B). Specifically, a 30-nucleotide (nt) exon
between exons 7 and 8 is alternatively spliced in NCAM-
140 and is designated VASE (variable alternatively spliced
exon) (Fig. 7A). The VASE-excluding isoform of NCAM-
140 (VASE!) promotes neurite outgrowth, while the
VASE-including isoform (VASE+) inhibits neurite out-
growth (Doherty et al. 1992). The embryonic brain
mainly expresses VASE! with gradual ascendancy until
final dominance of VASE+ expression toward adulthood,
except in regions such as the olfactory bulb, where ref-
ormation of synapses and turnover of neurons continue
(Small and Akeson 1990). Thus, the AS of VASE in
NCAM-140 is a critical switch for neuronal plasticity.
To confirm PQBP1’s effect on VASE, we designed primers
flanking the VASE exon and examined VASE+ and VASE!
isoforms by RT–PCR and electrophoresis (Fig. 7A). VASE+
was increased upon PQBP1 knockdown, while VASE! de-
creased (Fig. 7B), resulting in a significant decrease in
the ratio of VASE!/VASE+ expression in response to PQBP1
shRNA versus a control hairpin (Fig. 6B, Ncam1). These
results were confirmed with a second shRNA targeting
PQBP1 (Supplemental Fig. S6).
As a further confirmation that PQBP1 impacts the AS
of NCAM-140, we examined AS of NCAM-140 after
PQBP1 knockdown in neurons coexpressing the wild-
type PQBP1, DAG, and Y65C constructs from Figure 5A.
Interestingly, neurons rescued with wild-type PQBP1
restored the ratio of VASE!/VASE+ to levels observed in
control samples (Fig. 7C). In contrast, DAG and Y65C
were less effective in correcting the VASE!/VASE+ ratio
(Fig. 7C).
To test whether NCAM-140 is one of the PQBP1 targets
responsible for the defects observed in cells lacking
PQBP1, we examined the effect of restoring the ratio of
VASE! and VASE+. We coexpressed VASE! under the
hPGKpromoter in the lentiviral shRNAvector as described
above (Fig. 5A). Knockdown of PQBP1 was verified by
Western blot (Fig. 7D), and the change in the ratio of
VASE!/VASE+was verified by RT–PCR (Fig. 7E). Neurons
were transfected with the rescue construct (Fig. 7F), and
Sholl analysis on transfected neurons displayed a signifi-
cant recovery from the neurite outgrowth defect caused
by PQBP1 knockdown (Fig. 7G). These results confirm
the role of PQBP1 in the AS of NCAM-140 and modulat-
ing neurite outgrowth.
Discussion
In this study, we showed that the disease-associated
factor PQBP1 plays a role in the AS of mRNAs. We
Figure 6. PQBP1’s AS targets in mouse embryonic
cortical neurons. (A) A schematic of a defined AS event
and quantification of splicing changes. A hypothetical
alternatively spliced mRNA is shown, with light rect-
angles representing exons and black lines between
exons representing introns. The middle exon is the
alternatively spliced exon. The 59 IS is the start of
a splicing junction, and the 39 ES is the end of the
junction. The AS event shown here includes two sub-
AS junctions that share the same 59 IS. Light dashed
short lines mark RNA-seq reads that are mapped to sub-
AS junction 1, and dark solid short lines mark reads
mapped to sub-AS junction 2. The distribution of reads
mapped to the two sub-AS junctions was used for AS
quantification in our analysis. See also Supplemental
Figure S4, Supplemental Table S2, and the Supplemen-
tal Material. (B) RT–PCR validation of 10 randomly
picked AS events identified as PQBP1 targets and two
randomly picked AS events identified as non-PQBP1
targets in the computational analysis. Abat1 and Icmt
were predicted non-PQBP1 targets. The Y-axis depicts
the ratio between isoform 1 and isoform 2. Dlgap4,
Tmod3, Adam15, and Dclk1 follow the Y-axis on the
right side, while the rest follow the Y-axis on the left
side. The mean of three independent measurements 6
SD is shown. The differences between control and
PQBP1 knockdown (KD) samples were analyzed by one-way ANOVA test. (*) Statistically significant with P-value < 0.05; (**)
statistically significant with P-value < 0.01; (n.s.) not significant. (C) GO term functional enrichment of AS targets of PQBP1. Statistics
were calculated with all genes that are expressed in mouse embryonic cortical neurons (profiled from RNA-seq data) as the background.
The GO term enrichment profile here is specific compared with RNA-seq studies for other proteins in neurons (see the text). The X-axis
is the corrected P-value (FDR) in negative log for enrichment. See also Supplemental Table S4.
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demonstrated that PQBP1 associates with core spliceo-
some components and has a protein association net-
work enriched for other splicing factors. Following
down-regulation of PQBP1, we observed aberrant splic-
ing profiles for many mRNAs in both human cells and
primarymouse cortical neurons. Specifically in neurons,
mRNA profiling showed preferential misregulation of
AS in factors that are important for neurite outgrowth,
which is defective upon PQBP1 depletion. Collectively,
we showed that PQBP1 has a role in AS and indicate
aberrant AS as a possible mechanism underlying the
symptoms of neurological disorders associated with
PQBP1.
PQBP1 affects AS
Our work presents several lines of evidence that PQBP1
affects the AS of many pre-mRNAs. Previous work has
indicated an association of PQBP1 with mRNA process-
ing factors (Waragai et al. 1999, 2000; Okazawa et al.
2002; Komuro et al. 1999). We discovered that PQBP1
colocalizes with SC35 in nuclear speckles (Fig. 4B; Sup-
plemental Fig. S3A), which are nuclear subdomains en-
riched for many splicing regulatory factors (Spector and
Lamond 2011). Moreover, profiling of PQBP1-associated
proteins revealed a set of factors highly enriched in
splicing regulators and spliceosome components (Fig.
2E; Supplemental Table S1). Among these binding part-
ners, we also identified WBP11, a previously reported
interactor of PQBP1 (Supplemental Table S1; Komuro
et al. 1999). These results support PQBP1’s connection
with the splicing machinery.
PQBP1 affects U2 snRNP component SF3B1 function
We observed that PQBP1 did not associate with func-
tional AS target mRNAs in vivo in CLIP experiments,
suggesting that it does not bind directly to the AS targets
identified in HeLa cells (Fig. 3A), consistent with its
apparent lack of known RNA-binding domains (Fig. 2A).
SF3B1, which was previously shown to directly bind sub-
strate mRNAs and affect Bcl-x AS (Gozani et al. 1998;
Massiello et al. 2006) and was herein identified in PQBP1
affinity purifications (Supplemental Table S1), consti-
tuted a prime candidate to work together with PQBP1.
Consistent with this hypothesis, depletion of PQBP1
decreased SF3B1’s association with Bcl-x mRNA (Fig.
3D). In contrast, the binding of SF3B1 to Mcl1, a target
of SF3B1 (but not of PQBP1) was not affected by the
knockdown of PQBP1 (Fig. 3D). These findings suggest
that PQBP1 affects the association of SF3B1 with a dis-
tinct subset of substrate mRNAs. Furthermore, we found
that a subset of PQBP1 targets affected in their splicing
was similarly influenced by the knockdown of SF3B1
(Supplemental Fig. S5). SF3B1 is a central component of
the U2 snRNP. Recruitment of U2 snRNP to the intronic
branchpoint sequence (BPS) is a key step in the assembly
of the spliceosomal A complex and thus the selection of
splice sites (Wahl et al. 2009).We propose amodel whereby
through an association with SF3B1, PQBP1 influences the
recruitment of U2 snRNP to specific target sites, thus
affecting splicing decisions on a subset of mRNAs (Fig.
3E). The precise mechanism by which this occurs re-
mains to be explored.
Figure 7. PQBP1-modulated AS of NCAM-140 influences neurite
outgrowth. (A) A schematic of alternatively spliced region of
NCAM-140. Green rectangles are exons, and black lines are
introns. The gray rectangle marks the VASE. Arrowheads are
primers designed for RT–PCR and electrophoresis. (B) NCAM-
140 VASE splicing isoforms for neuron samples infected with
virus from a nontargeting control shRNA or a PQBP1 targeting
shRNA were analyzed by RT–PCR and gel electrophoresis. See
also Supplemental Figure S6. (C) RT–PCR quantification for
VASE! and VASE+. The ratio of the two isoform levels are
compared among neurons infected with virus from a nontarget-
ing control shRNA, an unmodified PQBP1 targeting shRNA,
or PQBP1 targeting shRNA constructs coexpressing exogenous
wild-type (WT) PQBP1, DAG, or Y65C. The mean of three
independent measurements 6 SD is shown. The differences
between samples were analyzed by one-way ANOVA test. (**)
Statistically significant with P-value < 0.01. (D) Western blot of
neurons infected with virus from a nontargeting shRNA, an
unmodified PQBP1 targeting shRNA, a PQBP1 targeting shRNA
construct coexpressing exogenous wild-type PQBP1, or a PQBP1
targeting shRNA construct coexpressing exogenous VASE! to
restore the ratio of VASE!/VASE+. (E) RT–PCR quantification for
VASE! and VASE+ expression levels of neurons infected with
virus from a nontargeting shRNA, an unmodified PQBP1 targeting
shRNA, or a PQBP1 targeting shRNA construct coexpressing
exogenous VASE! to restore the ratio of VASE!/VASE+. Themean
of three independent measurements 6 SD is shown. The differ-
ences between samples were analyzed by one-way ANOVA test.
(**) Statistically significant with P-value < 0.01. (F) Immunoflu-
orescence of individual neurons that were transiently transfected
with a PQBP1 targeting shRNA construct coexpressing exogenous
VASE! to restore the ratio of VASE!/VASE+ together with a GFP
vector. Neurons were grown on a layer of feeder glial cells. (G)
Sholl analysis of dendritic branching for individual neurons that
were transiently transfected with a nontargeting control shRNA,
an unmodified PQBP1 targeting shRNA, or a PQBP1 targeting
shRNA construct coexpressing exogenous VASE! to restore the
ratio of VASE!/VASE+ (mean 6 SE, n = 15–17).
Wang et al.
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PQBP1 affects the AS of mRNAs in neurons
Depletion of PQBP1 causes a decrease in outgrowth and
branching of dendrites in mouse primary cortical neurons
(Fig. 4G,H; Supplemental Fig. S3B,C). This morphological
defect was not apoptosis-related (Fig. 4E,F). Qualitatively,
dendrites close to the nucleus appeared more affected
than distal dendrites by knockdown of PQBP1 (Figs. 4H,
5D). The defect in neurite morphology caused by loss of
PQBP1 could be rescued by re-expression of wild-type
PQBP1 (Fig. 5C,D), confirming the correlation between
neurite deformity and the loss of PQBP1 expression.
Transcriptome-wide profiling revealed that PQBP1’s AS
targets were enriched for factors regulating neuron pro-
jection development (Fig. 6C).
To further investigate the effect of PQBP1 on neurons,
we focused on the VASE-associated isoforms of NCAM-
140 encoded by Ncam1, which has been implicated in
neurite outgrowth and development. Ncam1 contains
five Ig-like domains involved in homophilic binding of
Ncam1 either in cis or trans, which in turn controls cell–
cell interactions and the induction of neurite outgrowth
(Walsh and Doherty 1997). The AS of VASE determines
the inclusion or exclusion of the fourth Ig domain and
alters the homophilic binding of NCAM-140 (Lahrtz et al.
1997). The VASE! isoform of NCAM-140 stimulates—
while VASE+ inhibits—neurite outgrowth (Doherty et al.
1992; Liu et al. 1993; Saffell et al. 1994).
We found that the ratio of VASE!/VASE+ expression
corresponded to the level of functional PQBP1 and
neurite outgrowth (Figs. 4D, 5C, 7C,E,F). Moreover, res-
toration of the proper ratio of VASE!/VASE+ ‘‘rescued’’
the abnormal neurite outgrowth associated with the
knockdown of PQBP1 (Fig. 7F,G). These results identified
NCAM-140 as a critical target connecting PQBP1-medi-
ated AS to the cellular process of neurite projection
and outgrowth. However, the ability of enforced VASE!/
VASE+ expression to rescue the neurite outgrowth defect
caused by PQBP1 down-regulation does not exclude
the possibility that other PQBP1 targets contribute to
this phenotype. For example, PQBP1 AS targets are also
enriched in ARF-related proteins (Fig. 6C). The members
of the ARF family of small GTPases were previously
reported to affect dendritic branching and spine forma-
tion (Herna´ndez-Deviez et al. 2002; Moore et al. 2007).
A possible role for PQBP1 in neurological disorders
Clinical genetics identified mutations in PQBP1 as the
direct cause for Renpenning syndrome, a representative
XLMR disorder characterized by microcephaly, short
stature, multiple body malformations, and mental re-
tardation (Kalscheuer et al. 2003; Stevenson et al. 2005).
We examined the function of two disease-associated
PQBP1 variants—a truncated protein resulting from a DAG
deletion and a point mutation containing a Y65C muta-
tion in the WW domain. We discovered that the disease-
associated PQBP1 mutants had deficiencies in splicing-
related functions. Our proteomics profiling indicates that
the association between splicing-related factors and wild-
type PQBP1 was lost or altered in the Y65C and DAG
mutants, respectively (Supplemental Table S1). These
results indicate that the association of PQBP1 with
splicing factors is important for its function. In line with
their compromised association with the splicing machin-
ery, neither DAGnor Y65C restored the AS of NCAM-140
VASE when PQBP1 was knocked down in mouse primary
neurons (Fig. 7C). Furthermore, both mutants were also
unable to rescue the defects in neurite outgrowth upon
depletion of PQBP1 (Fig. 5E,F). Defects in dendritic de-
velopment are consistently found in many other mental
retardation disorders, including Fragile-X mental retarda-
tion and Rett syndrome (Parrish et al. 2007). Our results
suggest that disease-associated PQBP1 variants are de-
ficient in maintaining the proper function of PQBP1 in
AS. Moreover, aberrant splicing of specific AS targets may
contribute to the disease symptoms in PQBP1-related men-
tal retardation disorders.
In summary, we propose that PQBP1, a protein related
to neurological diseases, affects AS through association
with the core splicing complex. Aberrant AS of specific
targets resulting from misregulation of PQBP1 mutants
may be one of the causes of PQBP1-related neurological
disorders.
Materials and methods
Plasmids, cell culture, and siRNA transfection
Details of plasmid and stable cell line constructions are included
in the Supplemental Material. HeLa and 293Tcell lines (American
Type Culture Collection) were grown in standard conditions.
siRNAs were transfected with Hiperfect (Qiagen) at a final con-
centration of 40 nM. siRNAs were siGENOME siRNAs (Thermo
Scientific) for PQBP1 and firefly luciferase. Transfections were
optimized to reach$85% protein depletion 72 h post-transfection,
as determined by Western blotting.
Mouse cortical culture, plasmid transfection,
and lentivirus infection
Mouse embryonic cortical neurons were prepared and seeded as
in Kim et al. (2010). For direct neuron transfection, MISSION
shRNA lentivirus constructs for PQBP1 (Sigma) and a nontargeting
shRNA vector (Addgene Plasmid 1864) were transfected into neu-
rons on the day of seedingwith Lipofectamine 2000 (Invitrogen). For
lentiviral infection of neurons, 293T cells were transfected with
shRNA constructs and packaging vectors. Lentivirus-containing
supernatants were collected 48 h post-transfection. Neurons were
then incubated with the supernatants for 6 h on the day of seeding.
Infection was optimized to reach $60% protein depletion 72 h
post-infection, as determined by Western blotting.
RNA extraction and RT–PCR
Cellular RNAwas extracted by RNeasy minikit (Qiagen). RNAs
(1.5–4 mg) were reverse-transcribed by SuperScript First-Strand
Synthesis system (Invitrogen). Bcl-x and NCAM-140 VASE
splicing isoforms were analyzed by RT–PCR through primers
flanking the alternatively spliced region. A linear range for cDNA
input was determined by running a twofold dilution series of
28-cycle PCR reactions. Products were run on 5% Tris-Borate-
EDTA gels (Bio-Rad), stained with SYBR gold stain (Invitrogen),
and quantified with ImageJ software (National Institutes of
PQBP1 affects AS related to neurite outgrowth
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Health). Triplicate samples in the linear range were run to de-
termine isoform ratios. Real-time PCR primers were designed
with the software Primer3 (SourceForge) and verified by electro-
phoresis to generate single, correctly sized products. PCR reactions
were prepared with SYBRGreenmaster mix (Applied Biosystems),
run on a MasterCycler ep realplex (Eppendorf), and quantified by
the DDCt method. Primer sets are listed in Supplemental Table S5.
Tandem affinity immunopurification
Flag-HA-tagged PQBP1 and the Y65C and DAG mutants were
purified from HeLa cell extracts by tandem affinity purification
and visualized by silver stain as recently described (Adelmant
et al. 2012). Specific details are provided in the Supplemental
Material.
Sample preparation and mass spectrometry analysis
Sample preparation and liquid chromatography/tandem mass
spectrometry analysis were done with slight modifications to a
recently described method (Rozenblatt-Rosen et al. 2012). Spe-
cific details are provided in the Supplemental Material.
Western blotting
Cellular proteins were extracted with 13 RIPA buffer (13 PBS,
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, pro-
tease inhibitors). Ten micrograms to 30 mg of protein was loaded
onto each lane of a NuPAGE 4%–12% Bis-Tris gel. Proteins were
transferred onto PVDF membranes and probed with the follow-
ing primary antibodies diluted in 13 PBSTwith 5% nonfat milk:
a-PQBP1 (Santa Cruz Biotechnology), a-Flag (Sigma), a-HA (Roche),
a-actin (Chemicon), and a-SF3B1 (MBL).
CLIP
HeLa cells were cross-linked at 4000mJ/cm2with aUV Stratalinker
(Stratgene) and suspended in 13 RIPA buffer supplemented with
protease inhibitors, 10 mM DTT, and 0.4 U/mL RNaseOUT
(Invitrogen). Lysates were treated briefly with RQ1 RNase-free
DNase (Promega) and cleared by centrifugation. Dynal beads
(Invitrogen) that were precoupled with 10 mg of antibody or
nonrelevant IgG were incubated with the supernatants and
rocked for 4 h at 4°C. Beads were then washed three times with
the lysis buffer plus 300 mM NaCl and twice with 13 PNK
buffer (50 mM Tris-Cl at pH 7.4, 10 mM MgCl2, 0.5% NP-40).
RNA–protein complexes were eluted and treated with Protease
K (Ambion), and RNAs were extracted by acid phenol/chloroform.
Reverse transcriptionwas performedwith a 1:1mix of oligo-dTand
random hexamers, and cDNAs were analyzed by real-time PCR.
Immunofluorescence
Neurons were fixed with 4% paraformaldehyde and 2% sucrose/
PBS for 8 min. Cells were then washed three times with 13 PBS
and treated with 13 GDB (gelatin dilution buffer) buffer (0.3%
Triton, 0.1% gelatin) for 15 min. Cells were then incubated with
antibodies, stained with DAPI, and imaged on a Nikon Ti in-
verted fluorescence microscope. For costaining, we swapped the
fluorophores on secondary antibodies to confirm there was no
bleed-through in the fluorescence channels.
Annexin V staining
Neurons were incubated with FITC-conjugated Annexin V
(BioLegend) diluted 1:50 in medium for half an hour at 37°C.
Neurons were then directly imaged alive on a Nikon Ti inverted
fluorescence microscope.
RNA-seq sample preparation
Libraries were prepared from total RNA following the instruc-
tions of the TruSeq RNA sample preparation kit (Illumina).
Samples were then run on Illumina HiSeq 2000. Detailed com-
putational methods for AS target profiling are provided in the
Supplemental Material. The reported sequencing data have been
deposited in NCBI’s Gene Expression Omnibus (GEO) (Edgar
et al. 2002) and are accessible through GEO series accession
number GSE44402.
GO functional analysis
GO term enrichments for proteins associated with PQBP1 in
HeLa cells were determined with the DAVID (Database for
Annotation, Visualization, and Integrated Discovery) Bioinfor-
matics Database (Dennis et al. 2003; Huang et al. 2009). Func-
tional GO enrichments of PQBP1 AS targets in neurons were
determined with GoMiner software (Zeeberg et al. 2003).
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SUPPLEMENTAL MATERIALS FOR CHAPTER 2 
 
Supplemental experimental procedures can be accessed from: 
http://www.sciencedirect.com/science/article/pii/S0092867410007889 
 
Six supplemental tables and seven supplemental figures as described below can also be 
accessed from the website above. 
Table S2-1: Primary Bcl-x whole-genome siRNA screen data. 
Table S2-2: Bcl-x validation screen data. 
Table S2-3: Bcl2-overexpression screening results. 
Table S2-4: Results from Mcl1 counterscreen of Bcl-x regulators. 
Table S2-5: Mcl1 and Bcl-x kinase/phosphatase comparison. 
Table S2-6: Primer sets used in this study. 
 
Figure S2-1: Support Vector Machine (SVM) model for hit-identification in whole-
genome siRNA screen. 
Figure S2-2: Global analysis of screen assays. 
Figure S2-3: Screen hits regulate endogenous Bcl-x at physiologically significant levels. 
Figure S2-4: Screen hits regulate endogenous Mcl1 splicing. 
Figure S2-5: Pharmacological inhibition of AURKA alters endogenous Bcl-x and Mcl1 
splicing. 
Figure S2-6: Specific downregulation of ASF/SF2 by AURKA inhibition. 
Figure S2-7: Analysis of additional alternative splicing targets. 
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SUPPLEMENTAL MATERIALS FOR CHAPTER 3 
Supplemental Materials and Methods 
Plasmid Construction and Cell Lines 
Human PQBP1 construct was cloned from the cDNA of HeLa cells. Mouse NCAM-140 
VASE – was cloned from the mouse embryonic brain cDNA. ΔAG and Y65C were 
generated through PCR-mediated mutagenesis. FLAG-HA tandem tags were first cloned 
into the pBABE vector (BamHI/EcoRI) (Addgene) and PQBP1, ΔAG and Y65C were 
then cloned into the pBABE-FLAG-HA vector backbone (EcoRI/SalI). For the rescue 
constructs, puromycin resistance coding sequence was excised from the pLKO.1 
lentivirus vector carrying non-targeting shRNA or PQBP1 shRNA (BamHI/KpnI). 
FLAG-HA tagged human PQBP1, ΔAG, Y65C or mouse NCAM-140 VASE – isoform 
were then cloned into the vector using isothermal assembly (Gibson et al. 2009). All PCR 
primers in the cloning steps are listed in Table S3-2. 
Stable HeLa cell lines were made by the pBABE-puro retrovirus vectors. 293T 
cells were transfected with pBABE-puro-FLAG-HA-PQBP1/ΔAG/Y65C constructs 
together with packaging plasmids. Supernatants were collected after 48 hours and 72 
hours. HeLa cells were incubated with virus-containing supernatants for 12 hours. After 
recovery for 48 hours after the infection, HeLa cells were selected with puromycin and 
expanded.  
 
Tandem affinity immunopurification 
Whole-cell lysates from HeLa cells expressing FLAG-HA dual tagged PQBP1 constructs 
were prepared in FLAG-IP buffer (Adelmant et al. 2012). Flag-agarose slurry (Sigma) 
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was incubated with cell lysate for 4 hours at 4°C. After washing and elution with FLAG 
peptide (Sigma), the eluted products were incubated with HA-agarose slurry (Santa Cruz) 
overnight at 4°C. The immunopurified products with beads were then washed and eluted 
with HA peptide (Covance). 
 
Sample preparation for mass-spectrometry analysis  
Purified protein complexes were denatured and reduced by incubation at 56°C for 30 min 
in 10 mM DTT and 0.1% RapiGest (Waters). Protein digestion was carried out overnight 
at 37°C after adding 2 µg of trypsin and adjusting the pH to 8.0 with 1 M Tris. Tryptic 
peptide clean-up: RapiGest was removed from solution following the manufacturer’s 
protocol and tryptic peptides were purified by batch-mode reverse-phase C18 
chromatography (Poros 10R2, Applied Biosystems) using 40 µL of a 50% bead slurry in 
RP buffer A (0.1% trifluoroacetic acid), washed with 100 µL of the same buffer and 
eluted with 50 µL of RP buffer B (40% acetonitrile in 0.1% trifluoroacetic acid). After 
vacuum concentration, peptides were solubilized in 20 µL of 20 mM sodium phosphate 
(pH 7.4) and incubated with 20 µL of thiol-activated sepharose 4B (GE-healthcare) to 
remove excess HA peptide. Potential cysteine-containing peptides recovered in the flow-
through were alkylated at room temperature for 20 min in the dark by adding 
iodoacetamide at a final concentration of 20 mM. Peptides were further purified by strong 
cation exchange SCX chromatography (Poros 20HS, Applied Biosystems) using 20 µL of 
a 50% bead slurry in SCX buffer A (25% ACN in 0.1% formic acid), washed with 20 µL 
of the same buffer and eluted with 20 µL of SCX buffer B (25% ACN, 300 mM KCl in 
0.1% formic acid). 
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LC-MS/MS data acquisition  
After vacuum concentration, samples were loaded onto a pre-column (100 µm I.D.; 
packed with 4 cm POROS 10R2, Applied Biosystems) at a flow rate of 4 µL/min for 15 
min using a NanoAcquity Sample Manager (20 µL sample loop) and UPLC pump 
(Ficarro et al. 2009). After loading, the peptides were gradient eluted (1-30% B in 45 
min; buffer A: 0.2 M acetic acid, buffer B: 0.2 M acetic acid in acetonitrile) at a flow rate 
of ~50 nL/min to an analytical column (30 µm I.D. packed with 12 cm Monitor 5 mm 
C18 from Column Engineering, Ontario, CA), and introduced into an LTQ-Orbitrap XL 
mass spectrometer (ThermoFisher Scientific) by electrospray ionization (spray voltage = 
2200V). Three rapid LC gradients were included at the end of every analysis to minimize 
peptide carry-over between successive analyses and to re-equilibrate the columns. The 
mass spectrometer was programmed to operate in data dependent mode, such that the top 
8 most abundant precursors in each MS scan (detected in the Orbitrap mass analyzer, 
resolution = 60,000) were subjected to MS/MS (CAD, linear ion trap detection, collision 
energy = 35%, precursor isolation width = 2.8 Da, threshold = 20,000). Dynamic 
exclusion was enabled with a repeat count of 1 and a repeat duration of 15 sec.  
 
Database searching and identification of the associated protein spectrum for WT 
PQBP1, ΔAG and Y65C 
Orbitrap raw data files were processed within the multiplierz software environment 
(Parikh et al. 2009). MS spectra were recalibrated using the background ion Si(CH3)2O))6 
at m/z 445.12 +/- 0.03 and converted into a Mascot generic format (.mgf). Spectra were 
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searched using Mascot version 2.3 against 3 appended databases of i) human protein 
sequences (downloaded from RefSeq on 07/11/2011) ii) a database of common lab 
contaminants and iii) a decoy database generated by reversing the sequences from the 
human database. Search parameters specified a precursor ion mass tolerance of 1 Da, a 
product ion mass tolerance of 0.6 Da, and methionine oxidation (+16 Da) and cysteine 
carboxymethylation (+57 Da). The lists of peptide hits from the Mascot searches were 
filtered to exclude precursors with a mass error greater than 10 ppm. Sequence matches 
to the decoy database were used to enable a 1% false discovery rate (FDR) filtering of the 
resulting peptide identifications. After receiving a list of associated proteins for WT 
PQBP1 and the mutants from database search after LC-MS/MS, we filtered out proteins 
detected in any one of the replicates from the empty FLAG-HA vector integrated control 
samples and define the rest as the proteins that associated with WT PQBP1, ΔAG and 
Y65C. 
 
Antibodies 
Antibodies used in this study are listed as follows: α-PQBP1 (Santa Cruz); α-FLAG 
(Sigma); α-HA (Roche); α-actin (Chemicon); α-SF3B1 (MBL); α-MAP2 (Sigma); α-
SC35 (Abcam). 
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Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3-1 
(A) Gel analysis of RT-PCR of Bcl-x splicing isoforms for samples treated with a control siRNA 
targeting firefly luciferase and a second siRNA targeting PQBP1 (PQBP1 KD siRNA 2 in Figure 
3-1B) is shown. 
(B) Quantification of gel analysis as in (A).  Mean of three independent measurements +/- SD are 
shown. Changes were tested by 1-way ANOVA. **: statistically significant with p-value<0.01. 
(C) Quantification of real-time PCR data on 12 mRNAs that showed no significant AS changes 
between control and PQBP1 KD samples; APAF1, TNFSF13, GSTCD and PKM2 were also 
checked but showed either no or unstable readout, so are not included here. Y-axis depicts the 
ratio between amplicons for constitutive and alternative exonic regions; BCL2A1 and PCBP4 
follow the y-axis on the right side while the rest follow the y-axis on the left side. Light columns 
show the ratio of two amplicons from the control sample and dark columns from the PQBP1 KD 
sample. Mean of three independent measurements +/- SD are shown. Difference of the ratio 
between control and PQBP1 KD samples was analyzed by 1-way ANOVA test. 
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Figure S3-2. 
Quantification of steady state mRNA level of Bcl-x and Mcl1 in control and PQBP1 KD samples 
by RT-PCR. Data values normalized to rRNA expression and mean of three independent 
measurements +/- SD are shown. 
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Figure S3-3 
(A) IF staining of two additional rat embryonic cortical neurons for PQBP1 and SC35. Neurons 
were fixed and stained with antibodies listed on top of each panel.   
(B) Western blot showing depletion of PQBP1 in mouse embryonic cortical neurons infected by 
virus from the PQBP1-targeting shRNA in Figure 3-4C (PQBP1 KD shRNA 1), a second 
PQBP1-targeting shRNA (PQBP1 KD shRNA 2) and a non-targeting control shRNA. 
(C) IF staining of the morphology of mouse primary embryonic cortical neurons 5 days after 
infection with virus from a non-targeting control shRNA and a second PQBP1-targeting shRNA 
(PQBP1 KD shRNA 2 as in (A)). Green: MAP2 staining; blue: DAPI staining. 
(D) Western blot showing that the expression of shRNA-resistant human PQBP1 is not depleted 
by co-expression of the shRNA targeting mouse endogenous PQBP1. Lane 1 and 2 are samples 
co-transfected with a GFP-tagged mouse PQBP1 (mPQBP1-GFP) and a non-targeting control 
shRNA or a PQBP1-targeting shRNA. Lane 3 and 4 are samples transfected with a GFP-tagged, 
shRNA-resistant human PQBP1 (resis_hPQBP1-GFP) and a non-targeting control shRNA or a 
PQBP1-targeting shRNA. Antibodies used are listed on the right. GAPDH serves as the loading 
control.  
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Figure S3-3 (continued). 
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Figure S3-4  
(A) Western blot of mouse embryonic cortical neurons infected by virus from a non-targeting 
control shRNA and three different SF3B1-targeting shRNAs. Antibodies used are listed on the 
right. Actin serves as the loading control. 
(B) RT-PCR quantification of the AS change of 10 verified PQBP1-modulated AS events upon 
SF3B1 depletion (by shRNA 2 in Figure S3-4A), as described in Figure 3-6B. 
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Figure S3-5 
Real-time PCR quantification for VASE – and VASE + upon depletion of PQBP1 by a second 
shRNA is shown. The ratio of the two isoform expression was compared between neurons 
infected with virus from a non-targeting control shRNA and a second PQBP1-targeting shRNA. 
Mean of three independent measurements +/- SD are shown. Changes were tested by 1-way 
ANOVA. ∗: statistically significant with p-value<0.03. 
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Supplemental Tables 
All the supplemental tables described below can be accessed through the link: 
http://www.ncbi.nlm.nih.gov/pubmed/23512658 
 
Table S3-1. GO term enrichment for PQBP1 AS targets in mouse embryonic 
cortical neurons. 
The following data are enclosed: the GO category name; total number of genes in the 
corresponding GO category associated with the background gene set; number of genes within 
PQBP1 AS targets in the corresponding GO category; enrichment—the proportion of genes from 
PQBP1 AS targets in the category relative to the expected proportion; the one-sided Fisher exact 
p value corrected for multiple comparisons (fdr, false discovery rate). This table is generated by 
GoMiner™ online software (Zeeberg et al., 2003). 
 
Table S3-2. Primer sets used in this study.  
PCR primer sequences are listed here. Abbreviations are as follows: F=forward (5’) primer; 
R=reverse (3’) primer; A=amplicon for alternative regions; C=amplicon for constitutive regions. 
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SUPPLEMENTAL MATERIALS FOR CHAPTER 4 
All the supplemental tables described below can be accessed through the link: 
http://www.ncbi.nlm.nih.gov/pubmed/23512658 
 
Table S4-1. AS targets of PQBP1 identified from RNA-seq.  
The following data for AS events that experienced significant changes upon PQBP1 KD in mouse 
embryonic cortical neurons are enclosed: Gene name that the AS event belongs to; the AS event 
ID; sub-AS-junction IDs in this AS event; the corresponding genome coordinates for the sub-AS-
junctions; p-values of differential usage of the corresponding sub-AS-junction between control 
and PQBP1 KD samples (NA p-value: no statistical test applied because of low read count. See 
text); fold changes of usage (on log2 scale) for the sub-AS-junction between control and PQBP1 
KD samples. 
 
Table S4-2. AS events that are not affected by PQBP1 KD from RNA-seq. 
AS events that are not affected by PQBP1 KD in mouse embryonic cortical neurons are enclosed, 
with similar format as in Table S4-1. AS events that could not be mapped to any known genes 
based on current annotation of the mouse genome are not included here. 
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SUPPLEMENTAL MATERIALS FOR CHAPTER 5 
Supplemental Table S5-1: Parameters used for modeling the splicing-based device. 
Parameters Value 
k1  0.02  
k2  6.66 ×10−7  
l2  10−2  
k3  1.33×10−6  
l3  10−3  
k4  1  
k5  0.015  
d1  10−4  
d2  5 ×10−4  
d3  5 ×10−3  
 
 
